WorldWideScience

Sample records for arv drug patents

  1. Price Reversal Pattern of ARV Drugs: A Transaction-Cost Approach Digression

    Directory of Open Access Journals (Sweden)

    Frank LORNE

    2015-05-01

    Full Text Available A price reversal pattern of ARV drugs was noted across lower and middle income countries in that the lower-income countries have higher prices relative to higher-income countries based on a 2008-2009 Summary Report by World Health Organization. The transaction costs affecting AVR drug pricing can be broadly classified into two kinds: One between the final users and the opinion/knowledge experts, and the other between the opinion/knowledge experts and the manufacturers. Economist’s version of price discrimination needs to be modified by including transaction costs. Transaction costs also point to institution creditability factors that will affect NGO procurement.

  2. Can drug patents be morally justified?

    Science.gov (United States)

    Sterckx, Sigrid

    2005-01-01

    This paper offers a few elements of an answer to the question to what extent drug patents can be morally justified. Justifications based on natural rights, distributive justice and utilitarian arguments are discussed and criticized. The author recognizes the potential of the patents to benefit society but argues that the system is currently evolving in the wrong direction, particularly in the field of drugs. More than a third of the world's population has no access to essential drugs. The working of the patent system is an important determinant of access to drugs. This paper argues that drug patents are not easily justified and that the 'architecture' of the patent system should be rethought in view of its mission of benefiting society. PMID:15727003

  3. Arv & skifte

    DEFF Research Database (Denmark)

    Werlauff, Erik

    Værket giver et helhedsbillede af spørgsmål om arv, skifte, boafgift og eventuel boskat. Bogen er opdelt i en teoretisk del, hvor regelsættene behandles, og en praktisk del, der behandler en lang række spørgsmål om dødsboets behandling. Skiftereformen 2011, som stiller en række nye krav til...

  4. Patents and access to essential drugs.

    Science.gov (United States)

    Loff, Bebe

    2003-01-01

    This paper provides a brief overview of historical developments in patent law including its recent incorporation into world trade law. The impact of patents on access to essential drugs will be discussed. The relationship between intellectual property rights and the right to health will be considered. PMID:12886793

  5. [The patents game. Generic and biosimilar drugs].

    Science.gov (United States)

    Villamañán, E; González, D; Armada, E; Ruano, M; Álvarez-Sala, R; Herrero, A

    2016-01-01

    The protection provided by patents on medicines has a limited duration. The expiry of patents expiration allows copies of the drugs to be released, competing with original. At first, they were identical to the original, known as generic drugs, but in recent years, due to the marketing of biological therapies and the expiry of many of their patents, biosimilar drugs have also emerged. These are not exact copies of the original, but, like generic drugs, biosimilar drugs have to demonstrate equivalence to the reference drugs in quality, safety and efficacy. Nevertheless, despite their importance and contribution to sustainability of health system, doctors are sometimes unaware of differences between them, and their impact in terms of clinical and economic effects. An attempt is made to review and clarify certain aspects often unknown by physicians, despite their involvement in their use. PMID:26542789

  6. Patents associated with high-cost drugs in Australia.

    Directory of Open Access Journals (Sweden)

    Andrew F Christie

    Full Text Available Australia, like most countries, faces high and rapidly-rising drug costs. There are longstanding concerns about pharmaceutical companies inappropriately extending their monopoly position by "evergreening" blockbuster drugs, through misuse of the patent system. There is, however, very little empirical information about this behaviour. We fill the gap by analysing all of the patents associated with 15 of the costliest drugs in Australia over the last 20 years. Specifically, we search the patent register to identify all the granted patents that cover the active pharmaceutical ingredient of the high-cost drugs. Then, we classify the patents by type, and identify their owners. We find a mean of 49 patents associated with each drug. Three-quarters of these patents are owned by companies other than the drug's originator. Surprisingly, the majority of all patents are owned by companies that do not have a record of developing top-selling drugs. Our findings show that a multitude of players seek monopoly control over innovations to blockbuster drugs. Consequently, attempts to control drug costs by mitigating misuse of the patent system are likely to miss the mark if they focus only on the patenting activities of originators.

  7. Familie og arv

    DEFF Research Database (Denmark)

    Nielsen, Linda

    1995-01-01

    Familie og arv, familie, arv, børn, ægteskab, ægtefælle, skilsmisse, formuefællesskab, forældremyndighed, fælleseje, særråden, særeje, død, uskiftet bo, underholdspligt, samliv, tvangsarv, deling......Familie og arv, familie, arv, børn, ægteskab, ægtefælle, skilsmisse, formuefællesskab, forældremyndighed, fælleseje, særråden, særeje, død, uskiftet bo, underholdspligt, samliv, tvangsarv, deling...

  8. [Drug patents and other ways to protect pharmaceutical research].

    Science.gov (United States)

    Ohana, Patrick; Tardieu, Sophie; Blin, Olivier; Tassy, Sébastien; Sambuc, Roland

    2004-01-01

    Pharmaceutical research constitutes a significant cost for pharmaceutical companies. Because of the importance of the financial investment in research projects, companies must protect their discoveries. There are multiple ways to do this. First, the legal avenue can be divided into three parts: a pharmaceutical company can protect a new drug by a patent, then an additional patent or a secondary patent; moreover, since 1992 in Europe, the pharmaceutical industry has been able to extend a patent by the "Supplementary Protection Certificate" (le Certificat Complémentaire de Protection [CCP]). The nonjuridical way is to use the chiral "switch", which can extend patents close to expiring, thus enhancing profitability. PMID:15359623

  9. Competitive intelligence and patent analysis in drug discovery.

    Science.gov (United States)

    Grandjean, Nicolas; Charpiot, Brigitte; Pena, Carlos Andres; Peitsch, Manuel C

    2005-01-01

    Patents are a major source of information in drug discovery and, when properly processed and analyzed, can yield a wealth of information on competitors activities, R&D trends, emerging fields, collaborations, among others. This review discusses the current state-of-the-art in textual data analysis and exploration methods as applied to patent analysis.: PMID:24981938

  10. Social opdrift - social arv

    DEFF Research Database (Denmark)

    Ejrnæs, Morten; Gabrielsen, G.; Nørrung, Per

    "Social opdrift - social arv" stiller på flere måder spørgsmål ved begrebet social arv. Bogen konkluderer blandt andet, at langt de fleste børn, der opvokser i en socialt belastet familie, bliver velfungerende voksne. Professionelle, der møder socialt belastede familier, har derfor et stort ansvar....... Naturligvis skal der tages hånd om udsatte børn, men det kræver samtidig stor opmærksomhed at sørge for, at fokuseringen på den sociale arv ikke tager overhånd, så det bliver en selvopfyldende profeti."Social opdrift - social" arv viser, hvordan forskningsresultater er blevet fremlagt på en måde, som har...... medvirket til at skabe en skæv opfattelse af, at forældrenes problemer er hovedårsag til børns sociale problemer. I selvstændige analyser vises, hvordan data, der normalt bruges som "bevis" for den sociale arvs betydning, tydeligt illustrerer, at det er en undtagelse, at børn får sociale problemer af samme...

  11. Fair drug prices and the patent system.

    Science.gov (United States)

    Resnik, David B

    2004-06-01

    This paper uses John Rawls' theory of justice to defend the patent system against charges that it has an unfair effect on access to medications,from the perspective of national and international justice. The paper argues that the patent system is fair in a national context because it respects intellectual property rights and it benefits the least advantaged members of society by providing incentives for inventors, investors, and entrepreneurs. The paper also argues that the patent system is fair in an international context, provided that developed nations take steps to help disease-stricken countries secure internal justice. Fairness in a national or international context also requires that the patent system should include emergency exceptions to deal with short-term inequities. PMID:15487813

  12. 'Government Patent Use': A Legal Approach To Reducing Drug Spending.

    Science.gov (United States)

    Kapczynski, Amy; Kesselheim, Aaron S

    2016-05-01

    The high cost of patent-protected brand-name drugs can strain budgets and curb the widespread use of new medicines. An example is the case of direct-acting antiviral drugs for the treatment of hepatitis C. While prices for these drugs have come down in recent months, they still create barriers to treatment. Additionally, prescribing restrictions imposed by insurers put patients at increased risk of medical complications and contribute to transmission of the hepatitis C virus. We propose that the federal government invoke its power under an existing "government patent use" law to reduce excessive prices for important patent-protected medicines. Using this law would permit the government to procure generic versions of patented drugs and in exchange pay the patent-holding companies reasonable royalties to compensate them for research and development. This would allow patients in federal programs, and perhaps beyond, to be treated with inexpensive generic medicines according to clinical need-meaning that many more patients could be reached for no more, and perhaps far less, money than is currently spent. Another benefit would be a reduction in the opportunity for companies to extract monopoly profits that far exceed their risk-adjusted costs of research and development. PMID:27140984

  13. Heideggers sorte arv

    DEFF Research Database (Denmark)

    Olesen, Søren Gosvig

    2015-01-01

    Martin Heidegger var antisemit, men er hans tænkning og intellektuelle arv det også? Søren Gosvig Olesen opsøger den store tyske tænkers arvinger og bindene fra 1938-48 i Heideggers efterladte ’Sorte hæfter’, hvor den lille mands meninger blander sig med en stor tænkers tanker......Martin Heidegger var antisemit, men er hans tænkning og intellektuelle arv det også? Søren Gosvig Olesen opsøger den store tyske tænkers arvinger og bindene fra 1938-48 i Heideggers efterladte ’Sorte hæfter’, hvor den lille mands meninger blander sig med en stor tænkers tanker...

  14. Recent patents survey on self emulsifying drug delivery system.

    Science.gov (United States)

    Jethara, Sahilhusen I; Patel, Alpesh D; Patel, Mukesh R

    2014-01-01

    Self-Emulsifying Drug Delivery System is a unique feasible approach to overcome low oral bioavailability problem which is associated with the hydrophobic drugs due to their unparalleled potential as a drug delivery with the broad range of application. The estimated 40% of active pharmaceuticals are poorly water soluble. Now recently, formulation containing oral SEDDS has received much interest as it solve problems related to oral bioavailability, intra and inter-subject variability and lack of dose proportionality of hydrophobic drugs. Now a days, it is the first way to investigate the development of any kind of innovative dosage forms. Many important in-vitro characteristics such as surfactant concentration, oil/surfactant ratio, emulsion polarity, droplet size and zeta potential play an important role in oral absorption of drug from SEEDS. It can be orally administered in the form of SGC or HGC and also enhances bioavailability of drugs to increase solubility and minimizes the gastric irritation. After administration the drug remains entrapped in the oily droplets (inside the droplet or in the surfactant`s film at the interface) of the emulsion that are formed in the GIT upon self-emulsification process. It is also a bit problematic to say that the drug is being released from SMEDDS, it would be more precise to say that it diffuses out of oily droplets into the GIT media resulting in the formation of an equilibrium between the drug dissolved in oily droplets and the outer dispersed media (e.g. GIT fluids). Many of the application and preparation methods of SEDDS are reported by research articles and patents in different countries. We present an exhaustive and updated account of numerous literature reports and more than 150 patents published on SEDDS in the recent period. This current patent review is useful in knowledge of SEDDS for its preparations and patents in different countries with emphasis on their formulation, characterization and systematic optimization

  15. 37 CFR 1.775 - Calculation of patent term extension for a human drug, antibiotic drug or human biological product.

    Science.gov (United States)

    2010-07-01

    ... Human Services that applicant did not act with due diligence; (iii) One-half the number of days... extension for a human drug, antibiotic drug or human biological product. 1.775 Section 1.775 Patents... Review § 1.775 Calculation of patent term extension for a human drug, antibiotic drug or human...

  16. Adverse drug reaction, patent blue V dye and anaesthesia

    Directory of Open Access Journals (Sweden)

    Swagata Tripathy

    2012-01-01

    Full Text Available Background and Aim: Patent blue vital (PBV dye is used for varied perioperative indications, and has a potential for causing life-threatening allergic reactions. In this retrospective case series study, at a tertiary level neurosciences centre, we analysed the nature, management and outcome of adverse drug reaction to the preoperative use of PBV for marking vertebral level prior to back surgeries. Methods: Patients were identified from the theatre and radiology database. Data were collected from the patients′ notes retrieved from the medical records division. Results: Eleven of 1247 (0.88% patients experienced adverse reactions: 6 (0.48% patients had minor grade I reactions (urticaria, blue hives, pruritis or generalised rash, 4 (0.32% had grade II reactions (transient hypotension/bronchospasm/laryngospasm and grade III reaction (hypotension requiring prolonged vasopressor support was noted in 1 (0.08% patient. No mortality was seen. The time of onset (range 10-45 min frequently coincided with induction of anaesthesia or prone positioning of patient. Seven (63.6% cases were cancelled or postponed (range 2-63 days. Treatment varied independent of the grade of reaction. Allergy workup (often incomplete was done for 6 (54% patients. Conclusion: An awareness of the time of onset and infrequency of life-threatening reactions to patent blue dye may result in better management, less postponement, more complete workup and referral of these events.

  17. Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings

    Science.gov (United States)

    Stalter, Randy M; Moench, Thomas R; MacQueen, Kathleen M; Tolley, Elizabeth E; Owen, Derek H

    2016-01-01

    Introduction Poor adherence to product use has been observed in recent trials of antiretroviral (ARV)-based oral and vaginal gel HIV prevention products, resulting in an inability to determine product efficacy. The delivery of microbicides through vaginal rings is widely perceived as a way to achieve better adherence but vaginal rings do not eliminate the adherence challenges exhibited in clinical trials. Improved objective measures of adherence are needed as new ARV-based vaginal ring products enter the clinical trial stage. Methods To identify technologies that have potential future application for vaginal ring adherence measurement, a comprehensive literature search was conducted that covered a number of biomedical and public health databases, including PubMed, Embase, POPLINE and the Web of Science. Published patents and patent applications were also searched. Technical experts were also consulted to gather more information and help evaluate identified technologies. Approaches were evaluated as to feasibility of development and clinical trial implementation, cost and technical strength. Results Numerous approaches were identified through our landscape analysis and classified as either point measures or cumulative measures of vaginal ring adherence. Point measurements are those that give a measure of adherence at a particular point in time. Cumulative measures attempt to measure ring adherence over a period of time. Discussion Approaches that require modifications to an existing ring product are at a significant disadvantage, as this will likely introduce additional regulatory barriers to the development process and increase manufacturing costs. From the point of view of clinical trial implementation, desirable attributes would be high acceptance by trial participants, and little or no additional time or training requirements on the part of participants or clinic staff. We have identified four promising approaches as being high priority for further development

  18. Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings

    Directory of Open Access Journals (Sweden)

    Randy M Stalter

    2016-05-01

    Full Text Available Introduction: Poor adherence to product use has been observed in recent trials of antiretroviral (ARV-based oral and vaginal gel HIV prevention products, resulting in an inability to determine product efficacy. The delivery of microbicides through vaginal rings is widely perceived as a way to achieve better adherence but vaginal rings do not eliminate the adherence challenges exhibited in clinical trials. Improved objective measures of adherence are needed as new ARV-based vaginal ring products enter the clinical trial stage. Methods: To identify technologies that have potential future application for vaginal ring adherence measurement, a comprehensive literature search was conducted that covered a number of biomedical and public health databases, including PubMed, Embase, POPLINE and the Web of Science. Published patents and patent applications were also searched. Technical experts were also consulted to gather more information and help evaluate identified technologies. Approaches were evaluated as to feasibility of development and clinical trial implementation, cost and technical strength. Results: Numerous approaches were identified through our landscape analysis and classified as either point measures or cumulative measures of vaginal ring adherence. Point measurements are those that give a measure of adherence at a particular point in time. Cumulative measures attempt to measure ring adherence over a period of time. Discussion: Approaches that require modifications to an existing ring product are at a significant disadvantage, as this will likely introduce additional regulatory barriers to the development process and increase manufacturing costs. From the point of view of clinical trial implementation, desirable attributes would be high acceptance by trial participants, and little or no additional time or training requirements on the part of participants or clinic staff. We have identified four promising approaches as being high priority

  19. Natural products against cancer: A comprehensive bibliometric study of the research projects, publications, patents and drugs

    OpenAIRE

    Jian Du; Xiaoli L Tang

    2014-01-01

    Objectives: To analyze multi-source data including awards, publications, patents and drugs, and try to draw the whole landscape of the research and development community in the area of natural products (NPs) against cancer. Materials and Methods: Awards, publications, patents and drugs data from National Institute of Health/Natural Science Foundation of China (NIH/NSFC), PubMed, Derwent Innovation Index and Cortellis were collected. Bibliometric methodologies and technology are used to in...

  20. The Effect of Pharmaceutical Patent Term Length on Research and Development and Drug Expenditures in Canada

    OpenAIRE

    Grootendorst, Paul; Matteo, Livio Di

    2007-01-01

    While pharmaceutical patent terms have increased in Canada, increases in patented drug spending have been mitigated by price controls and retrenchment of public prescription drug subsidy programs. We estimate the net effects of these offsetting policies on domestic pharmaceutical R&D expenditures and also provide an upper-bound estimate on the effects of these policies on Canadian pharmaceutical spending over the period 1988–2002. We estimate that R&D spending increased by $4.4 billion (1997 ...

  1. Patent issues in drug development: Perspectives of a pharmaceutical scientist-attorney

    OpenAIRE

    Melethil, Srikumaran

    2005-01-01

    The major purpose of this article is to emphasize the need for pharmaceutical scientists to have a better understanding of patent fundamentals. This need is illustrated by analyses of key scientific and legal issues that arose during recent patent infringement cases involving Prozac, Prilosec, and Buspar. Economic incentives for drug discovery and development clash with societal needs for low-cost pharmaceuticals in the United States and all over the world. The Hatch-Waxman Act of 1984 was en...

  2. Compulsory patent licensing and local drug manufacturing capacity in Africa

    Directory of Open Access Journals (Sweden)

    Olasupo Ayodeji Owoeye

    2014-03-01

    Full Text Available Africa has the highest disease burden in the world and continues to depend on pharmaceutical imports to meet public health needs. As Asian manufacturers of generic medicines begin to operate under a more protectionist intellectual property regime, their ability to manufacture medicines at prices that are affordable to poorer countries is becoming more circumscribed. The Doha Declaration on the TRIPS Agreement and Public Health gives member states of the World Trade Organization (WTO the right to adopt legislation permitting the use of patented material without authorization by the patent holder, a provision known as “compulsory licensing”. For African countries to take full advantage of compulsory licensing they must develop substantial local manufacturing capacity. Because building manufacturing capacity in each African country is daunting and almost illusory, an African free trade area should be developed to serve as a platform not only for the free movement of goods made pursuant to compulsory licences, but also for an economic or financial collaboration towards the development of strong pharmaceutical manufacturing capacity in the continent. Most countries in Africa are in the United Nations list of least developed countries, and this allows them, under WTO law, to refuse to grant patents for pharmaceuticals until 2021. Thus, there is a compelling need for African countries to collaborate to build strong pharmaceutical manufacturing capacity in the continent now, while the current flexibilities in international intellectual property law offer considerable benefits.

  3. Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness.

    Directory of Open Access Journals (Sweden)

    Dobromir Dimitrov

    Full Text Available BACKGROUND: Four clinical trials have shown that oral and topical pre-exposure prophylaxis (PrEP based on tenofovir may be effective in preventing HIV transmission. The expected reduction in HIV transmission and the projected prevalence of drug resistance due to PrEP use vary significantly across modeling studies as a result of the broad spectrum of assumptions employed. Our goal is to quantify the influence of drug resistance assumptions on the predicted population-level impact of PrEP. METHODS: All modeling studies which evaluate the impact of oral or topical PrEP are reviewed and key assumptions regarding mechanisms of generation and spread of drug-resistant HIV are identified. A dynamic model of the HIV epidemic is developed to assess and compare the impact of oral PrEP using resistance assumptions extracted from published studies. The benefits and risks associated with ten years of PrEP use are evaluated under identical epidemic, behavioral and intervention conditions in terms of cumulative fractions of new HIV infections prevented, resistance prevalence among those infected with HIV, and fractions of infections in which resistance is transmitted. RESULTS: Published models demonstrate enormous variability in resistance-generating assumptions and uncertainty in parameter values. Depending on which resistance parameterization is used, a resistance prevalence between 2% and 44% may be expected if 50% efficacious oral PrEP is used consistently by 50% of the population over ten years. We estimated that resistance may be responsible for up to a 10% reduction or up to a 30% contribution to the fraction of prevented infections predicted in different studies. CONCLUSIONS: Resistance assumptions used in published studies have a strong influence on the projected impact of PrEP. Modelers and virologists should collaborate toward clarifying the set of resistance assumptions biologically relevant to the PrEP products which are already in use or soon to

  4. To Discuss the Adverse reaction of Chinese Patent Drug%浅谈中成药的不良反应

    Institute of Scientific and Technical Information of China (English)

    刘伦栋

    2014-01-01

    To discuss the adverse reaction of Chinese patent drug, to study and analysis the adverse reaction of Chinese patent drug in clinic, Chinese patent drug, adverse reaction should be valued and prevent drug abusing.%探讨中成药的不良反应,分析研究中成药在临床应用中的不良反应,且对中成药的不良反应应重视并防止滥用。

  5. Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV in Asian Settings: The Cross-Sectional Surveillance Study - PEDA Study.

    Directory of Open Access Journals (Sweden)

    Vorapot Sapsirisavat

    Full Text Available Ensuring that medicines meet quality standards is mandatory for ensuring safety and efficacy. There have been occasional reports of substandard generic medicines, especially in resource-limiting settings where policies to control quality may be less rigorous. As HIV treatment in Thailand depends mostly on affordable generic antiretrovirals (ARV, we performed quality assurance testing of several generic ARV available from different sources in Thailand and a source from Vietnam.We sampled Tenofovir 300mg, Efavirenz 600mg and Lopinavir/ritonavir 200/50mg from 10 primary hospitals randomly selected from those participating in the National AIDS Program, 2 non-government organization ARV clinics, and 3 private drug stores. Quality of ARV was analyzed by blinded investigators at the Faculty of Pharmaceutical Science, Chulalongkorn University. The analysis included an identification test for drug molecules, a chemical composition assay to quantitate the active ingredients, a uniformity of mass test and a dissolution test to assess in-vitro drug release. Comparisons were made against the standards described in the WHO international pharmacopeia.A total of 42 batches of ARV from 15 sources were sampled from January-March 2015. Among those generics, 23, 17, 1, and 1 were Thai-made, Indian-made, Vietnamese-made and Chinese-made, respectively. All sampled products, regardless of manufacturers or sources, met the International Pharmacopeia standards for composition assay, mass uniformity and dissolution. Although local regulations restrict ARV supply to hospitals and clinics, samples of ARV could be bought from private drug stores even without formal prescription.Sampled generic ARVs distributed within Thailand and 1 Vietnamese pharmacy showed consistent quality. However some products were illegally supplied without prescription, highlighting the importance of dispensing ARV for treatment or prevention in facilities where continuity along the HIV treatment

  6. Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study

    Science.gov (United States)

    Thammajaruk, Narukjaporn; Pussadee, Kanitta; Riyaten, Prakit; Kerr, Stephen; Avihingsanon, Anchalee; Phanuphak, Praphan; Ruxrungtham, Kiat

    2016-01-01

    Objectives Ensuring that medicines meet quality standards is mandatory for ensuring safety and efficacy. There have been occasional reports of substandard generic medicines, especially in resource-limiting settings where policies to control quality may be less rigorous. As HIV treatment in Thailand depends mostly on affordable generic antiretrovirals (ARV), we performed quality assurance testing of several generic ARV available from different sources in Thailand and a source from Vietnam. Methods We sampled Tenofovir 300mg, Efavirenz 600mg and Lopinavir/ritonavir 200/50mg from 10 primary hospitals randomly selected from those participating in the National AIDS Program, 2 non-government organization ARV clinics, and 3 private drug stores. Quality of ARV was analyzed by blinded investigators at the Faculty of Pharmaceutical Science, Chulalongkorn University. The analysis included an identification test for drug molecules, a chemical composition assay to quantitate the active ingredients, a uniformity of mass test and a dissolution test to assess in-vitro drug release. Comparisons were made against the standards described in the WHO international pharmacopeia. Results A total of 42 batches of ARV from 15 sources were sampled from January–March 2015. Among those generics, 23, 17, 1, and 1 were Thai-made, Indian-made, Vietnamese-made and Chinese-made, respectively. All sampled products, regardless of manufacturers or sources, met the International Pharmacopeia standards for composition assay, mass uniformity and dissolution. Although local regulations restrict ARV supply to hospitals and clinics, samples of ARV could be bought from private drug stores even without formal prescription. Conclusion Sampled generic ARVs distributed within Thailand and 1 Vietnamese pharmacy showed consistent quality. However some products were illegally supplied without prescription, highlighting the importance of dispensing ARV for treatment or prevention in facilities where continuity

  7. Recent Techniques and Patents on Solid Lipid Nanoparticles as Novel Carrier for Drug Delivery.

    Science.gov (United States)

    Khatak, Sunil; Dureja, Harish

    2015-01-01

    The various approaches have been utilized in the treatment of a variety of diseases by applying drug delivery system such as polymeric nanoparticles, self-emulsifying delivery systems, liposomes, microemulsions and micellar solutions. Recently, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) and lipid-drug conjugates (LDCs) have been exploited as a carrier of lipophilic and hydrophilic/amphiphilic substances for invasive and non-invasive routes of delivery. SLNs are colloidal drug carrier system and are like nanoemulsion, however, the lipid content in SLNs is solid in nature. These novel type of lipid nanoparticles with solid matrix offers to develop new prototype therapeutics in drug delivery, which could be used for controlled release, drug targeting, gene therapy, physical and chemical stability and site-specific drug delivery and thereby attracted the research groups worldwide. This manuscript overviews the recent patents, advantages, formulation techniques, stability aspects and applications of SLNs. PMID:27009132

  8. Como pesquisar o perfil patentário de um fármaco: o caso Efavirenz How to determine the patent profile of a drug: a case study of Efavirenz

    Directory of Open Access Journals (Sweden)

    Jaqueline Mendes Soares

    2010-01-01

    Full Text Available The importance of the patent system for researchers, especially in chemistry and related areas, is undeniable. In this context, this work aims at guiding the search in major search engines of patents, in order to map the patents related to a specific chemical compound and identify the material that each patent document protects. In this case study, it was performed a search for the drug efavirenz to demonstrate how to conduct a literature search in patents databases and to map patent applications at national and international levels.

  9. The Illusory Promise: Patents (Lack of) Power to Incentivize Drug Development for Poor Countries

    OpenAIRE

    Lau, Stacy

    2006-01-01

    Low-income countries suffer infectious and communicable diseases at a greater rate than any other income group. Because people living in these countries are not able to pay high drug prices, pharmaceutical companies do not have sufficient incentive to research and develop cures for infectious diseases. This essay examines strong intellectual property rights and patent enforcement as a solution to this problem. It will provide a description of the Trade-Related Aspects of Intellectual Property...

  10. International patenting in ophthalmology: An analysis of its structure and relevance for the development of drugs and diagnostics

    Directory of Open Access Journals (Sweden)

    Hermann AM Mucke

    2008-10-01

    Full Text Available Hermann AM Mucke, Peter Mucke, Eva MuckeHM Pharma Consultancy, Vienna, AustriaAbstract: While investigative ophthalmologists access peer-reviewed journals as part of their daily routine, and while they regularly visit scientific congresses, they rarely peruse patent documents as an information source. Among the reasons for this negligence are the incompatibility of patent search algorithms with those known from journal databases, a legalistic and frequently redundant language, and misconceptions about the nature of the patenting system. Here we present key data and analyses from the ophthalmology module of a patent database system that we are developing to address some of these problems. We show that international patent applications consistently reflect developer interest in the ocular drug and diagnostics field; that they are technically focused lead indicators of developments that frequently feature in peer-reviewed patenting only much later; and that patenting targets are well aligned with the unmet therapeutic needs of populations in industrialized countries. Most applications (74%–78% in years since 2006 are supported with experimental data, and most (on average, 80%–90% faced at least one objection to patentability during their initial stage of examination. In contrast to the peer-reviewed scenery that is highly diverse, the corresponding patenting arena shows a pronounced focus on the United States.Keywords: ophthalmology, eye diseases, iontophoresis, intellectual property, patents as topic, bibliographic databases

  11. Recent patents and advances on anti - tuberculosis drug delivery and formulations.

    Science.gov (United States)

    Vora, Chintan; Patadia, Riddhish; Mittal, Karan; Mashru, Rajashree

    2013-08-01

    Tuberculosis has remained, unambiguously, a significant health care problem since long times, particularly in developing countries. The endeavoring battle against multi drug resistant TB, multiple dosing, their prominent side effects and bioavailability hiccups related to fixed dose combinations has undeniably become a Herculean task indicating rigorous research requirement in anti TB drug therapy. In view of the fact that patenting a drug molecule, a drug delivery system or a formulation has been very fruitful for the growth and sustainment of pharmaceutical industry, a meticulous review of recent developments, providing a balanced view on merits/demerits, will facilitate researchers to update themselves, thereby focusing their research in more relevant areas to furnish desired quality traits. This article reviews the present scenario in terms of drug delivery approaches for TB chemotherapy. The review encompasses and summarizes recent patents and advances on variegated facets of dosage forms, together with from conventional solid oral to novel controlled release oral formulations and additionally alternative weapons for anti TB drug delivery. A critical review of multidisciplinary approaches to boost anti TB therapy may facilitate the scientists to resolve existing technological gaps. PMID:23244680

  12. Analysis of drugs illegally added into Chinese traditional patent medicine using surface-enhanced Raman scattering.

    Science.gov (United States)

    Zhang, Yan; Huang, Xiaoyan; Liu, Wenfang; Cheng, Zeneng; Chen, Chuanpin; Yin, Lihui

    2013-01-01

    Illegal chemicals, which could cause unpredictable side effects, may be added into traditional Chinese medicine (TCM) for a rapid healing effect. In this report, a surface-enhanced Raman scattering (SERS) analysis method for five kinds of illegally added drugs (rosiglitazone maleate, phenformin hydrochloride, metformin hydrochloride, pioglitazone hydrochloride and sibutramine hydrochloride) in Chinese traditional patent medicine (CTPM) has been demonstrated, including simultaneous detections of drug mixtures with CTPM. Silver colloidal, prepared by a sodium citrate reaction, was used as a SERS substrate. The optimum pH condition for each drug has also been explored because of its combined effect on protonation, surface charge, repulsion of an analyte and nanoparticles. Furthermore, the simultaneous detection of two or three kinds of these chemicals has been carried out. Characteristic peaks are employed for qualitative analysis. This is the first research using SERS for the analysis of drug mixtures in CTPM without any separation process. PMID:24107564

  13. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis.

    Directory of Open Access Journals (Sweden)

    Nathalie Vernaz

    Full Text Available BACKGROUND: Drug manufacturers have developed "evergreening" strategies to compete with generic medication after patent termination. These include marketing of slightly modified follow-on drugs. We aimed to estimate the financial impact of these drugs on overall healthcare costs and also to examine the impact of listing these drugs in hospital restrictive drug formularies (RDFs on the healthcare system as a whole ("spillover effect". METHODS AND FINDINGS: We used hospital and community pharmacy invoice office data in the Swiss canton of Geneva to calculate utilisation of eight follow-on drugs in defined daily doses between 2000 and 2008. "Extra costs" were calculated for three different scenarios assuming replacement with the corresponding generic equivalent for prescriptions of (1 all brand (i.e., initially patented drugs, (2 all follow-on drugs, or (3 brand and follow-on drugs. To examine the financial spillover effect we calculated a monthly follow-on drug market share in defined daily doses for medications prescribed by hospital physicians but dispensed in community pharmacies, in comparison to drugs prescribed by non-hospital physicians in the community. Estimated "extra costs" over the study period were €15.9 (95% CI 15.5; 16.2 million for scenario 1, €14.4 (95% CI 14.1; 14.7 million for scenario 2, and €30.3 (95% CI 29.8; 30.8 million for scenario 3. The impact of strictly switching all patients using proton-pump inhibitors to esomeprazole at admission resulted in a spillover "extra cost" of €330,300 (95% CI 276,100; 383,800, whereas strictly switching to generic cetirizine resulted in savings of €7,700 (95% CI 4,100; 11,100. Overall we estimated that the RDF resulted in "extra costs" of €503,600 (95% CI 444,500; 563,100. CONCLUSIONS: Evergreening strategies have been successful in maintaining market share in Geneva, offsetting competition by generics and cost containment policies. Hospitals may be contributing to increased

  14. 专利组合价值评估探讨——以药品专利组合为例%Patent Portfolio Evaluation:an Empirical Study Based on Drug Patent

    Institute of Scientific and Technical Information of China (English)

    曹晨; 胡元佳

    2012-01-01

    The paper is to develop an evaluation model of drug patent portfolio based on Lanjouw - Schankerman model and Parchomovsky - Wagner patent portfolio theory by retrieving data of 610 patent from 82 drugs marketed in USA. The paper obtains drug patent portfolio value index by integrating composite index of patent value of single patent; validates by running correlation analysis between sales and PPVI. The result shows that arithmetic separate integration model of CPIV fits patent portfolio evaluation most.%目的:以药品专利组合为例,构建基于Lanjouw-Schankerman专利价值评估模型与Parchomovsky-Wagner专利组合理论的专利组合价值评估模型.方法:以在美国上市的82个药品的610项专利为样本,通过整合单项专利的综合专利价值指数(composite index of patent value,CIPV),进而构成专利组合价值指数(patent portfolio value index,PPVI),并与对应药品的销售额进行相关分析采检验其显著度水平.结果:CIPV值算术平均数分块加和模型最适用于专利组合价值的评估.

  15. IN CIPRO WE TRUST: BUT HOW DO WE FEEL ABOUT OUR DRUG PATENT LAWS? (2002 Third Year Paper)

    OpenAIRE

    Bassan, Daniela

    2002-01-01

    In many ways, the terrorist attacks of September 11, 2001, crystallized national debate over drug patents both in Canada and the United States. This became clear when, at the height of the anthrax attacks in October, NBC's Tom Brokaw paid the following homage to the top anti-anthrax drug: In Cipro we trust. On the one hand, the public was eternally grateful for the research and development that led to the patented, life-saving CIPRO. On the other, the Canadian and United States governments i...

  16. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.

    Directory of Open Access Journals (Sweden)

    Amy S Nunn

    2007-11-01

    Full Text Available BACKGROUND: Little is known about the long-term drug costs associated with treating AIDS in developing countries. Brazil's AIDS treatment program has been cited widely as the developing world's largest and most successful AIDS treatment program. The program guarantees free access to highly active antiretroviral therapy (HAART for all people living with HIV/AIDS in need of treatment. Brazil produces non-patented generic antiretroviral drugs (ARVs, procures many patented ARVs with negotiated price reductions, and recently issued a compulsory license to import one patented ARV. In this study, we investigate the drivers of recent ARV cost trends in Brazil through analysis of drug-specific prices and expenditures between 2001 and 2005. METHODS AND FINDINGS: We compared Brazil's ARV prices to those in other low- and middle-income countries. We analyzed trends in drug expenditures for HAART in Brazil from 2001 to 2005 on the basis of cost data disaggregated by each ARV purchased by the Brazilian program. We decomposed the overall changes in expenditures to compare the relative impacts of changes in drug prices and drug purchase quantities. We also estimated the excess costs attributable to the difference between prices for generics in Brazil and the lowest global prices for these drugs. Finally, we estimated the savings attributable to Brazil's reduced prices for patented drugs. Negotiated drug prices in Brazil are lowest for patented ARVs for which generic competition is emerging. In recent years, the prices for efavirenz and lopinavir-ritonavir (lopinavir/r have been lower in Brazil than in other middle-income countries. In contrast, the price of tenofovir is US$200 higher per patient per year than that reported in other middle-income countries. Despite precipitous price declines for four patented ARVs, total Brazilian drug expenditures doubled, to reach US$414 million in 2005. We find that the major driver of cost increases was increased purchase

  17. The ARV roll out and the disability grant: a South African dilemma?

    Directory of Open Access Journals (Sweden)

    de Paoli Marina

    2012-02-01

    Full Text Available Abstract Background Prior to the antiretroviral (ARV drug roll out in 2004, people living with HIV (PLHIV in South Africa received disability grants when they were defined as "AIDS-sick". In the absence of available and effective medication, a diagnosis of AIDS portended disability. The disability grant is a critical component of South Africa's social security system, and plays an important role in addressing poverty among PLHIV. Given the prevalence of unemployment and poverty, disability grants ensure access to essential resources, like food, for PLHIV. Following the ARV roll out in South Africa, PLHIV experienced improved health that, in turn, affected their grant eligibility. Our aim is to explore whether PLHIV reduced or stopped treatment to remain eligible for the disability grant from the perspectives of both PLHIV and their doctors. Methods A mixed-methods design with concurrent triangulation was applied. We conducted: (1 in-depth semi-structured interviews with 29 PLHIV; (2 in-depth semi-structured interviews with eight medical doctors working in the public sector throughout the Cape Peninsula; (3 three focus group discussions with programme managers, stakeholders and community workers; and (4 a panel survey of 216 PLHIV receiving ARVs. Results Unemployment and poverty were the primary concerns for PLHIV and the disability grant was viewed as a temporary way out of this vicious cycle. Although loss of the disability grant significantly affected the well-being of PLHIV, they did not discontinue ARVs. However, in a number of subtle ways, PLHIV "tipped the scales" to lower the CD4 count without stopping ARVs completely. Grant criteria were deemed ad hoc, and doctors struggled to balance economic and physical welfare when assessing eligibility. Conclusions It is crucial to provide sustainable economic support in conjunction with ARVs in order to make "positive living" a reality for PLHIV. A chronic illness grant, a basic income grant or an

  18. Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064.

    Directory of Open Access Journals (Sweden)

    Iris Chen

    Full Text Available Antiretroviral (ARV drug use was analyzed in HIV-uninfected women in an observational cohort study conducted in 10 urban and periurban communities in the United States with high rates of poverty and HIV infection. Plasma samples collected in 2009-2010 were tested for the presence of 16 ARV drugs. ARV drugs were detected in samples from 39 (2% of 1,806 participants: 27/181 (15% in Baltimore, MD and 12/179 (7% in Bronx, NY. The ARV drugs detected included different combinations of non-nucleoside reverse transcriptase inhibitors and protease inhibitors (1-4 drugs/sample. These data were analyzed in the context of self-reported data on ARV drug use. None of the 39 women who had ARV drugs detected reported ARV drug use at any study visit. Further research is needed to evaluate ARV drug use by HIV-uninfected individuals.

  19. MORBILI PADA ANAK DALAM PENGOBATAN ANTI RETRO VIRAL (ARV

    Directory of Open Access Journals (Sweden)

    Surya Dipta Nugraha

    2016-03-01

    Full Text Available MEASLES IN CHILDREN WITH ANTI RETRO VIRAL (ARV ON TREATMENT ABSTRACT Introduction: Morbili is an acute viral infectious disease caused by a virus transmitted morbili. Morbili is a contagious acute viral infectious disease that is characterized by three stages: catarrhal stage, eruption stage and convalence stage. Another name morbili is measles, measles, or rubeola. Morbili caused by a virus that is classified as Family paramyxovirus, the virus genus morbili contained in nasopharyngeal secretions and blood during the prodromal period until 24 hours after the onset of spots. Case: Patient male, 6 years old, Hindu, Balinese tribe, came with complaints of febris since 5 days ago. Febris is not measured with a thermometer. The heat is felt up and down, getting better with medicine. Complaints red spots felt since 1 day ago. Originally discovered red spots appear in the neck area and then to the face and chest. The incidence of rash accompanied by itching and heat. This complaint is accompanied with nosebleeds 1 day ago, cough with sputum since 5 days ago and the red eye from one day ago. Patients feel the first time such complaints. Having a history of antiretroviral use regularly since 1.5 years old. Keywords: rash, morbili, HIV, antiretroviral drugs.

  20. Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: a retrospective claims data study from five local healthcare units in the Lombardy Region of Italy.

    Directory of Open Access Journals (Sweden)

    Giorgio L Colombo

    Full Text Available The scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent generic drugs in clinical practice seems to be limited in Italy as yet.We compared differences in outcomes between off-patent generic drugs and off-patent brand drugs in real clinical practice. The outcomes were: persistence and compliance with therapy, mortality, and other health resources consumption (hospitalizations, specialist examinations, other drugs and total costs. Retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASLs - Aziende Sanitarie Locali in the Lombardy Region of Italy. Data from the five ASLs were aggregated through a meta-analysis, which produced an estimate indicator of the mean or percentage difference between the two groups (branded vs. generic and their respective significance tests. The therapeutic areas and studied drugs were: diabetes: metformin - A10BA02; hypertension: amlodipine - C08CA01; dyslipidemia: simvastatin - C10AA01; psychiatry: sertraline - N06AB06; cardiology: propafenone - C01BC03; osteoporosis: alendronate - M05BA04.The 5 Local Healthcare Units (ASL represent a population of 3,847,004 inhabitants. The selected sample included 347,073 patients, or 9.02% of the total ASL population; 67% of the patients were treated with off-patent brand drugs. The average age was 68 years, with no difference between the two groups. After 34 months of observation, compliance and persistence were in favor to generic drugs in all therapeutic areas and statistically significant in the metformin, amlodipine, simvastatin, and sertraline groups. The clinical outcomes (hospitalizations, mortality, and other health costs show no statistically significant differences between off-patent generic vs. off-patent brand medicines.Off-patent generic drugs appear to be a therapy option of choice in Italy as well, based on clinical outcomes and economic consequences

  1. ION EXCHANGE RESINS: AN APPROACH TOWARDS TASTE MASKING OF BITTER DRUGS AND SUSTAINED RELEASE FORMULATIONS WITH THEIR PATENTS

    Directory of Open Access Journals (Sweden)

    Ajay Bilandi

    2013-08-01

    Full Text Available The purpose of this review is to cover various aspects related with the use of ion exchange resins for taste masking of bitter drugs and for formulating sustained release dosage form. Ion exchange resins are water insoluble cross-linked polymers containing a salt-forming group at repeating positions on the polymer chain and have the ability to exchange counter-ions within aqueous solutions surrounding them. The bitterness of pharmaceutical medicines plays a critical role in patient compliance, as the oral administration of bitter drugs is often hampered by their unpleasant taste which leads to non-compliance and further worsening of diseased condition. One of the popular approaches in the taste masking of bitter drugs is based on IER. For taste masking purpose weak cation exchange or weak anion exchange resins are used, depending on the nature of drug. The drug resin complex is absolutely tasteless with no after taste, and at the same time, its bioavailability is not affected. Sustained release dosage forms are designed to release a drug at a pre determined rate in order to maintain a constant drug concentration for a specific period of time with minimum side effects. The usage of IER during the development of sustained release formulations plays a significant role because of their drug retarding properties. In this review also incorporates various patents related to taste masking and sustained release formulations using IER.

  2. Abortide arv kahaneb Eestis iga aastaga / Rebekka Lotman

    Index Scriptorium Estoniae

    Lotman, Rebekka, 1978-

    2005-01-01

    Vt. ka Zdorovje dlja Vsehh 2005 märts, lk. 6. Kuigi abortide arv väheneb Eestis iga aastaga, tuleb naistearstide hinnangul oodata veel kümmekond aastat, et see langeks sama madalale tasemele nagu Põhjamaades. Lisaks diagramm abortide arvu kohta 1991-2004

  3. Tallinlaste arv kukkus alla 400 000 / Dagne Hanschmidt

    Index Scriptorium Estoniae

    Hanschmidt, Dagne

    2006-01-01

    Ilmunud ka: Postimees : na russkom jazõke 6. märts lk. 8. Rahvastikuregister kõrvaldas elanike nimekirjast kehtiva elamisloata isikud, mille tõttu kahanes Tallinna elanike arv 4766 inimese võrra. 1. märtsi seisuga on pealinlasi kokku 398 753 inimest

  4. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis

    OpenAIRE

    Nathalie Vernaz; Guy Haller; François Girardin; Benedikt Huttner; Christophe Combescure; Pierre Dayer; Daniel Muscionico; Jean-Luc Salomon; Pascal Bonnabry

    2013-01-01

    Editors' Summary Background The development of a new medical drug—from discovery of a new compound to regulatory approval for its use—can take many years and cost millions of dollars. In 1995 the World Trade Organization adopted an international law (Trade-Related Aspects of Intellectual Property Rights—TRIPS) by which pharmaceutical companies can protect their intellectual property through patents. Under TRIPS, pharmaceutical companies are granted exclusive manufacturing rights for up to 20 ...

  5. Valuable Patents

    OpenAIRE

    Allison, John R.; Mark A. Lemley; Moore, Kimberly A.; Trunkey, R. Derek

    2003-01-01

    While the theory of the patent system is premised on the idea that patents will be used to exclude competitors, only a tiny fraction of patents are ever enforced. Legal and economic scholars have theorized as to how to identify valuable patents based on their individual characteristics. In this paper, we present the results of the largest empirical study ever conducted of the patent system. We compare the characteristics of litigated patents to those of issued patents generally, and we find i...

  6. Generic Drugs

    Science.gov (United States)

    ... name drug. A brand- name drug has a patent. When the patent runs out— usually after 10 to 14 years— ... if you do not have drug coverage. Condition Diabetes Heart failure High cholesterol Migraine Brand-name drug ...

  7. Driving a decade of change: HIV/AIDS, patents and access to medicines for all

    Directory of Open Access Journals (Sweden)

    Hoen Ellen 't

    2011-03-01

    Full Text Available Abstract Since 2000, access to antiretroviral drugs to treat HIV infection has dramatically increased to reach more than five million people in developing countries. Essential to this achievement was the dramatic reduction in antiretroviral prices, a result of global political mobilization that cleared the way for competitive production of generic versions of widely patented medicines. Global trade rules agreed upon in 1994 required many developing countries to begin offering patents on medicines for the first time. Government and civil society reaction to expected increases in drug prices precipitated a series of events challenging these rules, culminating in the 2001 World Trade Organization's Doha Declaration on the Agreement on Trade-Related Aspects of Intellectual Property Rights and Public Health. The Declaration affirmed that patent rules should be interpreted and implemented to protect public health and to promote access to medicines for all. Since Doha, more than 60 low- and middle-income countries have procured generic versions of patented medicines on a large scale. Despite these changes, however, a "treatment timebomb" awaits. First, increasing numbers of people need access to newer antiretrovirals, but treatment costs are rising since new ARVs are likely to be more widely patented in developing countries. Second, policy space to produce or import generic versions of patented medicines is shrinking in some developing countries. Third, funding for medicines is falling far short of needs. Expanded use of the existing flexibilities in patent law and new models to address the second wave of the access to medicines crisis are required. One promising new mechanism is the UNITAID-supported Medicines Patent Pool, which seeks to facilitate access to patents to enable competitive generic medicines production and the development of improved products. Such innovative approaches are possible today due to the previous decade of AIDS activism

  8. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.

    Science.gov (United States)

    Hoen, Ellen 't; Berger, Jonathan; Calmy, Alexandra; Moon, Suerie

    2011-01-01

    Since 2000, access to antiretroviral drugs to treat HIV infection has dramatically increased to reach more than five million people in developing countries. Essential to this achievement was the dramatic reduction in antiretroviral prices, a result of global political mobilization that cleared the way for competitive production of generic versions of widely patented medicines.Global trade rules agreed upon in 1994 required many developing countries to begin offering patents on medicines for the first time. Government and civil society reaction to expected increases in drug prices precipitated a series of events challenging these rules, culminating in the 2001 World Trade Organization's Doha Declaration on the Agreement on Trade-Related Aspects of Intellectual Property Rights and Public Health. The Declaration affirmed that patent rules should be interpreted and implemented to protect public health and to promote access to medicines for all. Since Doha, more than 60 low- and middle-income countries have procured generic versions of patented medicines on a large scale.Despite these changes, however, a "treatment timebomb" awaits. First, increasing numbers of people need access to newer antiretrovirals, but treatment costs are rising since new ARVs are likely to be more widely patented in developing countries. Second, policy space to produce or import generic versions of patented medicines is shrinking in some developing countries. Third, funding for medicines is falling far short of needs. Expanded use of the existing flexibilities in patent law and new models to address the second wave of the access to medicines crisis are required.One promising new mechanism is the UNITAID-supported Medicines Patent Pool, which seeks to facilitate access to patents to enable competitive generic medicines production and the development of improved products. Such innovative approaches are possible today due to the previous decade of AIDS activism. However, the Pool is just one of a

  9. Production of antiretroviral drugs in middle- and low-income countries.

    Science.gov (United States)

    Pinheiro, Eloan dos Santos; Brüning, Karin; Macedo, M Fernanda; Siani, Antonio C

    2014-01-01

    This review outlines the main issues concerning the production of antiretroviral (ARV) drugs in middle- and low-income countries and the relevant political, legal and technical requirements for supporting such production. The requirements for efficient local production, including the manufacture of generic and branded products and public demand, have been considered from economic, market and socio-political perspectives. A steady and consistent government policy is crucial to success. Additional crucial factors in establishing local production are adequate infrastructure, qualified human resources in technical and managerial areas, and production-distribution logistics systems. The creation or strengthening of a national drug regulatory agency is a basic requirement. Production of ARVs relies on the structure of the international market for active pharmaceutical ingredients (APIs), which are highly monopolized for inclusion in branded or patented drugs, or are concentrated in a few Asian generic companies. Countries seeking to begin local production must develop strategies to overcome the various barriers. For instance, sub-Saharan African countries may benefit from developing multilateral health agreements with neighbouring countries. Such agreements are recommended and should be complemented by technology transfers, especially for the manufacture of APIs. Achieving a production level that is sustainable in the long term is crucial to maintaining patients' access to ARVs. PMID:25310755

  10. One of These Things Is Not Quite the Same: A Comparison of the Patent Doctrine of Equivalents with Suitability for Filing an Abbreviated New Drug Application

    OpenAIRE

    Halstead, David P.

    2002-01-01

    The doctrine of equivalents as applied to chemical patents is compared to the FDA’s findings of bioequivalence in reviewing suitability petitions for filing Abbreviated New Drug Applications (ANDAs). The doctrine of equivalents provides the greatest flexibility early in the drug-development process, gradually diminishing as the product refinements become increasingly minor. Determinations of bioequivalence, however, exhibit the reverse trend as applied to analogous situatio...

  11. Tööpuudus hiilib kikivarvul Võrumaale / Arved Breidaks

    Index Scriptorium Estoniae

    Breidaks, Arved, 1975-

    2008-01-01

    Võrumaal on töötute arv eelmise aastaga võrreldes tõusma hakanud: mullu suvel maakonnas registreeritud 3,9%-line töötuse määr asendus tänavu juuli lõpus 5,4%-lise töötusega. Lisa: Töötus Võrumaal. Vt. samas: Kuidas iseloomustate olukorda Võrumaa tööjõuturul? Vastavad Martin Arula (AS Toftan), Kaido Mäesalu (AS Suwem), Meelis Munski (AS Semuehitus), Indrek Klampe (OÜ Selista Ehitus), Andres Visanpuu (Võru TÜ)

  12. Can savings induced by off-patent drugs balance the increase of pharmaceutical expense associated with the high ageing rate of the italian population?

    Directory of Open Access Journals (Sweden)

    Pierluigi Russo

    2009-12-01

    Full Text Available

    Background: The predicted ageing rate of the Italian population is one of the highest worldwide and this condition is expected to produce a growing increase in pharmaceutical expenditure. The objective of this study was to assess whether or not off-patent drugs could counterbalance the economic effects generated by the aging of the Italian population in the next ten years.

    Methods: On the basis of the predicted ageing rate of the Italian population for the period 2008-2018, the average annual cumulative increase of pharmaceutical expenditure and potential savings generated by the future loss of patent coverage have been considered in order to identify the year of the Breakeven Point.

    Results: The economic effect induced by the progressive ageing of population produces an average of 0.94% cumulative increase in local pharmaceutical expenditure per year, corresponding to an incremental pharmaceutical expenditure of about € 116 millions per year. A number of 509 brands (103 active substances will lose their patent coverage in the next 10 years. Considering both the present legislation and a level of price reduction, after patent expiration, corresponding to 40%, it is predicted that the Breakeven Point will be achieved at the end of 2011.

    Conclusions: In this study, a long term balance between the predictable increase of pharmaceutical expenditure induced by the ageing of Italian population and savings produced by future off-patent drugs was not established. In order to assure the future sustainability of pharmaceutical expenditure, this study supports the need for the development of new health policy strategies.

  13. Patent protection strategies

    Directory of Open Access Journals (Sweden)

    Himanshu Gupta

    2010-01-01

    Full Text Available It is widely recognized that the pharmaceutical industry faces serious financial challenges. Large numbers of blockbuster drugs are losing patent protection and going generic. The pipeline of new drugs is too sparse to fill the gap and generate a platform for future growth. Moreover, many of the new products are biologics with much narrower target patient populations and comparatively higher prices relative to traditional pharmaceuticals. So now the time has come for pharmaceutical scientists to have a better understanding of patent fundamentals. This need is illustrated by analyses of key scientific and legal issues that arose during recent patent infringement cases involving Prozac, Prilosec, and Buspar. Facing this scenario, the pharmaceutical industry has moved to accelerate drug development process and to adopt at the same time different strategies to extend the life time of the patent monopoly to provide the economic incentives and utilizing it for drug discovery and development. This review covers the need of patent protection and various strategies to extend the patent.

  14. Google Patents: The global patent search engine

    OpenAIRE

    Alireza Noruzi; Mohammadhiwa Abdekhoda

    2014-01-01

    Google Patents (www.google.com/patents) includes over 8 million full-text patents. Google Patents works in the same way as the Google search engine. Google Patents is the global patent search engine that lets users search through patents from the USPTO (United States Patent and Trademark Office), EPO (European Patent Office), etc. This study begins with an overview of how to use Google Patent and identifies advanced search techniques not well-documented by Google Patent. It makes several sug...

  15. Patent foramen ovale

    Science.gov (United States)

    ... Drugs & Supplements Videos & Tools About MedlinePlus Show Search Search MedlinePlus GO GO About MedlinePlus Site Map FAQs Contact Us Health Topics Drugs & Supplements Videos & Tools Español You Are Here: Home → Medical Encyclopedia → Patent foramen ovale URL of this page: //medlineplus.gov/ ...

  16. Patent ductus arteriosus

    Science.gov (United States)

    ... Drugs & Supplements Videos & Tools About MedlinePlus Show Search Search MedlinePlus GO GO About MedlinePlus Site Map FAQs Contact Us Health Topics Drugs & Supplements Videos & Tools Español You Are Here: Home → Medical Encyclopedia → Patent ductus arteriosus URL of this page: //medlineplus.gov/ ...

  17. Patent urachus repair

    Science.gov (United States)

    ... Drugs & Supplements Videos & Tools About MedlinePlus Show Search Search MedlinePlus GO GO About MedlinePlus Site Map FAQs Contact Us Health Topics Drugs & Supplements Videos & Tools Español You Are Here: Home → Medical Encyclopedia → Patent urachus repair URL of this page: //medlineplus.gov/ ...

  18. Patent urachus repair - slideshow

    Science.gov (United States)

    ... Drugs & Supplements Videos & Tools About MedlinePlus Show Search Search MedlinePlus GO GO About MedlinePlus Site Map FAQs Contact Us Health Topics Drugs & Supplements Videos & Tools Español You Are Here: Home → Medical Encyclopedia → Patent urachus repair - series—Normal anatomy URL of this ...

  19. Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni.

    Science.gov (United States)

    El-Moslemany, Riham M; Eissa, Maha M; Ramadan, Alyaa A; El-Khordagui, Labiba K; El-Azzouni, Mervat Z

    2016-07-01

    A dual drug repurposing/nanotechnological approach was used to develop an alternative oral treatment for schistosomiasis mansoni using miltefosine (MFS), an anticancer alkylphosphocholine, and lipid nanocapsules (LNCs) as oral nanovectors. We demonstrated earlier that MFS possesses significant activity against different developmental stages of Schistosoma mansoni in the mouse model using 5 successive 20mg/kg/day oral doses. Moreover, an effective single dose (20mg/kg) oral treatment against the adult stage of S. mansoni in mice was developed using LNCs, particularly modified with CTAB, a positive charge imparting agent (MFS-LNC-CTAB(+)), or oleic acid as membrane permeabilizer (MFS-LNC-OA). Efficacy enhancement involved, at least in part, targeting of the worm tegument with MFS-LNCs as a new therapeutic entity. As the tegument surface charge and composition may differ in pre-patent stages of the parasite, it was of importance in the present study to assess the efficacy of a single oral dose of the two MFS-LNC formulations against invasive and immature stages for potential advantage relative to praziquantel. Results indicated potent schistosomicidal effects against both invasive and immature stages of S. mansoni in infected mice, efficacy being both formulation and developmental stage dependent. This was indicated by the significant reduction in the total worm burden of the invasive stage by 91.6% and 76.8% and the immature stage by 82.7% and 96.7% for MFS-LNC-CTAB+ and MFS-LNC-OA, respectively. Histopathological findings indicated amelioration of hepatic pathology with regression of the granulomatous inflammatory reaction and reduction in granulomas number and size, verifying marked improvement in architecture of hepatic lobules. From a clinical perspective, MFS-LNCs offer potential as an alternative single oral dose nanomedicine with a wide therapeutic profile for the mass chemotherapy of schistosomiasis mansoni. PMID:27039667

  20. Software Patents

    OpenAIRE

    Hellstadius, Åsa

    2010-01-01

    The purpose of this chapter is to give an overview of the main issues in regard to software patenting in the 21st century. The focus is on the question of patentability of software, since this is the area which has caused the most problems for patent offices and courts. The main systems of concern are the European and U.S. patent systems. The chapter begins with a presentation of the concept of software in section 2, followed by section 3 with a presentation of IP and patents and the internat...

  1. Decoding Patent Information Using Patent Maps

    OpenAIRE

    Liu, Chen-Yuan; Yang, James Chingyu

    2008-01-01

    Patent information is a derivative product from the legal patent system. This information, which includes patent applications, patent descriptions, patent gazettes, patent abstracts, and patent data, is prepared in exact compliance with the regulations and specifications of the patent acts. Patent information, different from other published circulating information, is legally well protected. For convenience, this study classifies patent information into bibliographic and numeric data to creat...

  2. 75 FR 34749 - Determination of Regulatory Review Period for Purposes of Patent Extension; BYSTOLIC; U.S. Patent...

    Science.gov (United States)

    2010-06-18

    ... Patent Extension; BYSTOLIC; U.S. Patent Nos. 5,759,580 and 6,545,040 AGENCY: Food and Drug Administration... has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug...

  3. Google Patents: The global patent search engine

    Directory of Open Access Journals (Sweden)

    Alireza Noruzi

    2014-06-01

    Full Text Available Google Patents (www.google.com/patents includes over 8 million full-text patents. Google Patents works in the same way as the Google search engine. Google Patents is the global patent search engine that lets users search through patents from the USPTO (United States Patent and Trademark Office, EPO (European Patent Office, etc. This study begins with an overview of how to use Google Patent and identifies advanced search techniques not well-documented by Google Patent. It makes several suggestions for improving Google Patents. This study also compares the citation counts provided by Google Patents for journals in the field of library and information science (LIS. Finally, it concludes that Google Patents provides a free alternative or complement to other patent databases. It also addressed the advantages of Google Patents, for example, easy-use search interface and fast search engine; convenient access to patent images in PDF format; and fast downloads of PDF patent documents.

  4. Quality patents.

    Science.gov (United States)

    Sinclair, K

    1994-01-01

    Watermark Patent and Trademark Attorneys has recently been accepted by the Council of National Association of Testing Authorities, Australia as operating a Quality Management System that complies with the requirements of AS3901/ISO9001 for the creation and servicing of Australian and overseas patents, trademarks and designs and provision of related advice. It is believed that Watermark is the first firm of Patent Attorneys in the world to achieve this. PMID:7765675

  5. Chasing Patents

    OpenAIRE

    Menezes, Flavio Marques; Pitchford, Rohan

    2002-01-01

    We examine the problem faced by a company that wishes to purchase patents in the hands of two di¤erent patent owners. Complementarity of these patents in the production process of the company is a prime e¢ciency reason for them being owned (or licenced) by the company. We show that this very same complementarity can lead to patent owners behaving strategically in bargaining, and delaying their sale to the company. When the company is highly leveraged, such ine¢cient delay is limited. Comparat...

  6. Arv1 promotes cell division by recruiting IQGAP1 and myosin to the cleavage furrow.

    Science.gov (United States)

    Sundvold, Hilde; Sundvold-Gjerstad, Vibeke; Malerød-Fjeld, Helle; Haglund, Kaisa; Stenmark, Harald; Malerød, Lene

    2016-03-01

    Cell division is strictly regulated by a diversity of proteins and lipids to ensure proper duplication and segregation of genetic material and organelles. Here we report a novel role of the putative lipid transporter ACAT-related protein required for viability 1 (Arv1) during telophase. We observed that the subcellular localization of Arv1 changes according to cell cycle progression and that Arv1 is recruited to the cleavage furrow in early telophase by epithelial protein lost in neoplasm (EPLIN). At the cleavage furrow Arv1 recruits myosin heavy chain 9 (MYH9) and myosin light chain 9 (MYL9) by interacting with IQ-motif-containing GTPase-activating protein (IQGAP1). Consequently the lack of Arv1 delayed telophase-progression, and a strongly increased incidence of furrow regression and formation of multinuclear cells was observed both in human cells in culture and in follicle epithelial cells of egg chambers of Drosophila melanogaster in vivo. Interestingly, the cholesterol-status at the cleavage furrow did not affect the recruitment of either IQGAP1, MYH9 or MYL. These results identify a novel function for Arv1 in regulation of cell division through promotion of the contractile actomyosin ring, which is independent of its lipid transporter activity. PMID:27104745

  7. Evaluating Patent Rights With Possible Patent Litigation

    OpenAIRE

    Deng Yi

    2012-01-01

    This paper examines how possible patent infringement and litigation may affect patent holders’ renewal decisions as well as our evaluation of underlying patent value. We utilize the renewal records of the EPO (European Patent Office) patents and estimate a stochastic patent renewal model in which patent holders face possible infringement and litigation costs. Estimation results indicate that when such possibilities exist, patent holders’ renewal behavior will change substantially, and our est...

  8. Geopolitical and cultural factors affecting ARV adherence on the US-Mexico border.

    Science.gov (United States)

    Shedlin, Michele G; Decena, Carlos Ulises; Beltran, Oscar

    2013-10-01

    The data discussed represent the findings from a study by the NIH-funded Hispanic Health Disparities Research Center, exploring the influence of institutional and psychosocial factors on adherence to antiretroviral medications by Mexican-origin persons living with AIDS on the US-Mexico Border. A qualitative approach was utilized consisting of clinic observations, baseline and follow-up interviews with patients (N = 113), key informant interviews (N = 9) and focus groups (5) with patients and health providers. Findings include the social-normative, institutional and geo-political factors affecting treatment and service delivery as well as individual variation and culturally patterned behaviors. ARV adherence and retention were found to depend on complex interactions and negotiation of co-occurring factors including the experience of medications and side-effects, patient/provider relationships, cultural norms and the changing dynamics of international borders. We note effects of drug-related violence which created border-crossing obstacles influencing mobility, access to services and adherence. PMID:22797951

  9. Patent protection strategies

    OpenAIRE

    Himanshu Gupta; Suresh Kumar; Saroj Kumar Roy; Gaud, R. S.

    2010-01-01

    It is widely recognized that the pharmaceutical industry faces serious financial challenges. Large numbers of blockbuster drugs are losing patent protection and going generic. The pipeline of new drugs is too sparse to fill the gap and generate a platform for future growth. Moreover, many of the new products are biologics with much narrower target patient populations and comparatively higher prices relative to traditional pharmaceuticals. So now the time has come for pharmaceutical scientists...

  10. 专利的公共政策--以印度首个专利强制许可案为例%Public Policy in Patent Regime:Citing the First Compulsory Licensing Case on Patented Drug in India

    Institute of Scientific and Technical Information of China (English)

    易继明

    2014-01-01

    2013年德国拜耳公司诉印度拿特科公司一案中,印度知识产权上诉委员会维持了授权拿特科公司的药品强制许可。这是印度首个专利强制许可案,对发展中国家有导向性作用,也将对欧美大型药剂企业的知识产权战略产生巨大影响。本世纪初建立在《多哈健康宣言》《总理事会决议》以及《修订TRIPS协议议定书》基础上的药品强制许可机制,让发展中国家和最不发达国家的民众能够负担起必要的基础药品,一定程度上缓解了这些国家某些公共健康危机。不过,机制建立至今,实际案例还是屈指可数。中国专利法上虽有这一制度,但却从未利用这一公共政策工具颁发过一例强制许可。在财产性权利和生命健康权利发生根本性冲突时,作为一种公共政策工具,专利强制许可可以在医药市场上加以运用。%The pharmaceutical case Natco v .Bayer in early 2013 , has ended with a first-time compulsory license of a patented drug being granted by the Indian Intellectual Property Appellate Board .As the very first compulsory license ever to be granted , this particular decision will exert its guiding effects on other developing nations, whilst substantially influencing the IP strategies of Euro-American pharmaceutical giants .The com-pulsory licensing mechanism of patented drugs based on the Doha Declaration , the Decision by the WTO Gen-eral Council on the Implementation of Paragraph 6 of The Doha Declaration in 2003 and Amendment of the TRIPS Agreement , has enabled developing nations and least developed nations to afford essential drugs , which in turn has alleviated certain public health crisis in these areas .However , actual cases of compulsory licenses have been rare since the establishment of the said mechanism .Such dilemma also troubles Chinese patent re-gime as the public policy doctrine has not been practically maneuvered despite its existence

  11. Patent Analysis with Innovative Patent Map System

    OpenAIRE

    Rain Chen; Chao-Chun Chen; Bei-Bei Yau

    2013-01-01

    Among the research on patents, the applications of Patent Map to Patent Analysis have been gradually emphasized. For three years, the researchers have applied Patent Map Theory Model to establishing Patent Map System (PMS) assisting decision-makers in Patent Analysis. Based on the system requirements, relevant function components are planned, and UML technology is utilized for the design and establishment of Patent Map Database. In the actual case study on non-glue rubber mat design, the rese...

  12. Patent office governance and patent system quality

    OpenAIRE

    Picard, Pierre; van Pottelsberghe de la Potterie, Bruno

    2011-01-01

    The present paper discusses the role of quality in patent systems from the perspective of patent offices' behavior and organization. After documenting original stylized facts, the paper presents a model in which patent offices set patent fees and the quality level of their examination processes. Various objectives of patent offices' governors are considered. We show that the quality of the patent system is maximal for the patent offices that maximises either the social welfare or its own prof...

  13. Patent Office Governance and Patent System Quality

    OpenAIRE

    Picard, Pierre; Pottelsberghe de la Potterie, Bruno van

    2011-01-01

    The present paper discusses the role of quality in patent systems from the perspective of patent offices' behavior and organization. After documenting original stylized facts, the paper presents a model in which patent offices set patent fees and the quality level of their examination processes. Various objectives of patent offices' governors are considered. We show that the quality of the patent system is maximal for the patent offices that maximises either the social welfare or its own prof...

  14. Extending the market exclusivity of therapeutic antibodies through dosage patents.

    Science.gov (United States)

    Storz, Ulrich

    2016-07-01

    Dosage patents are one way to extend the market exclusivity of an approved drug beyond the lifetime of the patent that protects the drug as such. Dosage patents may help to compensate the applicant for the long period where the active pharmaceutical ingredient as such is already under patent prosecution, but not on the market yet, due to lengthy development and approval procedures. This situation erodes part of the time the drug is marketed under patent protection. Dosage patents filed at a later date can provide remedy for this problem. Examples of successful and unsuccesful attempts, and the reasons for the respective outcomes, are provided in this article. PMID:27115842

  15. Determinants of adherence to antiretroviral drugs among people living with HIV/AIDS in the Ife-Ijesa zone of Osun state, Nigeria

    OpenAIRE

    Afolabi, Muhammed O; Kayode T. Ijadunola; Fatusi, Adesegun O.; Olasode, Olayinka A.

    2009-01-01

    Background: The advent of antiretroviral (ARV) drugs has transformed HIV/AIDS into a chronic manageable disease and strict adherence is required for the medication to be effective. However, factors influencing adherence to ARV therapy (ART) vary from country to country.Method: 120 subjects who received ARV drugs at a federal government-designated ART site located within the Obafemi Awolowo University Teaching Hospital complex, (OAUTHC), Ile-Ife, and a community-based non-governmental organisa...

  16. The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good.

    Science.gov (United States)

    Bermudez, Jorge; 't Hoen, Ellen

    2010-01-01

    Developing and delivering appropriate, affordable, well-adapted medicines for HIV/AIDS remains an urgent challenge: as first-line therapies fail, increasing numbers of people require costly second-line therapy; one-third of ARVs are not available in pediatric formulations; and certain key first- and second-line triple fixed-dose combinations do not exist or sufficient suppliers are lacking. UNITAID aims to help solve these problems through an innovative initiative for the collective management of intellectual property (IP) rights - a patent pool for HIV medicines. The idea behind a patent pool is that patent holders - companies, governments, researchers or universities - voluntarily offer, under certain conditions, the IP related to their inventions to the patent pool. Any company that wants to use the IP to produce or develop medicines can seek a license from the pool against the payment of royalties, and may then produce the medicines for use in developing countries (conditional upon meeting agreed quality standards). The patent pool will be a voluntary mechanism, meaning its success will largely depend on the willingness of pharmaceutical companies to participate and commit their IP to the pool. Generic producers must also be willing to cooperate. The pool has the potential to provide benefits to all. PMID:20309404

  17. Recent patents and patented technology platforms for pharmaceutical taste masking.

    Science.gov (United States)

    Kaushik, Deepak; Dureja, Harish

    2014-04-01

    Taste masking is an important factor in the development of oral dosage forms containing bitter active pharmaceutical ingredients. Currently numerous techniques are being applied to overcome this problem. Realizing this, several researchers and pharmaceutical companies are now engaged in developing novel techniques to address the problem of taste masking evident by numerous patents filed in this area in recent times. In this review the most recent patents for taste masking are discussed and how these patents overcome the limitations of conventional approaches of taste masking is also highlighted. Novel techniques based on some recent patents such as nanohybrid, melt extrusion, non-complex cyclodextrin compositions and off taste masking are providing new realms to taste masking of bitter drugs. The present article also provides an overview of various patented platform technologies based on different techniques/mechanisms employed for taste masking. The unique features and principles of taste-masking approaches used in various patented technologies are also discussed. A better understanding of these new patents and patented technologies will help researchers and pharmaceutical industries to select the appropriate platform, or to develop innovative products with improved taste masking properties. PMID:24499438

  18. Mentaliseringsbegrebet og dets arv fra Freuds begreb om binding

    DEFF Research Database (Denmark)

    Pedersen, Signe Holm

    2011-01-01

    Artiklen undersøger og diskuterer forskelle og ligheder mellem mentaliseringsbegrebet og Freuds bindingsbegreb. Begrebet mentalisering, som betegner en evne til at forholde sig refleksivt til egne og andres mentale tilstande, har indenfor de sidste fem- ti år vundet en central placering i klinisk...... psykologiske teoridannelser. Dets ophavsmænd Fonagy et al. forsøger imidlertid ikke at tage patent på begrebet, men peger på, at en række teoretikere har understreget betydningen af en refleksiv funktion. Alle disse begreber kan ifølge Fonagygruppen føres tilbage til Freuds begreb om binding. På baggrund af en...... udlægning af det oprindelige bindingsbegreb hos Freud, ønskes det i denne artikel at tydeliggøre den grundlæggende forskel på Freuds – og Fonagys subjektopfattelse....

  19. Patenting in Biotechnology

    Directory of Open Access Journals (Sweden)

    Sujit Bhattacharya

    2007-11-01

    Full Text Available The paper discusses the patentability of the biotechnological inventions and the international requirements and issues that emerge in addressing patenting of life forms and how they are resolved. It analyses the international patenting trends, patents that have significant impact and countries active in patenting. It also examines Indian patenting activity and its comparison with international trends to assess the Indian efforts.

  20. Spectroscopic classification of Gaia16arv as Type Ia supernova with the SEDM

    Science.gov (United States)

    Blagorodnova, N.; Neill, D.; Walters, R.

    2016-07-01

    The Caltech Time Domain Astronomy group reports the classification of Gaia16arv, discovered by the Gaia ESA survey. This transient was also reported by MASTER as OT J220727.43-053121.8, with discovery date 2016-06-16.09813 UT (Atel #9161).

  1. Tööõnnetuste arv Ida-Virus väheneb / Erika Prave

    Index Scriptorium Estoniae

    Prave, Erika, 1970-

    2004-01-01

    Ilmunud ka: Severnoje Poberezhje, 7. dets. 2004, lk. 3. Tööinspektsiooni viimase üheksa aasta statistikast järeldub, et tööõnnetuste arv on Ida-Virumaal aastatega vähenenud peaaegu poole võrra

  2. Püsiühenduste arv kasvas aastaga poole võrra / Tõnu Vare

    Index Scriptorium Estoniae

    Vare, Tõnu, 1947-

    2005-01-01

    Uuringufirma Point Topic andmetel oli 30. septembri 2004. a. seisuga Interneti püsiühenduste arv maailmas 136,4 miljonit. Diagrammid: Püsiühendustega leibkondade osakaal (%) Euroopas; 512 Kb/s allalaadimiskiirusega püsiühenduse kuutasu (eurodes)

  3. Paying for On-Patent Pharmaceuticals

    OpenAIRE

    Fuller, Richard L.; Goldfield, Norbert

    2016-01-01

    In this article we propose a new approach to pricing for patent-protected (on-patent) pharmaceuticals. We describe and define limit pricing as a method for drug companies to maximize revenue for their investment by offering budget-neutral pricing to encourage early adoption by payers. Under this approach, payers are incentivized to adopt innovative but expensive drugs more quickly if drug companies provide detailed analyses of the net impact of the new pharmaceutical upon total health budgets...

  4. Utilization Analysis of Traditional Patent Chinese Drugs in 116 Cases of Chronic Osteomyelitis%116例慢性骨髓炎患者中成药应用情况分析

    Institute of Scientific and Technical Information of China (English)

    雷凯君

    2011-01-01

    Objective To evaluate the utilization status of traditional patent Chinese drugs in chronic osteomyelitis patients in our hospital.Methods The orthopedic use status of traditional patent Chinese drugs with chronic osteomyelitis in our hospital during January to December 2009 was analyzed retrospectively and statistically. Results Among all patients in this study, the use rale of traditional patent Chinese drugs was 100%.Conclusion The utilization of traditional Chinese drugs in our hospital as TCM hospital is reasonable. But some problems such as inappropriate us and too long duration of administration exist, which should be further standardized.%目的 评价医院骨科慢性骨髓炎患者中成药应用情况.方法 回顾性调查2009年1月至2009年12月骨科慢性骨髓炎患者中成药应用资料.结果 中成药使用率为100%.结论 中成药使用情况较合理,但仍存在用药不当、用药时间长等问题,需进一步规范.

  5. ION EXCHANGE RESINS: AN APPROACH TOWARDS TASTE MASKING OF BITTER DRUGS AND SUSTAINED RELEASE FORMULATIONS WITH THEIR PATENTS

    OpenAIRE

    Ajay Bilandi; Amiya Kanta Mishra

    2013-01-01

    The purpose of this review is to cover various aspects related with the use of ion exchange resins for taste masking of bitter drugs and for formulating sustained release dosage form. Ion exchange resins are water insoluble cross-linked polymers containing a salt-forming group at repeating positions on the polymer chain and have the ability to exchange counter-ions within aqueous solutions surrounding them. The bitterness of pharmaceutical medicines plays a critical role in patient compliance...

  6. Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies

    Science.gov (United States)

    Ma, Yafeng; Luk, Alison; Young, Francis P.; Lynch, David; Chua, Wei; Balakrishnar, Bavanthi; de Souza, Paul; Becker, Therese M.

    2016-01-01

    Androgen receptor splice variant V7 (AR-V7) was recently identified as a valuable predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs): We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform with droplet digital polymerase chain reaction (ddPCR) to analyze total AR and AR-V7 expression from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection of AR-V7 in CTC samples from advanced prostate cancer (PCa) patients with AR-V7 detection limited to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor cells (CTCs) or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such as AR-V7 from non-invasive blood samples, so-called blood biopsies. PMID:27527157

  7. Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7 Detection from Prostate Cancer Patient Blood Biopsies

    Directory of Open Access Journals (Sweden)

    Yafeng Ma

    2016-08-01

    Full Text Available Androgen receptor splice variant V7 (AR-V7 was recently identified as a valuable predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs: We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform with droplet digital polymerase chain reaction (ddPCR to analyze total AR and AR-V7 expression from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection of AR-V7 in CTC samples from advanced prostate cancer (PCa patients with AR-V7 detection limited to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor cells (CTCs or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such as AR-V7 from non-invasive blood samples, so-called blood biopsies.

  8. Clinical application of common oral Chinese patent drugs for the treatment of hand-foot-mouth disease%治疗手足口病的常用口服中成药制剂

    Institute of Scientific and Technical Information of China (English)

    孟现民; 申理; 张永信; 董平

    2014-01-01

    手足口病近年来在国内时有流行报告,而临床经验证明传统中医药治疗手足口病有显著疗效。为了充分继承和发挥祖国传统中医药的优势、丰富医学理论建设以及为中成药制剂治疗手足口病的临床实践提供参考,本文就用于治疗手足口病的常用口服中成药制剂及临床研究数据作一总结和介绍。%There are several reports about hand-foot-mouth disease being epidemic in China recent years. It has been conifrmed in clinic that traditional Chinese medicine is of signiifcant beneift to the diagnosis and treatment of hand-foot-mouth disease, and many articles on Chinese patent drugs for hand-foot-mouth disease have been published. In order to fully inherit and promote the advantages of traditional Chinese medicine, enrich its medical theory and provide a reference for the clinical practice of Chinese patent drugs for the treatment of hand-foot-mouth disease, we summarize some clinical results from articles on common oral preparations of Chinese patent drugs that are effective for hand-foot-mouth disease in this review.

  9. Patent Quality and Pro-patent Policy

    OpenAIRE

    Koki Arai

    2010-01-01

    This paper analyzes the patent examination and litigation process in terms of a simple Perfect Bayesian Equilibrium model, and interprets the results in line with real pro-patent trends in the US and other countries. Each country’s pro-patent policy option is different from the other because of reflecting its own path-dependent patent situation. That is, when a country adopts an easy patent policy (a pro-patent policy), firms in the country gain larger payoffs in the short term. Hence, every ...

  10. Are patents impeding medical care and innovation?

    Directory of Open Access Journals (Sweden)

    E Richard Gold

    2010-01-01

    Full Text Available BACKGROUND TO THE DEBATE: Pharmaceutical and medical device manufacturers argue that the current patent system is crucial for stimulating research and development (R&D, leading to new products that improve medical care. The financial return on their investments that is afforded by patent protection, they claim, is an incentive toward innovation and reinvestment into further R&D. But this view has been challenged in recent years. Many commentators argue that patents are stifling biomedical research, for example by preventing researchers from accessing patented materials or methods they need for their studies. Patents have also been blamed for impeding medical care by raising prices of essential medicines, such as antiretroviral drugs, in poor countries. This debate examines whether and how patents are impeding health care and innovation.

  11. Swiss Patent Jurisprudence 2012

    OpenAIRE

    Rigamonti, Cyrill

    2013-01-01

    The new Swiss Federal Patent Court, with nationwide first-instance jurisdiction over all civil patent matters, has been operating since 1 January 2012. This article reviews and contextualizes the most important patent cases the Swiss Federal Patent Court and the Swiss Federal Supreme Court. It concludes that the revamped Swiss patent litigation system has the potential of turning Switzerland into a competitive venue for the adjudication of patent matters in Europe.

  12. Adherence to ARV medication in Romanian young adults: self-reported behaviour and psychological barriers

    OpenAIRE

    Dima, A.L.; Schweitzer, A.M.; Diaconiţă, R.; Remor, E.; Wanless, R.S.

    2012-01-01

    Adherence to antiretroviral (ARV) treatment during adolescence and young adulthood is a significant clinical issue for the current management of the HIV/AIDS epidemic in Romania. Understanding patients' own perceptions of their adherence behaviours and related psychological barriers is instrumental for developing robust interventions, and developing psychometrically sound instruments is essential for measuring adherence in this population. We adapted to Romanian an internationally validated q...

  13. How patent experts create patent breadth

    DEFF Research Database (Denmark)

    Beukel, Karin

    Science as an input to patented inventions is a fundamental of economic growth. However, our understanding of how science is transformed into patents is limited. In the present paper I seek to fill this gap by examining the micro-foundations of science-patent transformations. Using an inductive......, grounded theory approach to study the transformation of 12 scientific discoveries into patents I recast the relationship between science and patents: I show it as a particular process that affects patent breadth. Exploiting surplus patent breadth depends on the processes of abstraction and cognitive...... variety, which can be mobilized by patenting experts. The theory is tested using a recently published algebraic interpretive method for examining causal relationships in small-N studies....

  14. How patent experts create patent breadth

    DEFF Research Database (Denmark)

    Beukel, Karin

    2014-01-01

    Science as an input to patented inventions is a fundamental of economic growth. However, our understanding of how science is transformed into patents is limited. In the present paper I seek to fill this gap by examining the micro-foundations of science-patent transformations. Using an inductive......, grounded theory approach to study the transformation of 12 scientific discoveries into patents I recast the relationship between science and patents: I show it as a particular process that affects patent breadth. Exploiting surplus patent breadth depends on the processes of abstraction and cognitive...... variety, which can be mobilized by patenting experts. The theory is tested using a recently published algebraic interpretive method for examining causal relationships in small-N studies....

  15. Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study

    OpenAIRE

    Sapsirisavat, Vorapot; Vongsutilers, Vorasit; Thammajaruk, Narukjaporn; Pussadee, Kanitta; Riyaten, Prakit; Kerr, Stephen; Avihingsanon, Anchalee; Phanuphak, Praphan; Ruxrungtham, Kiat; ,

    2016-01-01

    Objectives Ensuring that medicines meet quality standards is mandatory for ensuring safety and efficacy. There have been occasional reports of substandard generic medicines, especially in resource-limiting settings where policies to control quality may be less rigorous. As HIV treatment in Thailand depends mostly on affordable generic antiretrovirals (ARV), we performed quality assurance testing of several generic ARV available from different sources in Thailand and a source from Vietnam. Met...

  16. An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile

    OpenAIRE

    Abud, MJ; Hall, B; Helmers, C

    2015-01-01

    We analyze the patent filing strategies of foreign pharmaceutical companies in Chile distinguishing between “primary” (active ingredient) and “secondary” patents (patents on modified compounds, formulations, dosages, particular medical uses, etc.). There is prior evidence that secondary patents are used by pharmaceutical originator companies in the U.S. and Europe to extend patent protection on drugs in length and breadth. Using a novel dataset that comprises all drugs registered in Chile bet...

  17. Comprehensive quantitative analysis of Chinese patent drug YinHuang drop pill by ultra high-performance liquid chromatography quadrupole time of flight mass spectrometry.

    Science.gov (United States)

    Wong, Tin-Long; An, Ya-Qi; Yan, Bing-Chao; Yue, Rui-Qi; Zhang, Tian-Bo; Ho, Hing-Man; Ren, Tian-Jing; Fung, Hau-Yee; Ma, Dik-Lung; Leung, Chung-Hang; Liu, Zhong-Liang; Pu, Jian-Xin; Han, Quan-Bin; Sun, Han-Dong

    2016-06-01

    YinHuang drop pill (YHDP) is a new preparation, derived from the traditional YinHuang (YH) decoction. Since drop pills are one of the newly developed forms of Chinese patent drugs, not much research has been done regarding the quality and efficacy. This study aims to establish a comprehensive quantitative analysis of the chemical profile of YHDP. ultra high-performance liquid chromatography quadrupole time of flight mass spectrometry (UHPLC-Q-TOF-MS/MS) was used to identify 34 non-sugar small molecules including 15 flavonoids, 9 phenolic acids, 5 saponins, 1 iridoid, and 4 iridoid glycosides in YHDP samples, and 26 of them were quantitatively determined. Sugar composition of YHDP in terms of fructose, glucose and sucrose was examined via a high performance liquid chromatography-evaporative light scattering detector on an amide column (HPLC-NH2P-ELSD). Macromolecules were examined by high performance gel permeation chromatography coupled with ELSD (HPGPC-ELSD). The content of the drop pill's skeleton component PEG-4000 was also quantified via ultra-high performance liquid chromatography coupled with charged aerosol detector (UHPLC-CAD). The results showed that up to 73% (w/w) of YHDP could be quantitatively determined. Small molecules accounted for approximately 5%, PEG-4000 represented 68%, while no sugars or macromolecules were found. Furthermore, YHDP showed no significant differences in terms of daily dosage, compared to YinHuang granules and YinHuang oral liquid; however, it has a higher small molecules content compared to YinHuang lozenge. PMID:27131804

  18. Detection and characterization of two co-infection variant strains of avian orthoreovirus (ARV) in young layer chickens using next-generation sequencing (NGS).

    Science.gov (United States)

    Tang, Yi; Lin, Lin; Sebastian, Aswathy; Lu, Huaguang

    2016-01-01

    Using next-generation sequencing (NGS) for full genomic characterization studies of the newly emerging avian orthoreovirus (ARV) field strains isolated in Pennsylvania poultry, we identified two co-infection ARV variant strains from one ARV isolate obtained from ARV-affected young layer chickens. The de novo assembly of the ARV reads generated 19 contigs of two different ARV variant strains according to 10 genome segments of each ARV strain. The two variants had the same M2 segment. The complete genomes of each of the two variant strains were 23,493 bp in length, and 10 dsRNA segments ranged from 1192 bp (S4) to 3958 bp (L1), encoding 12 viral proteins. Sequence comparison of nucleotide (nt) and amino acid (aa) sequences of all 10 genome segments revealed 58.1-100% and 51.4-100% aa identity between the two variant strains, and 54.3-89.4% and 49.5-98.1% aa identity between the two variants and classic vaccine strains. Phylogenetic analysis revealed a moderate to significant nt sequence divergence between the two variant and ARV reference strains. These findings have demonstrated the first naturally occurring co-infection of two ARV variants in commercial young layer chickens, providing scientific evidence that multiple ARV strains can be simultaneously present in one host species of chickens. PMID:27089943

  19. Patent Assessment Quality

    DEFF Research Database (Denmark)

    Burke, Paul F.; Reitzig, Markus

    2006-01-01

    The increasing number of patent applications worldwide and the extension of patenting to the areas of software and business methods have triggered a debate on "patent quality". While patent quality may have various dimensions, this paper argues that consistency in the decision making on the side of...... the patent office is one important dimension, particularly in new patenting areas (emerging technologies). In order to understand whether patent offices appear capable of providing consistent assessments of a patent's technological quality in such novel industries from the beginning, we study the...... concordance of the European Patent Office's (EPO's) granting and opoposition decisions for individual patents. We use the historical example of biotech patens filed between 1978 until 1986, the early stage of the industry. Our results indicate that the EPO shows systematically different assessments of...

  20. 75 FR 61493 - Agency Information Collection Activities; Proposed Collection; Comment Request; Patent Term...

    Science.gov (United States)

    2010-10-05

    ... review, which diminishes the value of the patent. In enacting the Drug Price Competition and Patent Term... Collection; Comment Request; Patent Term Restoration, Due Diligence Petitions, Filing, Format, and Content of... comment in response to the notice. This notice solicits comments on FDA's patent term...

  1. 75 FR 77878 - Determination of Regulatory Review Period for Purposes of Patent Extension; FREESTYLE NAVIGATOR

    Science.gov (United States)

    2010-12-14

    ... NAVIGATOR (U.S. Patent No. 5,262,035) from Abbott Diabetes Care Inc., and the Patent and Trademark Office... Patent Extension; FREESTYLE NAVIGATOR AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY... of Commerce, for the extension of a patent which claims that medical device. ADDRESSES:...

  2. Patent Information and Search

    OpenAIRE

    Pradeep P. Paranjpe

    2012-01-01

    An important purpose of working of the patent system has been to ensure that the complete details of the inventions sought to be patented pass in the public domain. Governments compensate the inventor for this public disclosure by granting patent. However, access to this information was limited to the ‘on site’availability in the patent offices and a limited number of libraries. Globalisation of economies forced internationalcooperation in the field of patents and this coincided with the adve...

  3. The Advanced Re-Entry Vehicle (ARV) a Development Step from ATV Toward Manned Transportation Systems

    Science.gov (United States)

    Bottacini, M.; Berthe, P.; Vo, X.; Pietsch, K.

    2011-08-01

    The Advanced Re-entry Vehicle (ARV) programme has been undertaken by Europe with the objective to contribute to the preparation of a future European crew transportation system, while providing a valuable logistic support to the ISS through an operational cargo return system. This development would allow: - the early acquisition of critical technologies; - the design, development and testing of elements suitable for the follow up human rated transportation system. These vehicles should also serve future LEO infrastructures and exploration missions. With the aim to satisfy the above objectives a team composed by major European industries and led by EADS Astrium Space Transportation is currently conducting the phase A of the programme under contract with the European Space Agency (ESA). Two vehicle versions are being investigated: a Cargo version, transporting cargo only to/from the ISS, and a Crew version, which will allow the transfer of both crew and cargo to/from the ISS. The ARV Cargo version, in its present configuration, is composed of three modules. The Versatile Service Module (VSM) provides to the system the propulsion/GNC for orbital manoeuvres and attitude control and the orbital power generation. Its propulsion system and GNC shall be robust enough to allow its use for different launch stacks and different LEO missions in the future. The Un-pressurised Cargo Module (UCM) provides the accommodation for about 3000 kg of un-pressurised cargo and is to be sufficiently flexible to ensure the transportation of: - orbital infrastructure components (ORU's); - scientific / technological experiments; - propellant for re-fuelling, re-boost (and deorbiting) of the ISS. The Re-entry Module (RM) provides a pressurized volume to accommodate active/passive cargo (2000 kg upload/1500 kg download). It is conceived as an expendable conical capsule with spherical heat- hield, interfacing with the new docking standard of the ISS, i.e. it carries the IBDM docking system, on a

  4. Social arv, ulighed og dagtilbuds betydning med henblik på mønsterbrydning

    DEFF Research Database (Denmark)

    Jensen, Bente

    2015-01-01

    virkeliggørelse og effekt ved et kombineret metodisk design af et casestudie og et randomiseret, kontrolleret eksperimentstudie.Baggrunden er mange årtiers forskningsmæssige påpegning af, at det ikke er lykkedes at dæmme op for negativ social arv og denne arvs konsekvenser i form af ulige muligheder......). Men også her er der forskellige tilgange til professionel udvikling med forskellige konsekvenser. I et igangværende review af litteraturen om ’Effective Approaches to Professional Development” (Jensen et al., 2015) er identificeret tre trends. En trend drejer sig om at styrke professionel...... kompetenceudvikling gennem korte ’on-the job-training’-kurser. En anden trend lægger vægt på, at professionel udvikling kan styrkes gennem supervision og coaching. En tredje trend lægger vægt på, at det er gennem samarbejde i lærende fællesskaber blandt professionelle, at de største virkninger opnås. Det er denne...

  5. 75 FR 75678 - Determination of Regulatory Review Period for Purposes of Patent Extension; STELARA

    Science.gov (United States)

    2010-12-06

    ..., MD 20993-0002, 301-796-3602. SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L... candidates for phototherapy or systemic therapy. Subsequent to this approval, the Patent and Trademark...

  6. The Software Patent Debate

    OpenAIRE

    Guadamuz, Andres

    2006-01-01

    The paper discusses the proposed European Directive on the Patentability of Computer-Implemented Inventions and the subsequent debate that followed. Do software patents - as argued by policymakers' - result in increased innovation?

  7. A guide of patent map

    International Nuclear Information System (INIS)

    This book introduces application and characteristic of patent information, types of patent information data and research of patent information, arrangement of patent information and patent map, analysis of patent information, necessity, writing period arrangement way of patent map, cases of patent map on selection of task of research and development, system of research and development and application, examples of PM such as MAP by year, application, technique, Inventor, and claim point map and computerization like data arrangement of PM patent, collection of analysis range and item analysis of patent, cases and written reports on patent analysis.

  8. 浅析《国家基本药物目录》中中成药的辨证应用%Application of Chinese Patent Medicine in Essential Drugs List

    Institute of Scientific and Technical Information of China (English)

    郭志军

    2011-01-01

    OBJECTIVE: To explore the application of Chinese patent medicine in National Essential Drugs List.METHODS:The main function and component of 102 kinds of Chinese patent medicine in National Essential Drugs List were analyzed according to the treatment theory based on differentiation of symptom-complex, such as yin-yang, exterior and interior, deficiency and excess, chills and fever, ascending, descending, sinking and floating, channel tropism.RESULTS & CONCLUSION: The application of Chinese patent medicine should be in line with package insert.Dosage and usage and the occurrence of ADR should be paid attention and observed.The philosophical characteristics of treatment theory based on differentiation of symptom-complex can be reflected by identifying yin-yang, exterior and interior, deficiency and excess, chills and fever, ascending, descending, sinking and floating, channel tropism%目的:为辨证应用(2009版)中的中成药提供参考.方法:通过分析102种中成药的功能主治和主要成分,按阴阳、表里、虚实、寒热、升降沉浮、归经等中医药的辨证论治思想进行分析.结果与结论:中医药以辨证论治为诊疗特点,临床应用中成药时,应注意辨析其适应证,严格按照说明书的用法用量使用,并密切观察不良反应的发生.

  9. Faktor-Faktor Yang Berhubungan Dengan Kepatuhan ODHA Dalam Menjalani Terapi ARV Di RSU. dr. Pirngadi Medan Tahun 2012

    OpenAIRE

    Lumbanbatu, Veronica Velisitas

    2013-01-01

    Antiretroviral therapy was a therapy that taken by people living with HIV/AIDS (PLWHA) to increase their life quality. Although it hasn’t been able to cure disease but antiretroviral therapy could suppress viral load and increase CD4 of PLWHA. More of people living with HIV/AIDS who received ARV, hope their life quality be better if ARV was used obediently. Adherence was a patient's behavior to comply with the provisions given by health workers that include discipline and obedi...

  10. Universities That Litigate Patents

    Science.gov (United States)

    Rooksby, Jacob H.

    2012-01-01

    American research universities frequently obtain and license patents to their faculty members' inventions. While university licensing is carefully tracked and thoroughly studied, little is known about university decisions to assertively litigate their patents through filing patent infringement lawsuits in federal court. Which universities…

  11. Digital library for patents

    OpenAIRE

    Chandra, Harish

    2002-01-01

    The present paper discusses the concept of digital library and it’s significance, various motivating factors for digital library application are also highlighted briefly. The uses of patents as a tool for protecting intellectual property rights (IPRs), major patents websites, literature on patents are discussed.

  12. 37 CFR 1.5 - Identification of patent, patent application, or patent-related proceeding.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Identification of patent, patent application, or patent-related proceeding. 1.5 Section 1.5 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN...

  13. Regulation and the circulation of knowledge: penicillin patents in Spain.

    Science.gov (United States)

    Romero de Pablos, Ana

    2011-01-01

    This paper tells the early history of penicillin patenting in Spain. Patents turn out to be useful instruments for analysing the management of knowledge and its circulation in different professional and geographical domains. They protected knowledge while contributing to standardisation. Patents also ensured quality and guaranteed reliability in manufacturing, delivering and prescribing new drugs. They gained special prominence by allowing the creation of a network in which political, economic and business, industrial power, public health and international cooperation fields came together. The main source of information used for this purpose has been the earliest patent applications for penicillin in Spain between 1948 and 1950, which are kept in the Historical Archives of the Oficina Española de Patentes y Marcas. The study of these patents for penicillin shows their role as agents in introducing this drug in Spain. PMID:22332464

  14. Patent Deployment Strategies and Patent Value in LED Industry

    OpenAIRE

    Ming-Fu Wu; Keng-Wei Chang; Wei Zhou; Juan Hao; Chien-Chung Yuan; Ke-Chiun Chang

    2015-01-01

    This study applies two variables in the measurement of company patent deployment strategies: patent family depth and earn plan ratio. Patent family depth represents the degree to which certain fields and markets are valued by the patent owner. Earn plan ratio defined as the ratio of the number of patent forward citations to patent family size. Earn plan ratio indicates the degree to which a patent family could be cited by later innovators and competitors. This study applies a logistic regress...

  15. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004–2011

    OpenAIRE

    Luo, Jing; Oliveira, Maria A; Ramos, Mariana BC; Maia, Aurélio; Osorio-de-Castro, Claudia GS

    2014-01-01

    Background Previous studies have described expenditures for antiretroviral (ARV) medicines in Brazil through 2005. While prior studies examined overall expenditures, they have not have analyzed drug procurement data in order to describe the role of court litigation on access and pricing. Methods ARV drug procurement from private sector sources for the years 2004–2011 was obtained through the general procurement database of the Brazilian Federal Government (SIASG). Procurement was measured in ...

  16. Strategic patenting and software innovation

    OpenAIRE

    Noel, Michael; Schankerman, Mark

    2013-01-01

    Strategic patenting is widely believed to raise the costs of innovating, especially in industries characterised by cumulative innovation. This paper studies the effects of strategic patenting on R&D, patenting and market value in the computer software industry. We focus on two key aspects: patent portfolio size, which affects bargaining power in patent disputes, and the fragmentation of patent rights (‘patent thickets’) which increases the transaction costs of enforcement. We develop a model ...

  17. Invention note and patent note

    International Nuclear Information System (INIS)

    This book deals with origin of invention and term related patent and invention, making idea, brain storming, 10 laws of invention skill, attitude of inventors, invention order, making good inventions, patent system, preparation of application, procedure and method of patent, management of patent, patent and trademark office, patent lawyer, copyright, new intellectual property right, industrial property right, trademark, invasion of industrial property right, patent, Judgment, preparation of items, application of industrial property right and effect of inventor and related people.

  18. Patent Deployment Strategies and Patent Value in LED Industry.

    Directory of Open Access Journals (Sweden)

    Ming-Fu Wu

    Full Text Available This study applies two variables in the measurement of company patent deployment strategies: patent family depth and earn plan ratio. Patent family depth represents the degree to which certain fields and markets are valued by the patent owner. Earn plan ratio defined as the ratio of the number of patent forward citations to patent family size. Earn plan ratio indicates the degree to which a patent family could be cited by later innovators and competitors. This study applies a logistic regression model in the analysis LED industry data. The results demonstrate that patent value has a positive relationship with the patent family depth, and earn plan ratio.

  19. Patent Deployment Strategies and Patent Value in LED Industry.

    Science.gov (United States)

    Wu, Ming-Fu; Chang, Keng-Wei; Zhou, Wei; Hao, Juan; Yuan, Chien-Chung; Chang, Ke-Chiun

    2015-01-01

    This study applies two variables in the measurement of company patent deployment strategies: patent family depth and earn plan ratio. Patent family depth represents the degree to which certain fields and markets are valued by the patent owner. Earn plan ratio defined as the ratio of the number of patent forward citations to patent family size. Earn plan ratio indicates the degree to which a patent family could be cited by later innovators and competitors. This study applies a logistic regression model in the analysis LED industry data. The results demonstrate that patent value has a positive relationship with the patent family depth, and earn plan ratio. PMID:26098313

  20. Software Patents and the EPO: Should software patents be granted under the European patent system?

    OpenAIRE

    Drengur Óla Þorsteinsson 1981

    2009-01-01

    This dissertation discusses the European patent system under the European Patent Convention of 1977 in relation to software patents. Software patents and their granting is a matter of some controversy throughout the world and it is debated whether or not such patents should be granted at all. The central question this dissertation addresses is whether software patents should be granted under the European patent system. For the purpose of answering this question the definitions ...

  1. Modeling HIV/AIDS Drug Price Determinants in Brazil: Is Generic Competition a Myth?

    OpenAIRE

    Constance Meiners; Luis Sagaon-Teyssier; Lia Hasenclever; Jean-Paul Moatti

    2011-01-01

    BACKGROUND: Brazil became the first developing country to guarantee free and universal access to HIV/AIDS treatment, with antiretroviral drugs (ARVs) being delivered to nearly 190,000 patients. The analysis of ARV price evolution and market dynamics in Brazil can help anticipate issues soon to afflict other developing countries, as the 2010 revision of the World Health Organization guidelines shifts demand towards more expensive treatments, and, at the same time, current evolution of internat...

  2. Effects of Hormonal Contraception on Anti-Retroviral Drug Metabolism, Pharmacokinetics and Pharmacodynamics

    OpenAIRE

    THURMAN, Andrea Ries; Anderson, Sharon; Doncel, Gustavo F.

    2014-01-01

    Among women, human immunodeficiency virus type 1 (HIV-1) infection is most prevalent in those of reproductive age. These women are also at risk of unintended or mistimed pregnancies. Hormonal contraceptives (HCs) are one of the most commonly used methods of family planning world-wide. Therefore concurrent use of HC among women on anti-retroviral medications (ARVs) is increasingly common. ARVs are being investigated and have been approved for pre-exposure prophylaxis (PrEP), and therefore drug...

  3. Standard-Essential Patents

    OpenAIRE

    Lerner, Josh; Tirole, Jean

    2013-01-01

    A major policy issue in standard setting is that patents that are ex-ante not that important may, by being included into the standard, become standard-essential patents (SEPs). In an attempt to curb the monopoly power that they create, most standard-setting organizations require the owners of patents covered by the standard to make a loose commitment to grant licenses on reasonable terms. Such commitments unsurprisingly are conducive to intense litigation activity. This paper builds a framewo...

  4. University, Patents and Innovations

    OpenAIRE

    Antonio B. Zaldívar Castro; Lierli Oconnor Montero

    2012-01-01

    The limited relevance of the patents in the Latin American-innovative-culture of the university context is determined by the omission of new inventions within the productive sector, particularly in Cuba. It is easy to offer the methodological resources together with an automated data system of searching and processing through the establishment of an agreement invention-invocation with the use of the statistics of patents, the International Classification of Patent (IPC) and the System of Clas...

  5. Patent Landscape for Nanotechnology

    OpenAIRE

    Alexey Streletskiy; Vladimir Zabavnikov; Emil Aslanov; Dmitriy Kotlov

    2015-01-01

    A methodological approach to patent landscaping for nanotechnology is considered in this paper. In the opinion of the authors, nanotechnologies have precedence over other technology trends that are confirmed by evaluation of the present and future market size of nanotechnology productions. An analysis of patent activity in Russia and the world is performed using patent landscape for nanotechnology as well as for metallurgy in the field of nanotechnology. A new metho...

  6. Patent litigation in Europe

    OpenAIRE

    Cremers, Katrin; Ernicke, Max; Gaessler, Fabian; Harhoff, Dietmar; Helmers, Christian; McDonagh, Luke; Schliessler, Paula; van Zeebroeck, Nicolas

    2016-01-01

    We compare patent litigation cases across four European jurisdictions - Germany, France, the Netherlands, and the UK - covering cases filed during the period 2000-2008. For our analysis, we assemble a new dataset that contains detailed information at the case, litigant, and patent level for patent cases filed at the major courts in the four jurisdictions. We find substantial differences across jurisdictions in terms of case loads. Courts in Germany hear by far the largest number of cases in a...

  7. Transdermal delivery: product and patent update.

    Science.gov (United States)

    Gupta, Himanshu; Babu, R J

    2013-12-01

    Transdermal drug delivery is an attractive alternative to the oral and parenteral drug delivery. Drugs which are prone to first-pass metabolism can be delivered easily in small doses with sustained blood levels through this method. An update to available products along with a review of clinical trials and patents are discussed in this study. In this review, we have compiled 16 drugs, i.e. Buprenorphine, Clonidine, Estradiol, Fentanyl, Granisetron, Lidocaine, Methylphenidate, Nicotine, Nitroglycerin, Oxybutynin, Rivastigmine, Rotigotine, Scopolamine, Selegiline, Testosterone, Influenza virus vaccine (Microneedle) and covering about 22 marketed products on the transdermal system. We present instrumental information on them along with the compilation of current clinical trials on transdermal systems. We summarize the contents of patents granted in last 5 years under different pharmacological categories. This article serves, accordingly as a source of available information focused on transdermal drug delivery research. PMID:24025130

  8. University, Patents and Innovations

    Directory of Open Access Journals (Sweden)

    Antonio B. Zaldívar Castro

    2012-05-01

    Full Text Available The limited relevance of the patents in the Latin American-innovative-culture of the university context is determined by the omission of new inventions within the productive sector, particularly in Cuba. It is easy to offer the methodological resources together with an automated data system of searching and processing through the establishment of an agreement invention-invocation with the use of the statistics of patents, the International Classification of Patent (IPC and the System of Classification of Industrial Activities. This procedure allows the placing of university-sector patents in a given economic sector, making possible their management for innovation.

  9. GM Crops: Patently Wrong?

    OpenAIRE

    Wilson, J.

    2007-01-01

    Abstract This paper focuses on the ethical justifiability of patents on Genetically Modified (GM) crops. I argue that there are three distinguishing features of GM crops that make it unethical to grant patents on GM crops, even if we assume that the patent system is in general justified. The first half of the paper critiques David Resnik’s recent arguments in favor of patents on GM crops. Resnik argues that we should take a consequentialist approach to the issue, and that the best way to do s...

  10. Performance of Patenting Firms

    DEFF Research Database (Denmark)

    Madsen, Erik Strøjer; Smith, Valdemar; Nielsen, Anders Østergaard

    2000-01-01

    Most countries focus on industries with high technology and the governments grant subsidies to innovating firms. However, there has been remarkable few studies of the performance of innovative firms or industries. This study examines the performance of patent active firms compared to the non-patenting...... firms within the manufacturing sector in Denmark. Performance is measured both by growth in employment as well as in the return on equity and profit share in turnover. The results suggest that differences in performance of patenting and non-patenting firms are very small, which questions the political...

  11. Monetary value estimation model for patent and patent application

    OpenAIRE

    Akaslan, Muhammed Fatih

    2011-01-01

    This study aims to contribute to estimating economic value of a patent/patent application for Biotechnology companies. To be able to perform a solid portfolio management of patents and patent applications, it is necessary to obtain an approximate economic value of patent/project in question. In this manner, this study seeks to answer the questions of how the value evolves throughout the filing process, what the value determinants of a patent are and how they affect...

  12. Antiretroviral drug supply challenges in the era of scaling up ART in Malawi.

    Science.gov (United States)

    Schouten, Erik J; Jahn, Andreas; Ben-Smith, Anne; Makombe, Simon D; Harries, Anthony D; Aboagye-Nyame, Francis; Chimbwandira, Frank

    2011-01-01

    The number of people receiving antiretroviral treatment (ART) has increased considerably in recent years and is expected to continue to grow in the coming years. A major challenge is to maintain uninterrupted supplies of antiretroviral (ARV) drugs and prevent stock outs. This article discusses issues around the management of ARVs and prevention of stock outs in Malawi, a low-income country with a high HIV/AIDS burden, and a weak procurement and supply chain management system. This system for ARVs, paid for by the Global Fund to Fight AIDS, Tuberculosis and Malaria, and bypassing the government Central Medical Stores, is in place, using the United Nations Children's Fund's (UNICEF's) procurement services. The system, managed by a handful of people who spend limited time on supply management, is characterized by a centrally coordinated quantification based on verified data from all national ART clinics, parallel procurement through UNICEF, and direct distribution to ART clinics. The model worked well in the first years of the ART programme with a single first-line ARV regimen, but with more regimens becoming available (e.g., alternative first-line, second-line and paediatric regimens), it has become more difficult to administer. Managing supplies through a parallel system has the advantage that weaknesses in the national system have limited influence on the ARV procurement and supply chain management system. However, as the current system operates without a central warehouse and national buffer stock capacity, it diminishes the ability to prevent ARV stock outs. The process of ordering ARVs, from the time that estimates are made to the arrival of supplies in health facilities, takes approximately one year. Addressing the challenges involved in maintaining ARVs through an efficient procurement and supply chain management system that prevents ARV stock outs through the establishment of a dedicated procurement team, a central warehouse and/or national buffer stock is a

  13. Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products?

    Science.gov (United States)

    Beall, Reed F.; Nickerson, Jason W.; Kaplan, Warren A.; Attaran, Amir

    2016-01-01

    Background Not all new drug products are truly new. Some are the result of marginal innovation and incremental patenting of existing products, but in such a way that confers no major therapeutic improvement. This phenomenon, pejoratively known as “evergreening”, can allow manufacturers to preserve market exclusivity, but without significantly bettering the standard of care. Other studies speculate that evergreening is especially problematic for medicine/device combination products, because patents on the device component may outlast expired patents on the medicine component, and thereby keep competing, possibly less-expensive generic products off the market. Materials and Methods We focused on four common conditions that are often treated by medicine/device product combinations: asthma and chronic obstructive pulmonary disease (COPD), diabetes, and severe allergic reactions. The patent data for a sample of such products (n = 49) for treating these conditions was extracted from the United States Food and Drug Administration’s Orange Book. Additional patent-related data (abstracts, claims, etc) were retrieved using LexisNexis TotalPatent. Comparisons were then made between each product’s device patents and medicine patents. Results Unexpired device patents exist for 90 percent of the 49 medicine/device product combinations studied, and were the only sort of unexpired patent for 14 products. Overall, 55 percent of the 235 patents found by our study were device patents. Comparing the last-to-expire device patent to that of the last-to-expire active ingredient patent, the median additional years of patent protection afforded by device patents was 4.7 years (range: 1.3–15.2 years). Conclusion Incremental, patentable innovation in devices to extend the overall patent protection of medicine/device product combinations is very common. Whether this constitutes “evergreening” depends on whether these incremental innovations and the years of extra patent

  14. Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?

    Directory of Open Access Journals (Sweden)

    Reed F Beall

    Full Text Available Not all new drug products are truly new. Some are the result of marginal innovation and incremental patenting of existing products, but in such a way that confers no major therapeutic improvement. This phenomenon, pejoratively known as "evergreening", can allow manufacturers to preserve market exclusivity, but without significantly bettering the standard of care. Other studies speculate that evergreening is especially problematic for medicine/device combination products, because patents on the device component may outlast expired patents on the medicine component, and thereby keep competing, possibly less-expensive generic products off the market.We focused on four common conditions that are often treated by medicine/device product combinations: asthma and chronic obstructive pulmonary disease (COPD, diabetes, and severe allergic reactions. The patent data for a sample of such products (n = 49 for treating these conditions was extracted from the United States Food and Drug Administration's Orange Book. Additional patent-related data (abstracts, claims, etc were retrieved using LexisNexis TotalPatent. Comparisons were then made between each product's device patents and medicine patents.Unexpired device patents exist for 90 percent of the 49 medicine/device product combinations studied, and were the only sort of unexpired patent for 14 products. Overall, 55 percent of the 235 patents found by our study were device patents. Comparing the last-to-expire device patent to that of the last-to-expire active ingredient patent, the median additional years of patent protection afforded by device patents was 4.7 years (range: 1.3-15.2 years.Incremental, patentable innovation in devices to extend the overall patent protection of medicine/device product combinations is very common. Whether this constitutes "evergreening" depends on whether these incremental innovations and the years of extra patent protection they confer are proportionately matched by

  15. What Is Patent Ductus Arteriosus?

    Science.gov (United States)

    ... page from the NHLBI on Twitter. What Is Patent Ductus Arteriosus? Patent ductus arteriosus (PDA) is a ... the lung arteries. Normal Heart and Heart With Patent Ductus Arteriosus Figure A shows the interior of ...

  16. Trends in nanotechnology patents applied to the health sector.

    Science.gov (United States)

    Antunes, Adelaide Maria de Souza; Alencar, Maria Simone de Menezes; da Silva, Cicera Henrique; Nunes, Jeziel; Mendes, Flavia Maria Lins

    2012-01-01

    The aim of the article is to present a method for identifying trends in patent applications for nanotechnology applied to the health sector around the world, based on the International Patent Classification. This classification divides the sector into: dental care, drugs, diagnostic kits, and medical apparatus & medical care. The Derwent database was mined for patent documents using nanotechnology terms associated with the IPC subclasses from the health subsectors. The number of patents was found to be rising, led by the United States, particularly universities and R centers. In the dental care subsector, nanotechnology was found to be used in composite material for manufacturing dental appliances. In drugs, the focus is on the use of nanoparticulate compositions comprising agents that are useful for a variety of diseases. In diagnostic kits, nanostructures have been patented that are capable of detecting target analytes. Meanwhile, in medical apparatus & medical care, patent applications have been made for nanocapsules and/or nanocomposite materials inserted in devices and guide catheters. A study was also made of patents in Brazil, where the same assignees and the same country (United States) as in the survey of global patents were found to be the leading patent applicants / holders. PMID:21875404

  17. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.

    OpenAIRE

    Suh***, D.C.; Manning, W G; Schondelmeyer, S; Hadsall, R S

    2000-01-01

    OBJECTIVE: To analyze the effect of multiple-source drug entry on price competition after patent expiration in the pharmaceutical industry. DATA SOURCES: Originators and their multiple-source drugs selected from the 35 chemical entities whose patents expired from 1984 through 1987. Data were obtained from various primary and secondary sources for the patents' expiration dates, sales volume and units sold, and characteristics of drugs in the sample markets. STUDY DESIGN: The study was designed...

  18. Patent holdings of US biotherapeutic companies in major markets.

    Science.gov (United States)

    Sebastian, Teena E; Yerram, Chandra Bindu; Saberwal, Gayatri

    2009-05-01

    In previous studies we examined the (United States, US) patent holdings of 109 largely North American biotech companies developing therapeutics that, in particular, have an interest in discovery stage science. There appears little correlation between the number of patents and the number of products of individual companies. Here we quantified and compared the 103 US-headquartered companies' patent holdings in Australia, Canada, Europe, Japan and the US. The companies demonstrate variable and surprising patterns of patent holdings across these countries or regions. For most companies, patent holdings are not in proportion to the importance of the country as a biotech or pharma market. These results have implications for the patenting strategies of small biotech companies involved in drug discovery. PMID:19429502

  19. Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP in a multicenter cohort of HIV-infected ARV-experienced patients

    Directory of Open Access Journals (Sweden)

    D Podzamczer

    2012-11-01

    Full Text Available Purpose of the study: Very scarce information has been published to date with the combination of ABC/3TC/NVP but it is currently being used in clinical practice in many centers in Spain. Our aim was to present the clinical experience with this regimen in a cohort of adult HIV-infected pts. Methods: Retrospective, multicenter, cohort study. Consecutive adult HIV-infected ARV-experienced pts, HLA-B*5701-negative, who started ABC/3TC/NVP between 2005–2010, with at least one follow-up visit, were included. Demographic, clinical and laboratory variables were assessed at baseline, month 1, and every 3–4 months thereafter. The primary end point was HIV-1 viral load (VL <40 c/mL at 48 weeks. Data were analyzed by intent-to-treat (ITT (non-completer=failure and on treatment (OT. Summary of results: 227 pts were included and followed up for a median of 30 (0.5–76 months. 75% male, 47 (24–83 years, 21% AIDS, 13% HCV+, baseline CD4 570 (32–1404 cells/µL and VL undetectable in 90% with a median of <1.59 (<1.59–5.1 log. Most pts were receiving NVP (63%, ABC (25% or both (4% in the previous regimen. ABC/3TC/NVP was initiated due to toxicity (42%, simplification (35% or other reasons (22% including to reduce drug cost. After 48 weeks, VL was <40 c/mL in 82% (ITT and 94% (OT, and in 94% (OT after 96 weeks. CD4 increased +63 (p<0.001 and +77 (p<0.001 cells/µL after 48 and 96 weeks, respectively. One or more drugs of the regimen were discontinued in 18% of pts during follow up: toxicity (7%, virologic failure (3%, lost to follow-up (3%, unrelated death (0.4% or other reasons (4%. No significant differences were observed in ALT, AST, or triglyceride changes during follow up. A significant increase of 7%, 10% and 14% was observed in total cholesterol, LDLc and HDLc, and a significant decrease in TC/HDL ratio (−5%, p=0.004 after 96 weeks, respectively. Conclusions: In this particular cohort of ARV-experienced pts previously receiving NVP or ABC, a

  20. Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection.

    Directory of Open Access Journals (Sweden)

    Joanne D Stekler

    Full Text Available OBJECTIVE: To evaluate minority variant drug resistance mutations detected by the oligonucleotide ligation assay (OLA but not consensus sequencing among subjects with primary HIV-1 infection. DESIGN/METHODS: Observational, longitudinal cohort study. Consensus sequencing and OLA were performed on the first available specimens from 99 subjects enrolled after 1996. Survival analyses, adjusted for HIV-1 RNA levels at the start of antiretroviral (ARV therapy, evaluated the time to virologic suppression (HIV-1 RNA<50 copies/mL among subjects with minority variants conferring intermediate or high-level resistance. RESULTS: Consensus sequencing and OLA detected resistance mutations in 5% and 27% of subjects, respectively, in specimens obtained a median of 30 days after infection. Median time to virologic suppression was 110 (IQR 62-147 days for 63 treated subjects without detectable mutations, 84 (IQR 56-109 days for ten subjects with minority variant mutations treated with ≥3 active ARVs, and 104 (IQR 60-162 days for nine subjects with minority variant mutations treated with <3 active ARVs (p = .9. Compared to subjects without mutations, time to virologic suppression was similar for subjects with minority variant mutations treated with ≥3 active ARVs (aHR 1.2, 95% CI 0.6-2.4, p = .6 and subjects with minority variant mutations treated with <3 active ARVs (aHR 1.0, 95% CI 0.4-2.4, p = .9. Two subjects with drug resistance and two subjects without detectable resistance experienced virologic failure. CONCLUSIONS: Consensus sequencing significantly underestimated the prevalence of drug resistance mutations in ARV-naïve subjects with primary HIV-1 infection. Minority variants were not associated with impaired ARV response, possibly due to the small sample size. It is also possible that, with highly-potent ARVs, minority variant mutations may be relevant only at certain critical codons.

  1. Monitoring and modeling the snowpack dynamics in the Arve upper catchment for hydrological purposes

    Science.gov (United States)

    Revuelto, Jesús; Lecourt, Grégoire; Charrois, Luc; Lafaysse, Matthieu; Condom, Thomas; Dumont, Marie; Morin, Samuel; Rabatel, Antoine; Six, Delphine; Vionnet, Vincent; Zin, Isabella

    2016-04-01

    Snow accumulation and its evolution over space and time have major importance for the hydrological cycle, especially at high elevations. The characteristics of mountain valley, such as a wide altitudinal range, large glaciated areas, snow presence all along the year; when combined with specific meteorological conditions like heat waves or extreme rain events, may originate dramatic flash floods, potentially affecting populated areas. Thus, improving snowpack monitoring and forecasting tools are needed to strength the reliability of warning systems. Nowadays, accurately characterising and simulating snowpack evolution over large areas still represents a challenge, and uncertainties arise. The study presented here is focused in analysing two different types of simulation of the snowpack dynamics, performed with different discretization approaches, distributed or semi-distributed, and how these could move forward assimilating remote sensing data from satellites. The considered study area is the Arve catchment at Chamonix, in the French Northern Alps. This valley has the previously mentioned characteristics: it comprises a large elevation range (between 1000 to 4800m asl, with large areas above 2000m asl) and about 32% of its extension (200km2) is glaciated. Thus, the hydrological cycle of this area is highly dependent on the snowpack and the glacier melt dynamics. The snowpack of the Arve catchment has been simulated from 1990 to 2014 with the Crocus model integrated within the SURFEX modelling platform. The input fields are provided by the SAFRAN reanalysis system and the simulations have been performed with both a semi-distributed (classifying terrain by aspect, elevation, slope and land use/land cover) and a distributed (250m spatial resolution grid cells over the study area) approaches. The use of these two approaches using the same snowpack model and same meteorological forcing, enables their comparison in terms of river discharges at several outlets; showing the

  2. Environmentally conscious patent histories

    Science.gov (United States)

    Crouch, Dennis D.; Crouch, Henry L.

    2004-02-01

    There is a need for investigators, legislators, and business leaders to understand the magnitude of innovation and discovery in the field of environmentally conscious technologies (ECTs). Knowledge of the "big picture" is important to providing a national and global account of actual environmental stewardship over the last twenty-five years. A recitation of the Environmental Protection Agency (EPA) supported Acts which have been enacted into law reveals one facet of the multifaceted dynamic of environmental consciousness. The popular discussion and debate, as well as partisan lobbying, which created the political forces leading to environmentally conscious legislation is another facet. A third facet is the corporate response to the threats and opportunities predicted by CEO"s and others through environmental scanning. This paper examines changes in environmentally conscious inventive effort by comparing data from United States Patents issued from 1976 through 2003. Patents are useful tool for measuring technological innovation because they are publicly available records of innovative activity. Although not all inventions result in patent applications, the monopoly rights granted on the invention give the inventor a strong incentive to obtain patents on any viable product or process. Among the results, we found a significant increase in patents relating to environmentally conscious products and processes during the period in question. Specifically, a dramatic increase in patent activity was seen for the decade of the 1990"s. Surprisingly, the patenting rate from 2000 to 2003 seems to have stabilized. Additionally public discussion of ECTs appears to have a positive impact on patent filings.

  3. Problem Solving with Patents

    Science.gov (United States)

    Moore, Jerilou; Sumrall, William J.

    2008-01-01

    Exploring our patent system is a great way to engage students in creative problem solving. As a result, the authors designed a teaching unit that uses the study of patents to explore one avenue in which scientists and engineers do science. Specifically, through the development of an idea, students learn how science and technology are connected.…

  4. A Patent Dilemma

    Science.gov (United States)

    Downes, Stephen

    2007-01-01

    When Blackboard unveiled its U.S. patent for 44 features of learning management systems and then filed a patent infringement suit against Design2Learn, the response of the educational technology community was negative and swift. Stephen Downes discusses why many educators oppose Blackboard's proprietary claims to technologies long considered in…

  5. Truth and falsity of patent

    International Nuclear Information System (INIS)

    This book describes the process of the effect to build the business of patent strongly in difficult situation. The titles of this contents are finally, lawsuit if formed, the task of patent application introduction of tasks of patent negotiation, negotiation with Fujitsu, Mitsubishi, Oki and NEC, amalgamation between LG semiconductor and Hyundai Electronic Industry, life in incorporated company, current condition of application for a patent, the method to process strategy patent, how to make strong patent and effective negotiation strategy for a patent and strategy of patent application.

  6. Searching bioremediation patents through Cooperative Patent Classification (CPC).

    Science.gov (United States)

    Prasad, Rajendra

    2016-03-01

    Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing with new patent applications. As patent databases maintained by them went online for free access to public as also for global search of prior art by examiners, the need arose for a common platform and uniform structure of patent databases. The diversity of different classification, however, posed problems of integrating and searching relevant patents across patent jurisdictions. To address this problem of comparability of data from different sources and searching patents, WIPO in the recent past developed what is known as International Patent Classification (IPC) system which most countries readily adopted to code their patents with IPC codes along with their own codes. The Cooperative Patent Classification (CPC) is the latest patent classification system based on IPC/European Classification (ECLA) system, developed by the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) which is likely to become a global standard. This paper discusses this new classification system with reference to patents on bioremediation. PMID:26812756

  7. HIV Drug Resistance-Associated Mutations in Antiretroviral Naïve HIV-1-Infected Latin American Children

    Directory of Open Access Journals (Sweden)

    Luis E. Soto-Ramirez

    2010-01-01

    Full Text Available Our goal was to describe the presence of HIV drug resistance among HIV-1-infected, antiretroviral (ARV naïve children and adolescents in Latin America and to examine resistance in these children in relation to drug exposure in the mother. Genotyping was performed on plasma samples obtained at baseline from HIV-1-infected participants in a prospective cohort study in Brazil, Argentina, and Mexico (NISDI Pediatric Study. Of 713 HIV-infected children enrolled, 69 were ARV naïve and eligible for the analysis. At enrollment, mean age was 7.3 years; 81.2% were infected with HIV perinatally. Drug resistance mutations (DRMs were detected in 6 (8.7%; 95% confidence interval 3.1–18.2% ARV-naïve subjects; none of the mothers of these 6 received ARVs during their pregnancies and none of the children received ARV prophylaxis. Reverse transcriptase mutations K70R and K70E were detected in 3 and 2 subjects, respectively; protease mutation I50 V was detected in 1 subject. Three of the 6 children with DRMs initiated ARV therapy during followup, with a good response in 2. The overall rate of primary drug resistance in this pediatric HIV-infected population was low, and no subjects had more than 1 DRM. Mutations associated with resistance to nucleoside reverse transcriptase inhibitors were the most prevalent.

  8. Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells

    Science.gov (United States)

    Mandal, Subhra; Zhou, You; Shibata, Annemarie; Destache, Christopher J.

    2015-08-01

    In the last decade, confocal fluorescence microscopy has emerged as an ultra-sensitive tool for real-time study of nanoparticles (NPs) fate at the cellular-level. According to WHO 2007 report, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is still one of the world's major health threats by claiming approximately 7,000 new infections daily worldwide. Although combination antiretroviral drugs (cARV) therapy has improved the life-expectancy of HIV-infected patients, routine use of high doses of cARV has serious health consequences and requires complete adherence to the regimen for success. Thus, our research goal is to fabricate long-acting novel cARV loaded poly(lactide-co-glycolic acid) (PLGA) nanoparticles (cARV-NPs) as drug delivery system. However, important aspects of cARV-NPs that require special emphasis are their cellular-uptake, potency, and sustained drug release efficiency over-time. In this article, ultra-sensitive confocal microscopy is been used to evaluate the uptake and sustained drug release kinetics of cARV-NPs in HeLa cells. To evaluate with the above goal, instead of cARV-drug, Rhodamine6G dye (fluorescent dye) loaded NPs (Rho6G NPs) have been formulated. To correlate the Rhodamin6G release kinetics with the ARV release from NPs, a parallel HPLC study was also performed. The results obtained indicate that Rho6G NPs were efficiently taken up at low concentration (delivery with the potential to reduce drug dosage as well as the number of drug administrations per month.

  9. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].

    Science.gov (United States)

    Jannuzzi, Anna Haydée Lanzillotti; Vasconcellos, Alexandre Guimarães; de Souza, Cristina Gomes

    2008-06-01

    Different forms of protection for inventions in the pharmaceutical industry point to strategies for the perpetuation of patent protection. Based on a literature review showing the specificities of patenting in the industry, the article provides a brief history of drug patents in Brazil, a discussion of patentable and non-patentable inventions, and the modalities and traits of patent protection that aim to extend the temporary monopoly granted under the patent. Such strategies include patents targeting polimorphs and optical isomers of drugs and drug combinations and specific clinical preparations, increasingly present in the drug patent claims filed by pharmaceutical companies. The study's objective is to discuss the specificities of drug patent claims in order to help develop expertise in the area and discuss the impact of expanding the scope of patent protection. In conclusion, while the tendency to expand towards more a permissive protective scope could produce opportunities for Brazilian national inventors, it could also be harmful to a policy for access to medicines. PMID:18545747

  10. Prescribing patterns of antiretroviral drugs in a section of the private health care sector of South Africa

    Directory of Open Access Journals (Sweden)

    Ronel Smit

    2006-04-01

    Full Text Available The general objective of this study was to investigate the prescribing patterns and cost of antiretroviral (ARV drugs in the private health care sector in South Africa by using a medicine claims database. Opsomming Die doel van hierdie studie was om die voorskryfpatrone en medisynekoste van antiretrovirale (ARV geneesmiddels in die private gesondheidsorgsektor in Suid-Afrika te ondersoek. *Please note: This is a reduced version of the abstract. Please refer to PDF for full text.

  11. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

    Directory of Open Access Journals (Sweden)

    Constance Meiners

    Full Text Available BACKGROUND: Brazil became the first developing country to guarantee free and universal access to HIV/AIDS treatment, with antiretroviral drugs (ARVs being delivered to nearly 190,000 patients. The analysis of ARV price evolution and market dynamics in Brazil can help anticipate issues soon to afflict other developing countries, as the 2010 revision of the World Health Organization guidelines shifts demand towards more expensive treatments, and, at the same time, current evolution of international legislation and trade agreements on intellectual property rights may reduce availability of generic drugs for HIV care. METHODS AND FINDINGS: Our analyses are based on effective prices paid for ARV procurement in Brazil between 1996 and 2009. Data panel structure was exploited to gather ex-ante and ex-post information and address various sources of statistical bias. In-difference estimation offered in-depth information on ARV market characteristics which significantly influence prices. Although overall ARV prices follow a declining trend, changing characteristics in the generic segment help explain recent increase in generic ARV prices. Our results show that generic suppliers are more likely to respond to factors influencing demand size and market competition, while originator suppliers tend to set prices strategically to offset compulsory licensing threats and generic competition. SIGNIFICANCE: In order to guarantee the long term sustainability of access to antiretroviral treatment, our findings highlight the importance of preserving and stimulating generic market dynamics to sustain developing countries' bargaining power in price negotiations undertaken with originator companies.

  12. Patent Application Outcomes across the Trilateral Patent Offices

    OpenAIRE

    Paul H. Jensen; Alfons Palangkaraya; Elizabeth Webster

    2005-01-01

    While most developed countries apply the same criteria to determine whether an invention is eligible to be protected by a patent, there are substantial procedural differences in the way in which different patent offices examine a patent application. This means that a patent application may be granted in one jurisdiction but rejected in others, which raises welfare concerns about the ability of patents to provide an ex ante incentive for investment. In this article, we analyze whether there ar...

  13. Financial Patent Quality: Finance Patents After State Street

    OpenAIRE

    Lerner, Joshua; Speen, Andrew; Baker, Mark; Leamon, Ann

    2016-01-01

    In the past two decades, patents of inventions related to financial services (“finance patents”), as well as litigation around these patents, have surged. One of the repeated concerns voiced by academics and practitioners alike has been about the quality of these patents in particular, and business method patents more generally. In particular, because so much of the prior work in these areas has not been patented, concerns have been expressed as to the extent to which the awards reflect this ...

  14. Patent Strategy and Layout Instrument--Derivative Design Patents

    OpenAIRE

    Rain Chen; Hsin-Yu Chang

    2014-01-01

    As product technology matures, consumers will shift the focus onto the appearance and design of products. In recent years, the fierce competition between Apple and Samsung in the consumer electronics market has pushed the design patent domain into the spotlight. In Taiwan, the amendment of Taiwan Patent Act in 2011 has the Associated Design Patent (ADP) system replaced by the Derivative Design Patent (DDP) system. This is definitely a major patent reform. The DDP system is similar to the cont...

  15. Patent family data and statistics at the European Patent Office

    OpenAIRE

    Walter G Park; Peter Hingley

    2009-01-01

    At the European Patent Office (EPO) a comprehensive data file called PRI is maintained of patent families. The file records are based on published patent documents, indexed by the priority number of the first patent filing, with information on subsequent patenting activities for that invention in the four major economic blocs: EPC contracting states, Japan, USA and Others. It is possible to filter the data in order to highlight the most important inventions, for example by selecting Trilatera...

  16. The Perils of Gene Patents

    OpenAIRE

    Salzberg, SL

    2012-01-01

    I argue here that gene patents, and patented genetic tests based on them, are a very bad idea. First, I discuss whether genes can reasonably be the subject of patents in the first place; I maintain that the answer is no. Second, I explain how gene patents interfere with scientific progress, slowing down the development of new cures and treatments for genetic diseases.

  17. The dynamics of patent citations

    OpenAIRE

    Marco, Alan C.

    2006-01-01

    The use of patent citations as a measure of patent "quality" increased dramatically in recent years. I estimate the hazard of patent citation, and find evidence of unobserved heterogeneity. Hazard estimation provides a means to separate patent quality from citation "inflation."

  18. Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis

    OpenAIRE

    Jiamsakul Awachana; Kantor Rami; Li Patrick CK; Sirivichayakul Sunee; Sirisanthana Thira; Kantipong Pacharee; Lee Christopher KC; Kamarulzaman Adeeba; Ratanasuwan Winai; Ditangco Rossana; Singtoroj Thida; Sungkanuparph Somnuek

    2012-01-01

    Abstract Background Accurate interpretation of HIV drug resistance (HIVDR) testing is challenging, yet important for patient care. We compared genotyping interpretation, based on the Stanford University HIV Drug Resistance Database (Stanford HIVdb), and virtual phenotyping, based on the Janssen Diagnostics BVBA’s vircoTYPE™ HIV-1, and investigated their level of agreement in antiretroviral (ARV) naive patients in Asia, where non-B subtypes predominate. Methods Sequences from 1301 ARV-naive pa...

  19. How Important are Noncorporate Patents?

    DEFF Research Database (Denmark)

    Schneider, Cédric

    2011-01-01

    This article analyses the innovative performances of noncorporate inventors using patent citations data from the European Patent Office. The results show that inventions patented outside an established corporate framework are on average less ‘important’ than corporate patents, but with large...... variations across technology classes. Patents applied for by independent inventors, start-ups and corporate firms are of comparable ‘quality’ in emerging technologies. The results also highlight that in these fields noncorporate patents are more ‘radical’ than corporate patents....

  20. Cómo encontrar patentes, setiembre 2010

    OpenAIRE

    Bonich, Mònica; Cervera-Farré, Albert; Santos-Hermosa, Gema

    2010-01-01

    Com es poden trobar les patents: què són les patents?, què es pot patentar?, qui assigna les patents? i com es poden trobar patents? Cómo encontrar patentes: ¿qué son las patentes?, ¿qué se puede patentar?, ¿quién asigna las patentes? y ¿cómo se pueden encontrar patentes? How to find patents: what are patents?, what can be patented?, who awards the patents? and how can patents be found?

  1. Patents, antibiotics, and autarky in Spain.

    Science.gov (United States)

    Romero De Pablos, Ana

    2014-01-01

    Patents on antibiotics were introduced in Spain in 1949. Preliminary research reveals diversification in the types of antibiotics: patents relating to penicillin were followed by those relating to streptomycin, erythromycin and tetracycline. There was also diversification in the firms that applied for patents: while Merck & Co. Incorporated and Schenley Industries Inc. were the main partners with Spanish antibiotics manufacturers in the late 1940s, this industrial space also included many others, such as Eli Lilly & Company, Abbott Laboratories, Chas. Pfizer & Co. Incorporated, and American Cyanamid Company in the mid-1970s. The introduction of these drugs in Spain adds new elements to a re-evaluation of the autarkic politics of the early years of the Franco dictatorship. PMID:26054209

  2. Text mining patents for biomedical knowledge.

    Science.gov (United States)

    Rodriguez-Esteban, Raul; Bundschus, Markus

    2016-06-01

    Biomedical text mining of scientific knowledge bases, such as Medline, has received much attention in recent years. Given that text mining is able to automatically extract biomedical facts that revolve around entities such as genes, proteins, and drugs, from unstructured text sources, it is seen as a major enabler to foster biomedical research and drug discovery. In contrast to the biomedical literature, research into the mining of biomedical patents has not reached the same level of maturity. Here, we review existing work and highlight the associated technical challenges that emerge from automatically extracting facts from patents. We conclude by outlining potential future directions in this domain that could help drive biomedical research and drug discovery. PMID:27179985

  3. Paying for On-Patent Pharmaceuticals

    Science.gov (United States)

    Goldfield, Norbert

    2016-01-01

    In this article we propose a new approach to pricing for patent-protected (on-patent) pharmaceuticals. We describe and define limit pricing as a method for drug companies to maximize revenue for their investment by offering budget-neutral pricing to encourage early adoption by payers. Under this approach, payers are incentivized to adopt innovative but expensive drugs more quickly if drug companies provide detailed analyses of the net impact of the new pharmaceutical upon total health budgets. For payers to adopt use of a new pharmaceutical, they would require objective third-party evaluation and pharmaceutical manufacturer accountability for projected outcomes efficacy of their treatments on population health. The pay for outcomes underpinning of this approach falls within the wider aspirations of health reform. PMID:26945298

  4. The revival of Phage Therapy to fight Antimicrobial Resistance – Part II: What about patent protection and alternative incentives?

    DEFF Research Database (Denmark)

    Minssen, Timo

    2014-01-01

    patentable subject matter. That the claims were directed to a specific regime optimizing the dosage for each patient to reduce side-effects of a particular drug (i.e. a typical claim in personalized medicine) did not rescue the patent. Then, in Myriad, the Court unanimously held that patent claims directed...... course very much (but not only) relate to the question of patentability. Various aspects might present obstacles to the patentability of technology relating to phage therapy. To not complicate the discussion and considering recent developments I decided to focus on some of aspects under US patent law....... Like in Europe, the first door to patentability that phage-related technology would need to pass concerns patent eligibility. In the last years the US Supreme Court has rendered an astonishing number of fundamental patent-decisions, including not less than four (!) landmark judgments on patent...

  5. ARV robotic technologies (ART): a risk reduction effort for future unmanned systems

    Science.gov (United States)

    Jaster, Jeffrey F.

    2006-05-01

    The Army's ARV (Armed Robotic Vehicle) Robotic Technologies (ART) program is working on the development of various technological thrusts for use in the robotic forces of the future. The ART program will develop, integrate and demonstrate the technology required to advance the maneuver technologies (i.e., perception, mobility, tactical behaviors) and increase the survivability of unmanned platforms for the future force while focusing on reducing the soldiers' burden by providing an increase in vehicle autonomy coinciding with a decrease in the total number user interventions required to control the unmanned assets. This program will advance the state of the art in perception technologies to provide the unmanned platform an increasingly accurate view of the terrain that surrounds it; while developing tactical/mission behavior technologies to provide the Unmanned Ground Vehicle (UGV) the capability to maneuver tactically, in conjunction with the manned systems in an autonomous mode. The ART testbed will be integrated with the advanced technology software and associated hardware developed under this effort, and incorporate appropriate mission modules (e.g. RSTA sensors, MILES, etc.) to support Warfighter experiments and evaluations (virtual and field) in a military significant environment (open/rolling and complex/urban terrain). The outcome of these experiments as well as other lessons learned through out the program life cycle will be used to reduce the current risks that are identified for the future UGV systems that will be developed under the Future Combat Systems (FCS) program, including the early integration of an FCS-like autonomous navigation system onto a tracked skid steer platform.

  6. A Theory of Patent Portfolios

    OpenAIRE

    CHOI, Jay Pil; GERLACH, Heiko

    2013-01-01

    This paper develops a theory of patent portfolios in which firms accumulate an enormous amount of related patents in diverse technology fields such that it becomes impractical to develop a new product that with certainty does not inadvertently infringe on other firms' patent portfolios. We investigate how litigation incentives for the holders of patent portfolios impact the incentives to introduce new products and draw welfare implications. We also consider a patent portfolio acquisition game...

  7. "Wacky" patents meet economic indicators

    OpenAIRE

    Czarnitzki, Dirk; Hussinger, Katrin; Schneider, Cédric

    2011-01-01

    This study investigates whether standard patent measures for the importance and basicness of patents are able to distinguish between “wacky” patents and a control group of randomly drawn patents. Our findings show that forward citations are good predictors of importance. However, the “wacky” patents have higher originality, generality and average citation lags than the controls, which suggests that these indicators should be interpreted carefully.

  8. 'Wacky' patents meet economic indicators

    OpenAIRE

    Czarnitzki, Dirk; Hussinger, Katrin; Schneider, Cédric

    2011-01-01

    This study investigates whether standard patent measures for the importance and basicness of patents are able to distinguish between “wacky” patents and a control group of randomly drawn patents. Our findings show that forward citations are good predictors of importance. However, the “wacky” patents have higher originality, generality and average citation lags than the controls, which suggests that these indicators should be interpreted carefully.

  9. Patent Portfolio Race and Secrecy

    OpenAIRE

    Illoong Kwon

    2008-01-01

    When firms can protect their innovations by secrecy or lead-time, the additional effect of patent protection is not obvious. This paper shows that when firms compete for a single innovation, patent protection still increases R&D investment but decreases social welfare due to over-investment. However, when firms compete for multiple complementary patents (called a patent portfolio), patent protection decreases R&D investment and decreases social welfare due to under-investment. If firms cannot...

  10. Patenting Nanomedicine in Europe

    DEFF Research Database (Denmark)

    Nordberg, Ana

    This work addresses the question of determining whether reinterpretation, reformulation or replacement of article 53 (c) of the European Patent Convention is viable and advisable. It does so by reference to novel or resurfacing interpretative concerns connected with emerging technologies exemplif......This work addresses the question of determining whether reinterpretation, reformulation or replacement of article 53 (c) of the European Patent Convention is viable and advisable. It does so by reference to novel or resurfacing interpretative concerns connected with emerging technologies...... exemplified by nanomedicine, while considering known interpretative issues and traditional objections to this provision. The debate concerning the patentability of ‘medical methods’ is multi-layered and complex. The ‘medical methods exception’ is a public policy mechanism, intended to introduce flexibility in...... the patent system in order to allow for the protection of core ethical values of society. Nanotechnology inventions blur the lines between patentable subject matter and what may fall under the exception from patentability. It is a good example of how in recent years, emerging technologies have been...

  11. Test Collections for Patent-to-Patent Retrieval and Patent Map Generation in NTCIR-4 Workshop

    OpenAIRE

    Fujii, Atsushi; IWAYAMA, Makoto; Kando, Noriko

    2004-01-01

    This paper describes the Patent Retrieval Task in the Fourth NTCIR Workshop, and the test collections produced in this task. We perform the invalidity search task, in which each participant group searches a patent collection for the patents that can invalidate the demand in an existing claim. We also perform the automatic patent map generation task, in which the patents associated with a specific topic are organized in a multi-dimensional matrix.

  12. Patent Height and Competition in Product Improvements.

    OpenAIRE

    Van Dijk, Theon

    1996-01-01

    The stringency of novelty requirements that patent offices use in judging patentability defines the height of patent protection. The author studies patent height in a duopoly where firms compete in product improvements. A competitor who wants to invent around the other's patent is restricted by a minimum improvement level. The author shows that low patent protection does not affect market equilibrium without patent protection. A patent holder can lose with medium patent heights but not if pat...

  13. Strategic management and utilization of patents

    International Nuclear Information System (INIS)

    This book deals with why does management of patents need?, system of management of patents with function and site of management of patents and system and composition, what does management of patents department do?, task like technical development, management regulation, patent information, management of patents in small business with technical development of small business, how does business manage the patents in real, introduction of management of patents in the U.S, Europe, Japan, and Korea, and management of patents as strategic management.

  14. Patent Statistics and IPR Laws Update Online

    Institute of Scientific and Technical Information of China (English)

    2006-01-01

    Patent Statistics Beginning from No.2 of 2005 of China Patents & Trademarks, the Statistics on Patent Applications & Grants in China, previously published under the column of Statistics, will be updated online, including the monthly Statistics on Patent Applications by Patent Category, the Patent Grants by Patent Category, the Domestic Patent Applications by Province, and the Overseas Patent Applications by Country, and their yearly statistics at www.cpt.cn or www.cpahkltd.com/cn/ Publications/staten.htm...

  15. Comprehension and application of patent information

    International Nuclear Information System (INIS)

    This book gives descriptions of conception of patent information such as the meaning, characteristic, function, investigation and map of patent information, pro-patent period and patent strategy of the business. It also deals with comprehension of patent information like publication of nations, patent document, patent procedure in Korea, patent procedure in Japan, the U.S, and Europe, article and function of patent document, patent information survey such as writing of search keyword, procedure of the survey and search site of other countries, patent analysis and patent map.

  16. Edison's vacuum coating patents

    International Nuclear Information System (INIS)

    Among the over one thousand patents bearing Thomas A. Edison's name are several for vacuum coating processes including chemical vapor deposition, evaporation, and sputter deposition. Beginning in 1880 Edison applied for patents that described carbon deposition processes that would now be called pyrolytic chemical vapor deposition. In 1884 Edison applied for a patent (granted in 1894) that described coating by evaporation in a vacuum by direct resistance heating or arc heating using a continuous current. Edison called the process 'electro vacuous deposition'. He prophetically wrote, 'the uses of the invention are almost infinite'. Edison also employed sputter deposition and in 1900 applied for a patent on a 'Process of Coating Phonograph Records'. Issued in 1902, the patent describes using a 'silent or brush electrical discharge' produced by an induction coil. The National Phonograph Company, one of Edison's many enterprises, used the sputtering process to deposit a thin layer of gold on wax phonograph cylinder masters that could then be electroplated to form molds to mass produce celluloid duplicates. The method was used for 20 years, from 1901 to 1921. It enabled the reproduction of cylinder grooves less than 0.001 in. deep at a density of 200 grooves per in. From 1913 to 1921, 10-in.-diameter Edison Diamond Disc phonograph records were made using the same method. Sputtering was abandoned in 1927, as it could not be scaled up to produce the 12 in. disks that were then introduced

  17. Strategic inputs into patent pools

    OpenAIRE

    Baron, Justus; Delcamp, Henry

    2010-01-01

    This article explores what factors determine the decision of a patent pool to accept new inputs. We propose a dynamic analysis of 1337 U.S. patent inputs into 7 important pools. This analysis highlights a trade-off between firm and patent characteristics as the determinants of inclusion of patents into pools. For instance we prove that firms already member of the pool or holding large patent portfolios are able to include lower quality patents. These findings can be explained both by bargaini...

  18. Patent Renewal Fees and Self-Funding Patent Offices

    OpenAIRE

    Gans Joshua S; King Stephen P; Lampe Ryan

    2004-01-01

    A socially optimal structure of application and renewal fees for patents would encourage the maximal number of applications while reducing effective patent length. We find, however, that when patent offices are required to be self-funding, resource constraints can distort this fee structure. Specifically, a financially constrained, but welfare-oriented, patent office will tend to raise initial application fees while lowering renewal fees. This creates two detriments to social welfare as it di...

  19. Humira: the impending patent battles over adalimumab biosimilars.

    Science.gov (United States)

    Norman, Peter

    2016-05-01

    The world's top selling drug, adalimumab (AbbVie's Humira), generated sales in excess of US$13 billion in 2015. The primary product patent expires in 2016 in the USA and 2018 in Europe. This has resulted in a rush by companies to develop adalimumab biosimilars and Amgen submitted regulatory filings for its product ABP-501 in late 2015 in both the USA and Europe. AbbVie has claimed its patent portfolio provides product protection until 2022, but an increasing number of patent challenges are being made and the filings for approval of biosimilars will see more challenges made over the next few years. PMID:27087201

  20. Patenting Nanomedicines Legal Aspects, Intellectual Property and Grant Opportunities

    CERN Document Server

    Souto, Eliana B

    2012-01-01

    "Patenting Nanomedicines: Legal Aspects, Intellectual Property and Grant Opportunities" focuses on the fundamental aspects of Patenting Nanomedicines applied in different "Drug Delivery and Targeting Systems". The promoters of new findings in this field of research are numerous and spread worldwide; therefore, managing intellectual property portfolios, and the acquisition and exploitation of new knowledge face several contingency factors. Today, the scientific community is discussing issues of economic outcomes in the field of Nanomedicines. Major concerns include questions

  1. [Treatment of senile diseases should prescribe Chinese patent medicine scientifically].

    Science.gov (United States)

    Zhao, Xin-Xiang

    2014-04-01

    Treatment of senile diseases by Chinese patent medicine should prescribe according to physiological and pathological specialty of the aged. It's necessary for treatment according to syndrome differentiation associating with the disease,reasonable combination of drugs avoiding adverse reactions,gentle medicine character but not fierce,small medicine quantity but not great, the use of Chinese patent medicine mild and tonic used properly but not excessively. PMID:24812911

  2. Security Interests in Patents and Patent Applications?

    Directory of Open Access Journals (Sweden)

    Pauline Stevens

    2006-04-01

    Full Text Available There is a question mark in the title of this article because more questions than answers have been encountered in researching the topic. The relative certainty with which owners of furniture, equipment, accounts and most other personal property can obtain credit by granting a security in their property rapidly dissipates when the property in question is intellectual property. Owners of patents and other intellectual property find barriers to obtaining secured credit that are not faced by other property owners because there is a historical gap between the federal law protecting rights of intellectual property owners and state laws addressing secured transactions. The increasing importance of intellectual property to the economy of the United States (patent filings having increased by seventy percent since 19962 raises the visibility of this gap and urges consideration of changes in law. This would permit owners of intellectual property access to the same financing opportunities that are available to owners of other personal property. There seems to be no public policy that justifies the current situation.

  3. Patent Races and Market Value

    DEFF Research Database (Denmark)

    Czarnitzki, Dirk; Hussinger, Katrin; Leten, Bart;

    Patent races are models of strategic interactions between firms competing to develop an invention. The winning firm secures a patent, protecting the invention from imitation. This paper tests the assumption made about the reward structure in patent races, both in discrete and complex industries. We...... identify patent race winners using detailed information from the patent examination reports at the European Patent Office (EPO). Estimates of a market value equation featuring large, R&D-intensive U.S., European and Japanese firms, show that if firms win patent races, their market value increases...... significantly. We further show that the gain in market value is significantly larger for patent race winners in discrete industries than for firms in complex industries....

  4. Recent Research on the Economics of Patents

    OpenAIRE

    Hall, Bronwyn H.; Dietmar Harhoff

    2012-01-01

    Recent research on the economics of patents is surveyed. The topics covered include theoretical and empirical evidence on patents as an incentive for innovation, the effectiveness of patents for invention disclosure, patent valuation, and what we know about the design of patent systems. We also look at what is known about some current policy areas, including software and business method patents, university patenting, and the growth in patent litigation.

  5. Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment

    Science.gov (United States)

    Ogunwuyi, Oluwaseun; Kumari, Namita; Smith, Kahli A.; Bolshakov, Oleg; Adesina, Simeon; Gugssa, Ayele; Anderson, Winston A.; Nekhai, Sergei; Akala, Emmanuel O.

    2016-01-01

    Highly active antiretroviral (ARV) therapy (HAART) for chronic suppression of HIV replication has revolutionized the treatment of HIV/AIDS. HAART is no panacea; treatments must be maintained for life. Although great progress has been made in ARV therapy, HIV continues to replicate in anatomical and intracellular sites where ARV drugs have restricted access. Nanotechnology has been considered a platform to circumvent some of the challenges in HIV/AIDS treatment. Dispersion polymerization was used to fabricate two types (PMM and ECA) of polymeric nanoparticles, and each was successfully loaded with four ARV drugs (zidovudine, lamivudine, nevirapine, and raltegravir), followed by physicochemical characterization: scanning electron microscope, particle size, zeta potential, drug loading, and in vitro availability. These nanoparticles efficiently inhibited HIV-1 infection in CEM T cells and peripheral blood mononuclear cells; they hold promise for the treatment of HIV/AIDS. The ARV-loaded nanoparticles with polyethylene glycol on the corona may facilitate tethering ligands for targeting specific receptors expressed on the cells of HIV reservoirs. PMID:27013886

  6. Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment.

    Science.gov (United States)

    Ogunwuyi, Oluwaseun; Kumari, Namita; Smith, Kahli A; Bolshakov, Oleg; Adesina, Simeon; Gugssa, Ayele; Anderson, Winston A; Nekhai, Sergei; Akala, Emmanuel O

    2016-01-01

    Highly active antiretroviral (ARV) therapy (HAART) for chronic suppression of HIV replication has revolutionized the treatment of HIV/AIDS. HAART is no panacea; treatments must be maintained for life. Although great progress has been made in ARV therapy, HIV continues to replicate in anatomical and intracellular sites where ARV drugs have restricted access. Nanotechnology has been considered a platform to circumvent some of the challenges in HIV/AIDS treatment. Dispersion polymerization was used to fabricate two types (PMM and ECA) of polymeric nanoparticles, and each was successfully loaded with four ARV drugs (zidovudine, lamivudine, nevirapine, and raltegravir), followed by physicochemical characterization: scanning electron microscope, particle size, zeta potential, drug loading, and in vitro availability. These nanoparticles efficiently inhibited HIV-1 infection in CEM T cells and peripheral blood mononuclear cells; they hold promise for the treatment of HIV/AIDS. The ARV-loaded nanoparticles with polyethylene glycol on the corona may facilitate tethering ligands for targeting specific receptors expressed on the cells of HIV reservoirs. PMID:27013886

  7. The Value of European Patents

    OpenAIRE

    Gambardella, Alfonso; Harhoff, Dietmar; VERSPAGEN, bart

    2008-01-01

    This paper employs data from an extensive European survey to produce one of the first systematic assessments of the private economic value of patents. The estimated mean of our patent value distribution is higher than 3 million Euros, the median is about one-tenth, and the mode is around a few thousand Euros. This is in line with previous findings about the skewed distribution of patent values. Our measure is significantly correlated with the number of patent citations, references, claims, an...

  8. Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999–2008

    Directory of Open Access Journals (Sweden)

    Kate Buchacz

    2012-01-01

    Full Text Available Background. Little is known about temporal trends in frequencies of clinically relevant ARV resistance mutations in HIV strains from U.S. patients undergoing genotypic testing (GT in routine HIV care. Methods. We analyzed cumulative frequency of HIV resistance among patients in the HIV Outpatient Study (HOPS who, during 1999–2008 and while prescribed antiretrovirals, underwent GT with plasma HIV RNA >1,000 copies/mL. Exposure ≥4 months to each of three major antiretroviral classes (NRTI, NNRTI and PI was defined as triple-class exposure (TCE. Results. 906 patients contributed 1,570 GT results. The annual frequency of any major resistance mutations decreased during 1999–2008 (88% to 79%, P=0.05. Resistance to PIs decreased among PI-exposed patients (71% to 46%, P=0.010 as exposure to ritonavir-boosted PIs increased (6% to 81%, P<0.001. Non-significant declines were observed in resistance to NRTIs among NRTI-exposed (82% to 67%, and triple-class-resistance among TCE patients (66% to 41%, but not to NNRTIs among NNRTI-exposed. Conclusions. HIV resistance was common but declined in HIV isolates from subgroups of ARV-experienced HOPS patients during 1999–2008. Resistance to PIs among PI-exposed patients decreased, possibly due to increased representation of patients whose only PI exposures were to boosted PIs.

  9. Patent Valuation and Real Options

    OpenAIRE

    Deger Alper

    2011-01-01

    As the knowledge economics grows rapidly, businesses increasingly invest intellectual property and the value of intellectual property; patent, trademark, copyright etc., more emphasized in business nowadays. Thus, the valuation of intellectual property, specifically patents, has been one of the most difficult investment problems both for practitioners and academics. Traditional valuation methods fail to account for the unique characteristics of patents; uncertainty and management flexibility....

  10. Used, Blocking and Sleeping Patents

    DEFF Research Database (Denmark)

    Torrisi, Salvatore; Gambardella, Alfonso; Giuri, Paola;

    2016-01-01

    sleeping patents. We also examine the association between used and unused patents and their characteristics such as family size, scope, generality and overlapping claims, technology area, type of applicant, and the competitive environment from where these patents originate. We discuss our results and...

  11. Do Patents Perform Like Property?

    OpenAIRE

    James Bessen; Michael J. Meurer

    2008-01-01

    Do patents provide critical incentives to encourage investment in innovation? Or, instead, do patents impose legal risks and burdens on innovators that discourage innovation, as some critics now claim? This paper reviews empirical economic evidence on how well patents perform as a property system.

  12. The fallacy of Software Patents

    CERN Document Server

    CERN. Geneva

    2015-01-01

    Software patents are usually used as argument for innovation but do they really promote innovation? Who really benefits from software patents? This talk attempts to show the problems with software patents and how they can actually harm innovation having little value for software users and our society in general.

  13. Patent Searching for Librarians and Inventors.

    Science.gov (United States)

    Wherry, Timothy Lee

    Information on patents is provided for librarians and laypersons requiring an understanding of the system and the processes involved. Chapter 1 discusses successful patents; terms and concepts; patent types; copyright; trademark; requirements; patent examiners; patent pending; expiration; patentee and assignee; and reissued patents. Chapter 2…

  14. Traditional Knowledge and Patent Protection: Conflicting Views On International Patent Standards

    Directory of Open Access Journals (Sweden)

    A Andrzejewski

    2010-12-01

    Full Text Available As diseases continue to spread around the globe, pharmaceutical and biotech companies continue to search for new and better drugs to treat them. Most of these companies have realised that useful compounds for these purposes may be found in the natural resources that indigenous and local communities use. And yet, even though the importance of these biological resources to global health and economic livelihood is well recognised, the legal ownership and control of this traditional knowledge is still very controversial. This article undertakes a comparative analysis of American and European, as well as international legal regulations on patent law and traditional knowledge. Key questions include: What is traditional knowledge? How have the national patent laws of these countries treated the protection of plant variety and plant genetic resources? What are the existing international standards for patents, and what implications do they have for protecting traditional knowledge? And finally, what protection systems are emerging for the future?

  15. Vietnamese Women's Struggle to Access Antiretroviral Drugs in a Context of Free Treatment

    DEFF Research Database (Denmark)

    Nguyen, Nam Thi Thu; Rasch, Vibeke; Bygbjerg, Ib Christian;

    2013-01-01

    This qualitative study aims to explore how HIV positive women living in a northern province of Vietnam experience seeking antiretroviral (ARV) treatment in the public health system, and how they address obstacles encountered along the way. Despite the fact that antiretroviral drugs were freely...... provided, they were not always accessible for women in need. A variety of factors at the population and health system level interacted in ways that often made access to ARV drugs a complicated and time-consuming process. We have suggested changes that could be made at the health system level that may help...

  16. 37 CFR 3.21 - Identification of patents and patent applications.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Identification of patents and patent applications. 3.21 Section 3.21 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND... for Recording § 3.21 Identification of patents and patent applications. An assignment relating to...

  17. Patent production is a prerequisite for successful exit of a biopharmaceutical company.

    Science.gov (United States)

    Saotome, Chikako; Nakaya, Yurie; Abe, Seiji

    2016-03-01

    Patents are especially important for the business of drug discovery; however, their importance for biopharmaceutical companies has not been revealed quantitatively yet. To examine the correlation between patents and long-term business outcome of biopharmaceutical companies we analyze annual number of patent families and business conditions of 123 public-listed biopharmaceutical companies established from 1990 to 1995 in the USA. Our results show the number of patent families per year correlates well with the business condition: average of the bankruptcy group is significantly smaller than those of the continuing and the merger and acquisitions (M&A) groups. In the M&A by big pharma group, the acquisition cost correlates with the number of annual patent families. However, patentability and strategy of foreign patent application are not different among the groups. Therefore, the productivity of invention is the key factor for success of biopharmaceutical companies. PMID:26721189

  18. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.

    Science.gov (United States)

    Mendoza, Yaxelis; Castillo Mewa, Juan; Martínez, Alexander A; Zaldívar, Yamitzel; Sosa, Néstor; Arteaga, Griselda; Armién, Blas; Bautista, Christian T; García-Morales, Claudia; Tapia-Trejo, Daniela; Ávila-Ríos, Santiago; Reyes-Terán, Gustavo; Bello, Gonzalo; Pascale, Juan M

    2016-01-01

    The use of antiretroviral therapy in HIV infected subjects prevents AIDS-related illness and delayed occurrence of death. In Panama, rollout of ART started in 1999 and national coverage has reached 62.8% since then. The objective of this study was to determine the level and patterns of acquired drug resistance mutations of clinical relevance (ADR-CRM) and surveillance drug resistance mutations (SDRMs) from 717 HIV-1 pol gene sequences obtained from 467 ARV drug-experienced and 250 ARV drug-naïve HIV-1 subtypes B infected subjects during 2007-2013, respectively. The overall prevalence of SDRM and of ADR-CRM during the study period was 9.2% and 87.6%, respectively. The majority of subjects with ADR-CRM had a pattern of mutations that confer resistance to at least two classes of ARV inhibitors. The non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K103N and P225H were more prevalent in both ARV drug-naïve and ARV drug-experienced subjects. The nucleoside reverse transcriptase inhibitor (NRTI) mutation M184V was more frequent in ARV drug-experienced individuals, while T215YFrev and M41L were more frequent in ARV drug-naïve subjects. Prevalence of mutations associated to protease inhibitors (PI) was lower than 4.1% in both types of subjects. Therefore, there is a high level of resistance (>73%) to Efavirenz/Nevirapine, Lamivudine and Azidothymidine in ARV drug-experienced subjects, and an intermediate to high level of resistance (5-10%) to Efavirenz/Nevirapine in ARV drug-naïve subjects. During the study period, we observed an increasing trend in the prevalence of ADR-CRM in subjects under first-line schemes, but not significant changes in the prevalence of SDRM. These results reinforce the paramount importance of a national surveillance system of ADR-CRM and SDRM for national management policies of subjects living with HIV. PMID:27119150

  19. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes

    Science.gov (United States)

    Mendoza, Yaxelis; Castillo Mewa, Juan; Martínez, Alexander A.; Zaldívar, Yamitzel; Sosa, Néstor; Arteaga, Griselda; Armién, Blas; Bautista, Christian T.; García-Morales, Claudia; Tapia-Trejo, Daniela; Ávila-Ríos, Santiago; Reyes-Terán, Gustavo; Bello, Gonzalo; Pascale, Juan M.

    2016-01-01

    The use of antiretroviral therapy in HIV infected subjects prevents AIDS-related illness and delayed occurrence of death. In Panama, rollout of ART started in 1999 and national coverage has reached 62.8% since then. The objective of this study was to determine the level and patterns of acquired drug resistance mutations of clinical relevance (ADR-CRM) and surveillance drug resistance mutations (SDRMs) from 717 HIV-1 pol gene sequences obtained from 467 ARV drug-experienced and 250 ARV drug-naïve HIV-1 subtypes B infected subjects during 2007–2013, respectively. The overall prevalence of SDRM and of ADR-CRM during the study period was 9.2% and 87.6%, respectively. The majority of subjects with ADR-CRM had a pattern of mutations that confer resistance to at least two classes of ARV inhibitors. The non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K103N and P225H were more prevalent in both ARV drug-naïve and ARV drug-experienced subjects. The nucleoside reverse transcriptase inhibitor (NRTI) mutation M184V was more frequent in ARV drug-experienced individuals, while T215YFrev and M41L were more frequent in ARV drug-naïve subjects. Prevalence of mutations associated to protease inhibitors (PI) was lower than 4.1% in both types of subjects. Therefore, there is a high level of resistance (>73%) to Efavirenz/Nevirapine, Lamivudine and Azidothymidine in ARV drug-experienced subjects, and an intermediate to high level of resistance (5–10%) to Efavirenz/Nevirapine in ARV drug-naïve subjects. During the study period, we observed an increasing trend in the prevalence of ADR-CRM in subjects under first-line schemes, but not significant changes in the prevalence of SDRM. These results reinforce the paramount importance of a national surveillance system of ADR-CRM and SDRM for national management policies of subjects living with HIV. PMID:27119150

  20. Lovely but dangerous: The impact of patent citations on patent duration

    OpenAIRE

    Maurseth, Per Botolf

    2001-01-01

    What is the impact of patent citations on patent renewal behaviour? Patent citations are commonly used as an indicator of technology spillovers. For cited patents therefore, patent citations have a potentially ambiguous impact. On the one hand, patent citations may indicate a scientific breakthrough, a high value of the cited patent and therefore a long survival period. On the other hand, patent citations may indicate competing innovations that render the cited patent obsolete. By discriminat...

  1. Patent Valuation and Real Options

    Directory of Open Access Journals (Sweden)

    Deger Alper

    2011-01-01

    Full Text Available As the knowledge economics grows rapidly, businesses increasingly invest intellectual property and the value of intellectual property; patent, trademark, copyright etc., more emphasized in business nowadays. Thus, the valuation of intellectual property, specifically patents, has been one of the most difficult investment problems both for practitioners and academics. Traditional valuation methods fail to account for the unique characteristics of patents; uncertainty and management flexibility. Patents are option-like assets that give the owner a bundle of options; to commercialize the products, to file foreign application, to license the innovation etc. Real options represent the application of options methodology to strategic business decisions, and real option method provides a richer framework to analyse the issues that confront the valuation of patent. This paper uses real option model as a framework to correctly evaluate patent and contains real option model application to patent valuation.

  2. Labor Mobility and Patenting Activity

    DEFF Research Database (Denmark)

    Kaiser, Ulrich; Kongsted, Hans Christian; Rønde, Thomas

    We measure the quantitative importance of labor mobility as a vehicle for the transmission of knowledge and skills across firms. For this purpose we create a unique data set that matches all applications of Danish firms at the European Patent Office to linked employer-employee register data for the...... years 1999-2002. The Danish workforce is split into "R&D workers", who hold a bachelor's or a master's degree in a technical field, and "non{R&D workers". We find that mobile R&D workers ("R&D joiners"') contribute more to patenting activity than immobile R&D workers. Furthermore, R&D workers who have...... previously been employed by a patenting firm ("patent exposed workers") have a larger effect on patenting activity than R&D workers without this experience. Patent exposed R&D joiners constitute the most productive group of workers: for firms that patented prior to 1999, one additional worker of this type...

  3. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

    Directory of Open Access Journals (Sweden)

    Delforge Marie-Luce

    2008-02-01

    Full Text Available Abstract Background Guidelines established for the treatment of HIV-1 infection and genotype interpretation do not apply for HIV-2. Data about antiretroviral (ARV drug efficacy and resistance mutations is scarce. Methods Clinical data about HIV-2 infected patients in Belgium and Luxembourg were collected and the effect of ARV therapy on plasma viral load and CD4 counts were analysed. Viral RNA encoding for protease (PR and reverse transcriptase (RT from ARV-naïve and treated patients were sequenced. Results Sixty-five HIV-2 infected patients were included in this cohort. Twenty patients were treated with 25 different ARV combinations in a total of 34 regimens and six months after the start of ARV therapy, only one third achieved viral load suppression. All of these successful regimens bar one contained protease inhibitors (PIs. Mean CD4 gains in the group of viral load suppressors and the group of patients treated with PI-containing regimens were respectively significantly higher than in the group of non-suppressors and the group of PI-sparing regimens. The most frequent mutations selected under therapy (compared to HIV-2 ROD were V71I, L90M and I89V within PR. Within RT, they were M184V, Q151M, V111I and K65R. All of these mutations, except K65R and M184V, were also found in variable proportions in ARV-naïve patients. Conclusion Despite a high rate of ARV treatment failure, better virological and immunological results were achieved with PI-containing regimens. The analysis of polymorphic positions and HIV-2 specific mutations selected during therapy showed for the first time that transmission of drug resistant viruses has occurred in Belgium and Luxembourg. The high heterogeneity in ARV combinations reflects a lack of guidelines for the treatment of HIV-2 infection.

  4. Assessment of analytical techniques for characterization of crystalline clopidogrel forms in patent applications

    Directory of Open Access Journals (Sweden)

    Luiz Marcelo Lira

    2014-04-01

    Full Text Available The aim of this study was to evaluate two important aspects of patent applications of crystalline forms of drugs: (i the physicochemical characterization of the crystalline forms; and (ii the procedure for preparing crystals of the blockbuster drug clopidogrel. To this end, searches were conducted using online patent databases. The results showed that: (i the majority of patent applications for clopidogrel crystalline forms failed to comply with proposed Brazilian Patent Office guidelines. This was primarily due to insufficient number of analytical techniques evaluating the crystalline phase. In addition, some patent applications lacked assessment of chemical/crystallography purity; (ii use of more than two analytical techniques is important; and (iii the crystallization procedure for clopidogrel bisulfate form II were irreproducible based on the procedure given in the patent application.

  5. Development and tuning of an original search engine for patent libraries in medicinal chemistry

    OpenAIRE

    Pasche, Emilie; Gobeill, Julien; Kreim, Olivier; Oezdemir-Zaech, Fatma; Vachon, Therese; Lovis, Christian; Ruch, Patrick

    2014-01-01

    BACKGROUND: The large increase in the size of patent collections has led to the need of efficient search strategies. But the development of advanced text-mining applications dedicated to patents of the biomedical field remains rare, in particular to address the needs of the pharmaceutical & biotech industry, which intensively uses patent libraries for competitive intelligence and drug development. METHODS: We describe here the development of an advanced retrieval engine to search information ...

  6. [Analyses on positive influence of harmonous development of traditional Chinese medicine compounds' researchs and patent protection].

    Science.gov (United States)

    Yang, Xujie; Xiao, Shiying; Guo, Zan; Wang, Zhimin; You, Yun

    2012-01-01

    Current patent protection of traditional Chinese medicine (TCM) compounds is far from being satisfactory with increasing research and development achievements. As patent protection of traditional Chinese medicine compounds is closely related with many fields such as research and development of new TCM drugs, industrial development and TCM internationalization, the development of research and harmonious development of TCM compounds and their patent protection is bound to have a far-reaching influence on domestic and even international societies. PMID:22741453

  7. How Patent Function Integration with R&D Influence the Value of Patents

    DEFF Research Database (Denmark)

    Beukel, Karin; Valentin, Finn

    Patent strategies are endogenous to firm appropriability. However, to what extent does firm’s R&D teams’ engagement with patent experts influence the value of patents? We estimate the relationship between firm’s R&D use of patent functions on patent value in Biotech firms. Controlling for...... characteristics of scientific team, firm effects, and other patent value indicators, we find that having a firm specific (in-house) internal patent function is a driver of patent value. In addition, we find that the way in which patent functions create patent value differs dependent on whether the firm has...... internal patent function or not. In-house patent functions create value through narrow patents, whereas, firms with no in-house patent function create valuable patents by the use of broader scoped patents. Our results point to a strong effect of firm specific patent functions, but also explain how firms...

  8. Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP in a multicentre cohort of HIV-infected, ARV-naïve patients

    Directory of Open Access Journals (Sweden)

    Daniel Podzamczer

    2014-11-01

    Full Text Available Purpose: Very scarce information has been published to date with the combination of ABC/3TC/NVP but it is currently being used in clinical practice in Spain and Portugal. Our aim was to present the clinical experience with this regimen in a cohort of adult HIV-infected antiretroviral (ARV-naïve patients. Methods: Retrospective, multicentre, cohort study. Consecutive adult HIV-infected ARV-naïve HLA-B*5701-negative patients, who started ABC/3TC/NVP between 2005-2013, with at least one follow-up visit, were included. Demographic, clinical and laboratory variables were assessed at baseline, month 1, and every three–four months thereafter. The primary end point was HIV-1 viral load (VL<40 c/mL at 48 weeks. Data were analyzed by intent-to-treat (ITT (switch=failure, and missing=failure and on treatment (OT analyses. Results: 78 patients were included. Median follow up was 26 (0.1-84 months. 86% were male, median age 41 (23-69 years, 9% had AIDS, 8% were HCV+, baseline CD4 was 275 (10-724 cells/µL and median VL 4.58 (3.02-6.92 log. After 48 weeks, VL was<40 c/mL in 89.8% (OT, 79.7% (M=F and 65.4% (S=F and at 96 weeks in 88.5%, 78.9% and 61.6%, respectively. CD4 increased +246 (p<0.001 and +292 (p<0.001 cells/uL after 48 and 96 weeks, respectively. One or more drugs of the regimen were discontinued in 33 (42.3% patients. In 15 (19.2% patients (13 NVP, 2 ABC/3TC therapy was stopped due to toxicity after a median of one month (in only two cases after six months of follow up: 80% of them had rash/liver toxicity. Six (7.7% patients discontinued ART due to virologic failure, five (6.4% because of other reasons and seven (9% were lost to follow-up. ALT but not AST significantly increased (+0.07 ukat/L at 96 weeks, p=0.033. A significant increase of 25%, 26% and 42% in total cholesterol, LDLc and HDLc, respectively, and a significant decrease in TC/HDL ratio (6%, p=0.008 was observed after 96 weeks. Conclusions: Despite a considerable proportion of

  9. Science of invention patent

    International Nuclear Information System (INIS)

    This book tells science of invention patent about new way of invention and creative solution for problems, basic conception of TRIZ, resolution of physical contradictory and technical contradictory, development of system and types of evolution, change of thinking for solving the problems, analysis of structure for problem solution, problem solution using scientific phenomenon and effect, use of standard solution and algorithm of creative problem solution.

  10. Conflict resolution, public goods and patent thickets

    OpenAIRE

    Harhoff, Dietmar; Von Graevenitz, Georg; Wagner, Stefan

    2013-01-01

    Post-grant validity challenges at patent offices rely on the private initiative of third parties to correct mistakes made by patent offices. We hypothesize that incentives to bring post-grant validity challenges are reduced when many firms benefit from revocation of a patent and when firms are caught up in patent thickets. Using data on opposition against patents at the European Patent Office we show that opposition decreases in fields in which many others profit from patent revocations. More...

  11. Patent Pools: Intellectual Property Rights and Competition

    OpenAIRE

    Rodriguez, Victor

    2010-01-01

    Patent pools do not correct all problems associated with patent thickets. In this respect, patent pools might not stop the outsider problem from striking pools. Moreover, patent pools can be expensive to negotiate, can exclude patent holders with smaller numbers of patents or enable a group of major players to form a cartel that excludes new competitors. For all the above reasons, patent pools are subject to regulatory clearance because they could result in a monopoly. The aim of this article...

  12. Extracting value from ipr through patent brokerage

    OpenAIRE

    Mario F. Benassi; Gidion T. Geenen

    2013-01-01

    We investigate the role of patent brokers in creating and extracting value from patents. Based on theoretical discussions, distinctive patent market conditions are associated with specific benefits of patent brokers. We provide a conceptual model to frame the role of patent brokers. We identify patent market dimensions that are likely to affect broker selection and argue why companies should carefully select patent brokers. We conclude with an outline of implications and suggestions for empir...

  13. Patents, Inducement Prizes, and Contestant Strategy

    OpenAIRE

    Davis, Jerome; Davis, Lee

    2007-01-01

    Debate over the merits of patents versus inducement prizes has tended to ignore the signaling roles of patents, and totally ignores the impact of patent signaling on prize contests. This paper asks: How does patent signaling affect the strategic choices of firms considering entering prize contests? First, we consider contests that do not allow patenting, then contests that do. If patenting is not allowed, we argue, patent-holders, both internal and external to the contest, can adversely impac...

  14. Prevalence and type of drug-drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda

    Directory of Open Access Journals (Sweden)

    K Seden

    2012-11-01

    Full Text Available Scale-up of HIV services in countries such as Uganda has resulted in a rapid increase in facilities offering antiretrovirals (ARVs and an increase in healthcare workers trained to deliver care. Consequently, evaluating medication safety is increasingly important in these settings. Data from developed countries suggest that drug-drug interactions (DDIs involving ARVs are common, occurring at rates of 14–58%. Few data are available from low resource settings, however a study of 996 Kenyan patients found that 33.5% were at risk of clinically significant DDIs. We evaluated the prevalence and type of ARV DDIs and the patients most at risk in an African outpatient setting. A random sample of patients taking current ARVs and accessing care at the Infectious Diseases Institute, Makerere University, Kampala was selected from the clinic database. The most recent prescription for each patient was screened for DDIs using www.hiv-druginteractions.org. Clinical significance of DDIs was assessed by two of us using a previously developed technique evaluating: likelihood of interaction, therapeutic index of affected drug and severity of potential adverse effect. From 1000 consecutive patients 99.6% were taking≥1 co-medication alongside their ARV regimen (mean 1.89. 24.5% had≥1 potential DDI, with a total of 335 DDIs observed. Of these, 255 DDIs were considered clinically significant, affecting 18.8% of patients. Only 0.3% of DDIs involved a contraindicated combination. There was a higher rate of potential DDIs observed in patients taking TB treatment (p=0.0047, who were WHO stage 3 or 4 (p=0.001, or patients taking ≥2 co-medications alongside ARVs (p<0.0001 (Fishers exact test. Patient age, gender, CD4 count and weight did not affect risk for DDIs. Co-medications commonly associated with potential DDIs were antibiotics (6.2% of 1000 patients, anthelminthics (4.6% and antifungals (3.5%. Potential DDIs involving ARVs occur at similar rates in resource

  15. Recreational Drugs and HIV

    Science.gov (United States)

    ... To date, there are no case reports or studies of interactions between ketamine and ARVs. LSD The metabolism of LSD is not understood. Interactions with ARVs are possible but unknown. Marijuana (see fact sheet 731) There are no known ...

  16. Polymorphs and prodrugs and salts (oh my!: an empirical analysis of "secondary" pharmaceutical patents.

    Directory of Open Access Journals (Sweden)

    Amy Kapczynski

    Full Text Available BACKGROUND: While there has been much discussion by policymakers and stakeholders about the effects of "secondary patents" on the pharmaceutical industry, there is no empirical evidence on their prevalence or determinants. Characterizing the landscape of secondary patents is important in light of recent court decisions in the U.S. that may make them more difficult to obtain, and for developing countries considering restrictions on secondary patents. METHODOLOGY/PRINCIPAL FINDINGS: We read the claims of the 1304 Orange Book listed patents on all new molecular entities approved in the U.S. between 1988 and 2005, and coded the patents as including chemical compound claims (claims covering the active molecule itself and/or one of several types of secondary claims. We distinguish between patents with any secondary claims, and those with only secondary claims and no chemical compound claims ("independent" secondary patents. We find that secondary claims are common in the pharmaceutical industry. We also show that independent secondary patents tend to be filed and issued later than chemical compound patents, and are also more likely to be filed after the drug is approved. When present, independent formulation patents add an average of 6.5 years of patent life (95% C.I.: 5.9 to 7.3 years, independent method of use patents add 7.4 years (95% C.I.: 6.4 to 8.4 years, and independent patents on polymorphs, isomers, prodrug, ester, and/or salt claims add 6.3 years (95% C.I.: 5.3 to 7.3 years. We also provide evidence that late-filed independent secondary patents are more common for higher sales drugs. CONCLUSIONS/SIGNIFICANCE: Policies and court decisions affecting secondary patenting are likely to have a significant impact on the pharmaceutical industry. Secondary patents provide substantial additional patent life in the pharmaceutical industry, at least nominally. Evidence that they are also more common for best-selling drugs is consistent with accounts of

  17. Imitation versus Innovation Costs: Patent policies under common patent length

    OpenAIRE

    ICHIDA Toshihiro

    2013-01-01

    This paper investigates the interaction between innovation and imitation costs for heterogeneous ideas (industries). It analyzes the effect of various patent-related policies under the common patent length across different industries. It also looks at a policy that will strengthen trade secrets such as the Soleau envelope policy. Under the common term of patent with moderate assumption about the joint distribution of costs, the model predicts the existence of imitating products which are succ...

  18. Patent dispute: Delhi High Court gives a boost to access to affordable medicines.

    Science.gov (United States)

    Menghaney, Leena

    2010-01-01

    The Delhi High Court has rejected the petition filed by Bayer Corporation seeking to stop the Drugs Controller of India (DCGI) from registering a generic version of a patented cancer drug. The case was filed in 2008 by Bayer to try and introduce "patent linkage" which involves linking the registration (marketing approval) of drugs with their patent status. If Bayer's plea for "patent linkage" had been accepted by the court, it would have undermined public health safeguards contained in India's patent legislation. This comment discusses the Bayer case in the context of efforts by multinational pharmaceutical companies to introduce barriers to generic competition, the only proven means of reducing the prices of medicines to make them affordable to those in need. Bayer has filed an appeal in the Supreme Court, indicating that it does not intend to give up. PMID:20432882

  19. Patent Boxes Design, Patents Location and Local R&D

    OpenAIRE

    Annette Alstadsæter; Salvador Barrios; Nicodème, Gaëtan J.A.; Agnieszka Skonieczna; Antonio Vezzani

    2015-01-01

    Patent boxes have been heavily debated for their role in corporate tax competition. This paper uses firm-level data for the period 2000-2011 for the top 2,000 corporate research and development (R&D) investors worldwide to consider the determinants of patent registration across a large sample of countries. Importantly, we disentangle the effects of corporate income taxation from the tax advantage of patent boxes. We also exploit a new and original dataset on patent box features such as the co...

  20. Patent Boxes Design, Patents Location and Local R&D

    OpenAIRE

    Annette Alstadsæter; Salvador Barrios; Gaëtan Nicodème; Agnieszka Maria Skonieczna; Antonio Vezzani

    2015-01-01

    Patent boxes have been heavily debated for their role in corporate tax competition.This paper uses firm-level data for the period 2000-2011 for the top 2,000 corporate R&D investors worldwide to consider the determinants of patent registration across a large sample of countries. Importantly, we disentangle the effects of corporate income taxation from the tax advantage of patent boxes. We also exploit a new and original dataset on patent box features such as the conditionality on performing r...

  1. How Gene Patents May Inhibit Scientific Research

    OpenAIRE

    Campo-Engelstein, Lisa; Chan, Tiffany

    2015-01-01

    In this paper, we point out three possible ways gene patents could impede scientific research. First, gene patent laws might exacerbate the culture of secrecy ubiquitous in science. Second, gene patents may limit researchers’ ability to study poly or multigenic diseases without access to all genetic etiologies. Third, gene patents could result in a “patent thicket”.

  2. How Gene Patents May Inhibit Scientific Research

    Directory of Open Access Journals (Sweden)

    Campo-Engelstein, Lisa

    2015-02-01

    Full Text Available In this paper, we point out three possible ways gene patents could impede scientific research. First, gene patent laws might exacerbate the culture of secrecy ubiquitous in science. Second, gene patents may limit researchers’ ability to study poly or multigenic diseases without access to all genetic etiologies. Third, gene patents could result in a “patent thicket”.

  3. Guidelines and Procedures for Patent Application

    OpenAIRE

    Mercado, Aster I.

    1991-01-01

    To educate Filipinos on IPR, this article provides a rigorous discussion on the Philippine patent system and patent law. It identifies the patentable grant, the requirements of patentability and records a step-by-step patent application. This article has been presented during the DOST-PIDS Seminar-Discussion on “Intellectual Property Rights: Policy Issues and Perspectives” on December 13, 1991.

  4. 75 FR 17380 - Patents Ombudsman Pilot Program

    Science.gov (United States)

    2010-04-06

    ... procedure. See Request for Comments on Patents Ombudsman Pilot Program, 74 FR 55212 (Oct. 27, 2009), 1348... United States Patent and Trademark Office Patents Ombudsman Pilot Program AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Notice. SUMMARY: The United States Patent and Trademark...

  5. 43 CFR 6.52 - Patents.

    Science.gov (United States)

    2010-10-01

    ... 43 Public Lands: Interior 1 2010-10-01 2010-10-01 false Patents. 6.52 Section 6.52 Public Lands: Interior Office of the Secretary of the Interior PATENT REGULATIONS Licenses § 6.52 Patents. Patents in... sublicenses, are classified as follows: (a) Class A. Patents, other than those referred to in paragraph (c)...

  6. 37 CFR 501.9 - Patent protection.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent protection. 501.9 Section 501.9 Patents, Trademarks, and Copyrights UNDER SECRETARY FOR TECHNOLOGY, DEPARTMENT OF COMMERCE UNIFORM PATENT POLICY FOR RIGHTS IN INVENTIONS MADE BY GOVERNMENT EMPLOYEES § 501.9 Patent protection....

  7. A Minimum Optimal Patent Term

    OpenAIRE

    Duffy, John F

    2005-01-01

    Most investigations of the optimal patent term problem have followed Nordhaus's assumption that setting and optimal patent term requires balancing the incentives necessary to encourage innovation against the inefficiencies associated with longer lasting monopoly rights. Nordhaus, however, relied upon a static model in which all investments and innovations occur at a fixed time. If the times of investments and innovation are not fixed, the time of patent expiration becomes a "U-shaped" functio...

  8. Framing the patent troll debate.

    Science.gov (United States)

    Risch, Michael

    2014-02-01

    The patent troll debate has reached a fevered pitch in the USA. This editorial seeks to frame the debate by pointing out the lack of clarity in defining patent trolls and their allegedly harmful actions. It then frames the debate by asking currently unanswered questions: Where do troll patents come from? What are the effects of troll assertions? Will policy changes improve the system? PMID:24354803

  9. Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

    Science.gov (United States)

    Kelly, Sean G; Nyaku, Amesika N; Taiwo, Babafemi O

    2016-04-01

    The advent of combination antiretroviral therapy (ART) has significantly decreased AIDS-related morbidity and mortality. Nevertheless, the benefits of ART are only realized through adherence to lifelong treatment. Though contemporary antiretroviral (ARV) drugs have fewer adverse effects in comparison to older ARV drugs, many agents are associated with negative or unknown long-term effects. There is increasing evidence that two-drug (dual-therapy) regimens may be an effective alternative to the currently recommended three-drug (triple-therapy) regimens. In this review, we provide a comprehensive and critical review of recently completed and ongoing trials of dual-therapy regimens in treatment-naïve and treatment-experienced HIV-1-infected patients. We also review current HIV/AIDS society recommendations regarding dual therapy as well as future therapeutic possibilities. PMID:26886135

  10. Measuring Innovation Using Patent Data

    OpenAIRE

    Svensson, Roger

    2015-01-01

    Firms and governments spend billions of dollars on R&D every year. To increase social welfare, the results of R&D must be commercialized so that consumers can benefit from improved products and lower prices. One measure of R&D output is patents; however, most patent databases contain no information on whether patents have been commercialized, i.e., whether innovations have been introduced in the market. This paper applies a new method to identify innovations in patent databases by relating tr...

  11. 77 FR 4509 - Patent Public Advisory Committee Public Hearings on the Proposed Patent Fee Schedule

    Science.gov (United States)

    2012-01-30

    ... United States Patent and Trademark Office 37 CFR Chapter I Patent Public Advisory Committee Public Hearings on the Proposed Patent Fee Schedule AGENCY: United States Patent and Trademark Office, Department... (AIA), the United States Patent and Trademark Office (USPTO) may set or adjust by rule any patent...

  12. 37 CFR 1.710 - Patents subject to extension of the patent term.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patents subject to extension of the patent term. 1.710 Section 1.710 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES Adjustment and...

  13. Achieving clinical equality in an influenza pandemic: patent realities.

    Science.gov (United States)

    Kane, Eileen M

    2009-01-01

    A twenty-first century novel influenza A (H1N1) pandemic is currently unfolding, and the eventual scope of this public health crisis is not clear. In addition, ongoing surveillance of the avian influenza A (H5N1) virus reveals outbreaks of human-to-human transmission of the virus, with significant mortality. Effective pandemic management depends on pharmaceutical intervention with two different clinical objectives: the generation of an immune response to specific viral strains (vaccination) and the reduction of viral replication in an infected individual (antiviral administration). The ability to offer pharmaceutical interventions for a public health crisis depends on three factors: development, capacity, and access. Pharmaceutical measures must be developed, capacity must be established, and access must be ensured. The article discusses the three nodes of patenting that influence the availability of pharmaceutical countermeasures in an influenza pandemic. Identification of the causative influenza virus is the first step in pandemic management and precedes vaccine design, and the virus and its RNA sequence are both knowledge assets and inputs for vaccine design. Vaccine development, therefore, will be influenced by any patents on the genetic sequences or proteins of the pandemic virus, as well as on novel methods for vaccine production, the actual vaccine or adjuvant technology, all of which are relevant to the assembly of a working vaccine on short notice. Pharmaceutical treatment of influenza infection during a pandemic could also rely on use of patented antiviral drugs, whose efficacy may be revealed as the pandemic unfolds. Unlike vaccines, these are not generally developed de novo for a pandemic, but their availability could be dependent on the exercise of patent rights by market incumbents. Patent rights could control capacity, which may determine access. Pandemic planning must consider how patenting can influence development, capacity and access to

  14. La cayorra sin patente

    OpenAIRE

    Herzovich, Guido

    2013-01-01

    En otro tiempo, tal vez la cayorra sin patente hubiera podido aspirar a las páginas del Manual de zoología fantástica de Borges, donde América Latina, generalmente tan prolífica en bestias, aportaba sin embargo únicamente una : la chancha con cadenas, oriunda de la ciudad de Córdoba. Para las autoridades (incluidas las literarias), la cayorra fue seguramente en aquel tiempo tan furtiva como la chancha, aunque sin duda más ubicua. Cuando se la quería avistar, también esta "cayorra" de la front...

  15. Patent arterial duct

    OpenAIRE

    Martin Robin P; Elmasry Ola A; Forsey Jonathan T

    2009-01-01

    Abstract Patent arterial duct (PAD) is a congenital heart abnormality defined as persistent patency in term infants older than three months. Isolated PAD is found in around 1 in 2000 full term infants. A higher prevalence is found in preterm infants, especially those with low birth weight. The female to male ratio is 2:1. Most patients are asymptomatic when the duct is small. With a moderate-to-large duct, a characteristic continuous heart murmur (loudest in the left upper chest or infraclavi...

  16. Patent statistics: a good indicator for innovation in China? Assessment of impacts of patent subsidy programs on patent quality

    OpenAIRE

    Dang, Jangwei; Motohashi, Kazuyuki

    2013-01-01

    This paper investigates whether patent subsidy programs aimed at promoting regional innovations have aroused a large number of low-quality applications in China and created biased patent statistics as an indicator for innovations. We found that patent filing fee subsidies encouraged filing of low-quality patent, resulting in a decreased grant rate. Though reward conditioned on grants increased patent grant rate, it also brought patents with narrow claim breadth. Our empirical results confirme...

  17. Patent Overlay Mapping: Visualizing Technological Distance

    CERN Document Server

    Kay, Luciano; Youtie, Jan; Porter, Alan L; Rafols, Ismael

    2012-01-01

    The purpose of this paper is to present a new global patent map that represents all technological categories, and a method to locate patent data of individual organizations and technological fields on the global map. This second patent overlay map technique is shown to be of potential interest to support competitive intelligence and policy decision-making. The global patent map is based on similarities in citing-to-cited relationships between categories of the International Patent Classification (IPC) of European Patent Office (EPO) patents from 2000 to 2006. This patent dataset, extracted from PatStat database, represents more than 760,000 patent records in more than 400 IPC categories. To illustrate the kind of analytical support offered by this approach, the paper shows the overlay of nanotechnology-related patenting activities of two companies and two different nanotechnology subfields on to the global patent map. The exercise shows the potential of patent overlay maps to visualize technological areas and...

  18. SureChEMBL: a large-scale, chemically annotated patent document database.

    Science.gov (United States)

    Papadatos, George; Davies, Mark; Dedman, Nathan; Chambers, Jon; Gaulton, Anna; Siddle, James; Koks, Richard; Irvine, Sean A; Pettersson, Joe; Goncharoff, Nicko; Hersey, Anne; Overington, John P

    2016-01-01

    SureChEMBL is a publicly available large-scale resource containing compounds extracted from the full text, images and attachments of patent documents. The data are extracted from the patent literature according to an automated text and image-mining pipeline on a daily basis. SureChEMBL provides access to a previously unavailable, open and timely set of annotated compound-patent associations, complemented with sophisticated combined structure and keyword-based search capabilities against the compound repository and patent document corpus; given the wealth of knowledge hidden in patent documents, analysis of SureChEMBL data has immediate applications in drug discovery, medicinal chemistry and other commercial areas of chemical science. Currently, the database contains 17 million compounds extracted from 14 million patent documents. Access is available through a dedicated web-based interface and data downloads at: https://www.surechembl.org/. PMID:26582922

  19. Business Method Patents, Innovation, and Policy

    OpenAIRE

    Hall, Bronwyn H.

    2003-01-01

    The trickle of business method patents issued by the United States Patent Office became a flood after the State Street Bank decision in 1998. Many scholars, both legal and economic, have critiqued both the quality of these patents and the decision itself. This paper discusses the likely impact of these patents on innovation. It first reviews the facts about business method and internet patents briefly and then explores what economists know about the relationship between the patent system and ...

  20. Patent Overlay Mapping: Visualizing Technological Distance

    OpenAIRE

    Kay, Luciano; Newman, Nils; Youtie, Jan; Porter, Alan L.; Rafols, Ismael

    2012-01-01

    This paper presents a new global patent map that represents all technological categories and a method to locate patent data of individual organizations and technological fields on the global map. This overlay map technique may support competitive intelligence and policy decision making. The global patent map is based on similarities in citing-to-cited relationships between categories of the International Patent Classification (IPC) of European Patent Office (EPO) patents from 2000 to 2006. Th...

  1. Sequential Innovation and Optimal Patent Design

    OpenAIRE

    Christian Riis; Xianwen Shi

    2012-01-01

    We study optimal patent design in a setting with sequential innovation. Firms innovate by undertaking "research" activities to generate new ideas and by undertaking "development" activities to transform these ideas into viable products. Both innovation incentives and the welfare costs of patent monopoly are multidimensional. We characterize optimal patent policy, and in particular, the tradeoff between patent length and patent breadth in this setting. The optimal size of the patent reward is ...

  2. Constructing an Intelligent Patent Network Analysis Method

    OpenAIRE

    Wu, Chao-Chan; Yao, Ching-Bang

    2012-01-01

    Patent network analysis, an advanced method of patent analysis, is a useful tool for technology management. This method visually displays all the relationships among the patents and enables the analysts to intuitively comprehend the overview of a set of patents in the field of the technology being studied. Although patent network analysis possesses relative advantages different from traditional methods of patent analysis, it is subject to several crucial limitations. To overcome the drawbacks...

  3. Social and Technological Efficiency of Patent Systems

    OpenAIRE

    Thomas VALLEE (LEN - IAE Nantes); Yildizoglu, Murat

    2004-01-01

    This article develops an evolutionary model of industry dynamics in order to carry out a richer theoretical analysis of the consequences of a stronger patent system. The first results obtained in our article are rather consistent with the anti-patent arguments and they do not favour the case for a stronger patent system: higher social welfare and technical progress are observed in our model in industries with milder patent systems (lower patent height and patent life).

  4. The Academic Advantage: Gender Disparities in Patenting

    OpenAIRE

    Sugimoto, Cassidy R.; Ni, Chaoqun; West, Jevin D.; Larivière, Vincent

    2015-01-01

    We analyzed gender disparities in patenting by country, technological area, and type of assignee using the 4.6 million utility patents issued between 1976 and 2013 by the United States Patent and Trade Office (USPTO). Our analyses of fractionalized inventorships demonstrate that women’s rate of patenting has increased from 2.7% of total patenting activity to 10.8% over the nearly 40-year period. Our results show that, in every technological area, female patenting is proportionally more likely...

  5. Of Smart Phone Wars and Software Patents

    OpenAIRE

    Stuart Graham; Saurabh Vishnubhakat

    2013-01-01

    Among the main criticisms currently confronting the US Patent and Trademark Office are concerns about software patents and what role they play in the web of litigation now proceeding in the smart phone industry. We will examine the evidence on the litigation and the treatment by the Patent Office of patents that include software elements. We present specific empirical evidence regarding the examination by the Patent Office of software patents, their validity, and their role in the smart phone...

  6. Commercialization, Renewal and Quality of Patents

    OpenAIRE

    Svensson, Roger

    2011-01-01

    One of the major reasons why inventors are awarded patents by governments is they encourage R&D investments and commercialization of inventions. If the patent holder commercializes his invention, he has stronger incentives to retain the patent. The purpose here is to empirically analyze the relationship between commercialization and the renewal of patents. At the same time, I take into account defensive patent strategies (e.g. deterring competitors from utilizing the patent) and pointedly ask...

  7. Optimal patent policies: A survey

    DEFF Research Database (Denmark)

    Poulsen, Odile

    2002-01-01

    government uses two policy tools, the optimal breadth and length. We show that theoretical models give very different answers to what is the optimal patent policy. In particular, we show that the optimal patent policy depends among othet things on the price elasticity of demand, the intersectoral elasticity...

  8. Online Patent Searching: The Realities.

    Science.gov (United States)

    Kaback, Stuart M.

    1983-01-01

    Considers patent subject searching capabilities of major online databases, noting patent claims, "deep-indexed" files, test searches, retrieval of related references, multi-database searching, improvements needed in indexing of chemical structures, full text searching, improvements needed in handling numerical data, and augmenting a subject search…

  9. Wacky Patents Meet Economic Indicators

    DEFF Research Database (Denmark)

    Czarnitzki, Dirk; Hussinger, Katrin; Schneider, Cédric

    2011-01-01

    We investigate whether standard indicators can distinguish between “wacky” patents and a control group. Forward citations are good predictors of importance. However, “wacky” patents have higher originality, generality and citation lags, suggesting that these indicators should be interpreted...

  10. An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings

    Directory of Open Access Journals (Sweden)

    Kathleen M MacQueen

    2014-09-01

    Full Text Available Introduction: Product adherence and its measurement have emerged as a critical challenge in the evaluation of new HIV prevention technologies. Long-acting ARV-based vaginal rings may simplify use instructions and require less user behaviour, thereby facilitating adherence. One ARV-based ring is in efficacy trials and others, including multipurpose rings, are in the pipeline. Participant motivations, counselling support and measurement challenges during ring trials must still be addressed. In previous HIV prevention trials, this has been done largely using descriptive and post-hoc methods that are highly variable and minimally evaluated. We outline an interdisciplinary framework for systematically investigating promising strategies to support product uptake and adherence, and to measure adherence in the context of randomized, blinded clinical trials. Discussion: The interdisciplinary framework highlights the dual use of adherence measurement (i.e. to provide feedback during trial implementation and to inform interpretation of trial findings and underscores the complex pathways that connect measurement, adherence support and enacted adherence behaviour. Three inter-related approaches are highlighted: 1 adherence support – sequential efforts to define motivators of study product adherence and to develop, test, refine and evaluate adherence support messages; 2 self-reported psychometric measures – creation of valid and generalizable measures based in easily administered scales that capture vaginal ring use with improved predictive ability at screening, baseline and follow-up that better engage participants in reporting adherence; and 3 more objective measurement of adherence – real-time adherence monitoring and cumulative measurement to correlate adherence with overall product effectiveness through innovative designs, models and prototypes using electronic and biometric technologies to detect ring insertion and/or removal or expulsion

  11. The Tiger Awakens: The Tumultuous Transformation of India’s Patent System and the Rise of Indian Pharmaceutical Innovation

    Directory of Open Access Journals (Sweden)

    Janice M. Mueller

    2007-04-01

    Full Text Available The first day of January 2005 marked a dramatic turning point in the history of India. By deliberately excluding pharmaceutical products from patent protection for the previous 34 years, India became a world leader in high-quality generic drug manufacturing. But India’s entry into the global economy at the end of the 20th century, as evidenced by membership in the World Trade Organization (WTO, compelled the nation to once again award patents on drugs. Moreover, India henceforth would have to apply internationally-accepted criteria for granting patents, and the term of its patents would have to extend twenty years beyond filing.

  12. Patent arterial duct

    Directory of Open Access Journals (Sweden)

    Martin Robin P

    2009-07-01

    Full Text Available Abstract Patent arterial duct (PAD is a congenital heart abnormality defined as persistent patency in term infants older than three months. Isolated PAD is found in around 1 in 2000 full term infants. A higher prevalence is found in preterm infants, especially those with low birth weight. The female to male ratio is 2:1. Most patients are asymptomatic when the duct is small. With a moderate-to-large duct, a characteristic continuous heart murmur (loudest in the left upper chest or infraclavicular area is typical. The precordium may be hyperactive and peripheral pulses are bounding with a wide pulse pressure. Tachycardia, exertional dyspnoea, laboured breathing, fatigue or poor growth are common. Large shunts may lead to failure to thrive, recurrent infection of the upper respiratory tract and congestive heart failure. In the majority of cases of PAD there is no identifiable cause. Persistence of the duct is associated with chromosomal aberrations, asphyxia at birth, birth at high altitude and congenital rubella. Occasional cases are associated with specific genetic defects (trisomy 21 and 18, and the Rubinstein-Taybi and CHARGE syndromes. Familial occurrence of PAD is uncommon and the usual mechanism of inheritance is considered to be polygenic with a recurrence risk of 3%. Rare families with isolated PAD have been described in which the mode of inheritance appears to be dominant or recessive. Familial incidence of PAD has also been linked to Char syndrome, familial thoracic aortic aneurysm/dissection associated with patent arterial duct, and familial patent arterial duct and bicuspid aortic valve associated with hand abnormalities. Diagnosis is based on clinical examination and confirmed with transthoracic echocardiography. Assessment of ductal blood flow can be made using colour flow mapping and pulsed wave Doppler. Antenatal diagnosis is not possible, as PAD is a normal structure during antenatal life. Conditions with signs and symptoms of

  13. TREATMENT OF WASTEWATER FROM CHINESE PATENT DRUGS MILL WITH FE/C/UASB/HCR/AIR FLOATATION PROCESS%铁碳微电解—UASB—两级HCR—气浮工艺处理中成药生产废水

    Institute of Scientific and Technical Information of China (English)

    任朝斌; 孙润超

    2012-01-01

    Wastewater from Chinese patent drugs mill treated with the process of Fe-C/UASB/HCR/Air Floatation was introduced. The running results of the actual operation showed that the system was highly efficient and easily manageable, with pH, COD, BOD5, SS of the effluent were 8.21~8.56,41.20~49.65 mg/L, 12.95~15.60 mg/L, 12~24 mg/L, respectively. The effluent quality met the requirements of water pollutants discharge standard(G8 21906-2008). This experiment may provide a reference to the wastewater treatment of other Chinese patent drugs.%介绍了铁炭微电解-UASB-两级HCR-气浮工艺在中成药生产废水处理工程中的应用.运行结果表明,该系统处理效果好、性能稳定、维护管理方便,出水pH为8.21~8.56,COD为41.20~49.65mg/L,BOD5为12.95~15.60mg/L,p(SS)为12.00~24.00mg/L,经处理后的排水水质指标执行GB 21906-2008规定的标准.

  14. Pharmaceutical Patents: Incentives for R&D or Marketing?

    OpenAIRE

    Brekke, Kurt Richard; Straume, Odd Rune

    2008-01-01

    We analyse how a patent-holding pharmaceutical firm may strategically use advertising of existing drugs to affect R&D investments in new (differentiated) drugs, and thereby affect the probability distribution of future market structures in the industry. Within a fairly general model framework, we derive exact conditions for advertising and R&D being substitute strategies for the incumbent firm and show that it may overinvest in advertising to reduce the incentive for an entrant to invest in R...

  15. Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs.

    Directory of Open Access Journals (Sweden)

    Karolin Hijazi

    Full Text Available Anti-retroviral (ARV -based microbicides are one of the strategies pursued to prevent HIV-1 transmission. Delivery of ARV drugs to subepithelial CD4+ T cells at concentrations for protection is likely determined by drug transporters expressed in the cervicovaginal epithelium. To define the role of drug transporters in mucosal disposition of topically applied ARV-based microbicides, these must be tested in epithelial cell line-based biopharmaceutical assays factoring the effect of relevant drug transporters. We have characterised gene expression of influx and efflux drug transporters in a panel of cervicovaginal cell lines and compared this to expression in cervicovaginal tissue. We also investigated the effect of dapivirine, darunavir and tenofovir, currently at advanced stages of microbicides development, on expression of drug transporters in cell lines. Expression of efflux ABC transporters in cervical tissue was best represented in HeLa, Ect1/E6E7 and End1/E6E7 cell lines. Expression of influx OCT and ENT transporters in ectocervix matched expression in Hela while expression of influx SLCO transporters in vagina was best reflected in VK2/E6E7 cell line. Stimulation with darunavir and dapivirine upregulated MRP transporters, including MRP5 involved in transport of tenofovir. Dapivirine also significantly downregulated tenofovir substrate MRP4 in cervical cell lines. Treatment with darunavir and dapivirine showed no significant effect on expression of BCRP, MRP2 and P-glycoprotein implicated in efflux of different ARV drugs. Darunavir strongly induced expression in most cell lines of CNT3 involved in cell uptake of nucleotide/nucleoside analogue reverse transcriptase inhibitors and SLCO drug transporters involved in cell uptake of protease inhibitors. This study provides insight into the suitability of cervicovaginal cell lines for assessment of ARV drugs in transport kinetics studies. The modulatory effect of darunavir and dapivirine on

  16. Pharmaceutical patents and generic entry competition: the role of marketing exclusivity

    OpenAIRE

    MIYAGIWA Kaz; WAN, Yunyun

    2015-01-01

    Extensive tests required by FDA severely curtail effective patent length for innovation drugs, raising concern that incentives to develop new drugs are insufficient in the U.S. The Hatch-Waxman Act addresses this issue with a five-year patent extension. At the same time, Hatch-Waxman promotes generic entry by reducing the entry cost for generics and by granting 180-day marketing exclusivity to a first challenger of the patent. While these two objectives seem at odds with other, we show that i...

  17. A Study on the patent application strategy for China from the viewpoint of the patent application procedure and patent application conditions in China

    OpenAIRE

    Yaji, Kazufumi

    2008-01-01

    This paper examines strategies for patent applications in China, focusing on the differences between Chinese patent law and Japanese patent law about the process of filling patent applications and the data on the number of patent applications to China in various technology fields. Strategies for patent applications in China for Japanese companies are proposed taking account of differences between Chinese patent law and Japanese patent law and the viewpoint of patent application data.

  18. Valley heat deficit as a bulk measure of wintertime particulate air pollution in the Arve River Valley

    Science.gov (United States)

    Chemel, Charles; Arduini, Gabriele; Staquet, Chantal; Largeron, Yann; Legain, Dominique; Tzanos, Diane; Paci, Alexandre

    2016-03-01

    Urbanized valleys are particularly vulnerable to particulate air pollution during the winter, when ground-based stable layers or cold-air pools persist over the valley floor. We examine whether the temporal variability of PM10 concentration in the section of the Arve River Valley between Cluses and Servoz in the French Alps can be explained by the temporal variability of the valley heat deficit, a bulk measure of atmospheric stability within the valley. We do this on the basis of temperature profile and ground-based PM10 concentration data collected during wintertime with a temporal resolution of 1 h or finer, as part of the Passy-2015 field campaign conducted around Passy in this section of valley. The valley heat deficit was highly correlated with PM10 concentration on a daily time scale. The hourly variability of PM10 concentrations was more complex and cannot be explained solely by the hourly variability of the valley heat deficit. The interplay of the diurnal cycles of emissions and local dynamics is demonstrated and a drainage mechanism for observed nocturnal dilution of near-surface PM10 concentrations is proposed.

  19. Assessing the impact of a food supplement on the nutritional status and body composition of HIV-infected Zambian women on ARVs

    OpenAIRE

    Musonda Mofu; Handema Ray; Chipeta James; Munthali Grace K; Byrne Nuala M; Zulu Rodah M; Hills Andrew P

    2011-01-01

    Abstract Background Zambia is a sub-Saharan country with one of the highest prevalence rates of HIV, currently estimated at 14%. Poor nutritional status due to both protein-energy and micronutrient malnutrition has worsened this situation. In an attempt to address this combined problem, the government has instigated a number of strategies, including the provision of antiretroviral (ARV) treatment coupled with the promotion of good nutrition. High-energy protein supplement (HEPS) is particular...

  20. Modeling HIV Vaccines in Brazil: Assessing the Impact of a Future HIV Vaccine on Reducing New Infections, Mortality and Number of People Receiving ARV

    OpenAIRE

    Maria Goretti P. Fonseca; Steven Forsythe; Alexandre Menezes; Shilpa Vuthoori; Cristina Possas; Valdiléa Gonçalves Veloso; Francisca de Fátima Lucena; John Stover

    2010-01-01

    BACKGROUND: The AIDS epidemic in Brazil remains concentrated in populations with high vulnerability to HIV infection, and the development of an HIV vaccine could make an important contribution to prevention. This study modeled the HIV epidemic and estimated the potential impact of an HIV vaccine on the number of new infections, deaths due to AIDS and the number of people receiving ARV treatment, under various scenarios. METHODS AND FINDINGS: The historical HIV prevalence was modeled using Spe...

  1. 77 FR 26289 - Determination of Regulatory Review Period for Purposes of Patent Extension; PRADAXA

    Science.gov (United States)

    2012-05-03

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of...

  2. 77 FR 26288 - Determination of Regulatory Review Period for Purposes of Patent Extension; HALAVEN

    Science.gov (United States)

    2012-05-03

    ... as the patented item (human drug product, animal drug product, medical device, food additive, or... applicant may receive. A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the...

  3. 76 FR 14671 - Determination of Regulatory Review Period for Purposes of Patent Extension; ISTODAX

    Science.gov (United States)

    2011-03-17

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of...

  4. 75 FR 79381 - Determination of Regulatory Review Period for Purposes of Patent Extension; FOLOTYN

    Science.gov (United States)

    2010-12-20

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of...

  5. 75 FR 53314 - Determination of Regulatory Review Period for Purposes of Patent Extension; PRISTIQ

    Science.gov (United States)

    2010-08-31

    ... as the patented item (human drug product, animal drug product, medical device, food additive, or... applicant may receive. A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the...

  6. 78 FR 6826 - Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI

    Science.gov (United States)

    2013-01-31

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of...

  7. 77 FR 20644 - Determination of Regulatory Review Period for Purposes of Patent Extension; FLECTOR

    Science.gov (United States)

    2012-04-05

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of...

  8. 77 FR 26556 - Determination of Regulatory Review Period for Purposes of Patent Extension; EQUIDONE GEL

    Science.gov (United States)

    2012-05-04

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For animal... an animal drug product will include all of the testing phase and approval phase as specified in 35...

  9. 77 FR 26291 - Determination of Regulatory Review Period for Purposes of Patent Extension; LASTACAFT

    Science.gov (United States)

    2012-05-03

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of...

  10. 75 FR 78714 - Determination of Regulatory Review Period for Purposes of Patent Extension; ANGIOMAX

    Science.gov (United States)

    2010-12-16

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of...

  11. 75 FR 53315 - Determination of Regulatory Review Period for Purposes of Patent Extension; ONGLYZA

    Science.gov (United States)

    2010-08-31

    ... as the patented item (human drug product, animal drug product, medical device, food additive, or... applicant may receive. A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the...

  12. Developing a Systematic Patent Search Training Program

    Science.gov (United States)

    Zhang, Li

    2009-01-01

    This study aims to develop a systematic patent training program using patent analysis and citation analysis techniques applied to patents held by the University of Saskatchewan. The results indicate that the target audience will be researchers in life sciences, and aggregated patent database searching and advanced search techniques should be…

  13. 78 FR 7759 - Patent Cooperation Treaty

    Science.gov (United States)

    2013-02-04

    ... Patent and Trademark Office Patent Cooperation Treaty ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing effort to reduce...: Susan K. Fawcett, Records Officer, Office of the Chief Information Officer, United States Patent...

  14. 78 FR 60256 - Initial Patent Applications

    Science.gov (United States)

    2013-10-01

    ... Patent and Trademark Office Initial Patent Applications ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing efforts to..., United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Federal...

  15. 75 FR 20561 - Patent Term Extension

    Science.gov (United States)

    2010-04-20

    ... Patent and Trademark Office Patent Term Extension ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing effort to reduce... the Chief Information Officer, United States Patent and Trademark Office, P.O. Box 1450,...

  16. 77 FR 16813 - Patent Processing (Updating)

    Science.gov (United States)

    2012-03-22

    ... United States Patent and Trademark Office Patent Processing (Updating) ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing... Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450....

  17. 75 FR 23227 - Initial Patent Applications

    Science.gov (United States)

    2010-05-03

    ... Patent and Trademark Office Initial Patent Applications ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing efforts to..., Records Officer, Office of the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box...

  18. 78 FR 67339 - Initial Patent Applications

    Science.gov (United States)

    2013-11-12

    ... Patent and Trademark Office Initial Patent Applications ACTION: Proposed collection; Extension of Comment Period. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing efforts... Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Federal Rulemaking Portal:...

  19. 78 FR 31885 - Patent Term Extension

    Science.gov (United States)

    2013-05-28

    ... Patent and Trademark Office Patent Term Extension ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing effort to reduce...: Susan K. Fawcett, Records Officer, Office of the Chief Information Officer, United States Patent...

  20. 76 FR 72000 - Patent, Trademark & Copyright Acts

    Science.gov (United States)

    2011-11-21

    ... Geological Survey Patent, Trademark & Copyright Acts AGENCY: U.S. Geological Survey, Interior. ACTION: Notice...., Suite 200, Kennesaw, GA 30144, on U.S. Patent Application Serial No. 12/133,666, and a divisional patent application to be filed shortly at the Patent and Trademark Office, both entitled ``Anaerobic...

  1. Research method of nuclear patent information

    International Nuclear Information System (INIS)

    When faced with a huge amount of nuclear patent information, the key to effective research include: (1) Choose convenient way to search, quick access to nuclear technology related patents; (2) To overcome the language barrier, analysis the technical content of patent information; (3) Organize the publication date of retrieved patent documents, analysis the status and trends of nuclear technology development; (4) Research the patented technology of main applicants; (5) Always pay attention to the legal status of patent information, free use the invalid patents, at the same time avoid the patent infringement. Summary, patent information is important to obtain the latest technical information source, and the research work of patent information is a comprehensive understanding and mastery way for advanced nuclear technology. (authors)

  2. Rightpollex: From Patent To Startup

    Science.gov (United States)

    Leba, Monica; Ionica, Andreea Cristina; Dobra, Remus

    2015-07-01

    RightPollex is an innovative product patented and developed by a multidisciplinary team from the University of Petrosani. The paper presents not only the idea and implementation possibilities of this patent, but also the current stage on the path towards the development of startups, an initiative of our university together with a private investor. The result of this initiative is JV Sensor Ventures that supports several startups.

  3. ROYALTY COLLECTION FOR PATENTED LIVESTOCK

    OpenAIRE

    Lesser, William H.

    1993-01-01

    Allowing animal patents provides potential benefits and costs for livestock producers. Costs, considered here, are royalty payments and collection mechanisms, made more complex by the unknown future distribution of multiple patented traits in the herd. This article evaluates three proposed collection systems, Qualified Sales, registration and pooled royalties. The first two are imposed only on breeding stock and at first sale, creating a cash flow and risk factor for producers. The third coll...

  4. Patent foramen ovale: Unanswered questions

    OpenAIRE

    Mojadidi, MK; Christia, P; Salamon, J; Liebelt, J; T Zaman; Gevorgyan, R; Nezami, N; Mojaddedi, S; Elgendy, IY; Tobis, JM; Faillace, R

    2015-01-01

    The foramen ovale is a remnant of the fetal circulation that remains patent in 20-25% of the adult population. Although long overlooked as a potential pathway that could produce pathologic conditions, the presence of a patent foramen ovale (PFO) has been associated with a higher than expected frequency in a variety of clinical syndromes including cryptogenic stroke, migraines, sleep apnea, platypnea-orthodeoxia, deep sea diving associated decompression illness, and high altitude pulmonary ede...

  5. Considerations in vaccine patent protection.

    Science.gov (United States)

    Brazell, Lorna

    2010-12-01

    This feature article discusses the basic principles of patentability as related to vaccine research, and outlines recent cases in the US and EU in which vaccine patents have been considered. Issues regarding eligibility for supplementary protection, as currently being considered by the Court of Justice of the EU, are also outlined, as well as the implications of such issues in protecting future vaccine research. PMID:21154148

  6. Tax attractiveness and the location of patents

    OpenAIRE

    Dinkel, Andreas; Schanz, Deborah

    2015-01-01

    This paper analyzes the impact of taxation on the location of patents within multinational groups. Based on groups with parents from 36 countries globally and their patent holdings in 36 European countries, we provide insight into the determinants of three subsequent decisions: (1) the decision of whether to locate patents abroad; (2) in which countries to locate patents; and (3) how many patents to locate in each country. Our findings indicate that multinationals take the tax attractiveness ...

  7. Patent Examination Decisions and Strategic Trade Behavior

    OpenAIRE

    Alfons Palangkaraya; Paul Jensen; Elizabeth Webster

    2006-01-01

    This paper examines whether strategic trade behavior can explain the fact that the US, Japanese and European Patent Offices – the USPTO, the JPO and the EPO – often make different decisions about whether to grant (or reject) a given patent application. We analyse this issue by considering whether examination decisions across the patent offices vary systematically by inventor nationality, patent quality and technology area using a matched sample of 33,305 non-PCT patent applications granted ...

  8. Measuring Technological Distance for Patent Mapping

    OpenAIRE

    Yan, Bowen; Luo, Jianxi

    2015-01-01

    Recent works in the information science literature have presented cases of using patent databases and patent classification information to construct network maps of technology fields, which aim to aid in competitive intelligence analysis and innovation decision making. Constructing such a patent network requires a proper measure of the distance between different classes of patents in the patent classification systems. Despite the existence of various distance measures in the literature, it is...

  9. Patent perspectives for corticosteroids based ophthalmic therapeutics.

    Science.gov (United States)

    Suresh, Preeti K; Sah, Abhishek K

    2014-01-01

    Eye inflammation, if untreated at right time poses the risk of vision loss. Several categories of drugs are available in the global market, but corticosteroids are still used for the treatment of ocular inflammation including anterior/ posterior uveitis, age related macular degeneration (AMD) and post cataract surgery inflammation. Although corticosteroids have well-documented side effects as compared to non steroidal anti-inflammatory drugs (NSAIDs), but they are still regarded as better anti-inflammatory agents for treating ocular inflammations. The prime concern with conventional formulations such as (ophthalmic solutions, suspensions, ointments) is low drug bioavailability due to precorneal barrier of the eye, tear turnover and rapid drainage of drug via nasolacrimal drainage and drug induced systemic toxicity. To overcome these limitations, various novel formulations of corticosteroids have been explored. These include nanoparticles, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), nanomicelles, in-situ gels, iontophoresis, liposomes, nanoemulsions, microemulsions and ocular implants for the effective ophthalmic delivery of the corticosteroids. Topical nanocarriers have also been demonstrated to be promising vectors with potential application in the ophthalmic therapeutics. This review summarizes the clinical findings and patents on various corticosteroids as ocular pharmacotherapeutics. PMID:25020063

  10. Patent foramen ovale.

    Science.gov (United States)

    Homma, Shunichi; Messé, Steven R; Rundek, Tatjana; Sun, Yee-Ping; Franke, Jennifer; Davidson, Karina; Sievert, Horst; Sacco, Ralph L; Di Tullio, Marco R

    2016-01-01

    Patent foramen ovale (PFO) is the most common congenital heart abnormality of fetal origin and is present in approximately ∼25% of the worldwide adult population. PFO is the consequence of failed closure of the foramen ovale, a normal structure that exists in the fetus to direct blood flow directly from the right to the left atrium, bypassing the pulmonary circulation. PFO has historically been associated with an increased risk of stroke, the mechanism of which has been attributed to the paradoxical embolism of venous thrombi that shunt through the PFO directly to the left atrium. However, several studies have failed to show an increased risk of stroke in asymptomatic patients with a PFO, and the risk of stroke recurrence is low in patients who have had a stroke that may be attributed to a PFO. With the advent of transoesophageal and transthoracic echocardiography, as well as transcranial Doppler, a PFO can be routinely detected in clinical practice. Medical treatment with either antiplatelet or anticoagulation therapy is recommended. At the current time, closure of the PFO by percutaneous interventional techniques does not appear to reduce the risk of stroke compared to conventional medical treatment, as shown by three large clinical trials. Considerable controversy remains regarding the optimal treatment strategy for patients with both cryptogenic stroke and PFO. This Primer discusses the epidemiology, mechanisms, pathophysiology, diagnosis, screening, management and effects on quality of life of PFO. PMID:27188965

  11. Considerations on patent valuation based on patent classification and citation in biotechnological field

    Science.gov (United States)

    Mihara, Kenji

    Regarding innovation measurement utilizing patent information, a number of researchers are making great efforts to measure a "patent value (patent quality)." For patent valuation, patent classification and citation are often utilized as patent information. Also, biotechnological field is attracting attention from the viewpoint of application to environmental or medical study, and considerable researches on patent valuation are ongoing in this technical field. However, it is not enough recognized that researchers cannot be too careful when they deal with classification information in the biotech field because patent classification structure in this field is not well-established. And also, it is not known enough that citation patterns of both academic papers and patent documents are so complicated that the patterns cannot be easily generalized. In this article, the issues above were verified from a position based on working experiences of biotech patent examiner at Japan Patent Office, and considerations and implications were given on what patent valuation should be.

  12. Nikola Tesla’s Patent Applications for Which Patents Were Not Granted

    OpenAIRE

    S. Šarboh

    2013-01-01

    In this paper are presented the results of an investigation directed to discovering and identifying Nikola Tesla’s patent applications filed with the United States Patent Office, but for which appropriate patents were not granted to him. The investigation showed that Tesla had at least 33 American patent applications for which patents were not granted, that shed a new light on his inventive activities in the United States of America. The subject matter of these patent applications are differe...

  13. The Effect of Patent Grant on the Geographic Reach of Patent Sales

    OpenAIRE

    Drivas, Kyriakos; Fafaliou, Irene; Fampiou, Elpiniki; Yannelis, Demetrius

    2014-01-01

    This paper examines whether patents increase the geographic reach of the market for ideas. By employing a dataset of 25,127 US patents traded between US located firms, we find that patents sold during application phase are less likely to be traded outside the seller‟s state than patents that have been issued. To tackle the endogeneity issues we employ coarsened exact matching techniques. We find that patent grant increases the likelihood of a patent to ...

  14. Patent thickets and the market for innovation: evidence from settlement of patent disputes

    OpenAIRE

    Galasso, Alberto; Schankerman, Mark

    2008-01-01

    We study how fragmentation of patent rights ('patent thickets') and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the 'pro-patent shift' of CAFC. The model also predicts tha...

  15. Economics of Patent Pools When Some (but not all) Patents are Essential

    OpenAIRE

    Daniel Quint

    2006-01-01

    Patent pools are agreements by multiple patent owners to license certain patents to third parties as a package, and often in conjunction with the development of a technological standard. A key distinction made by regulators—between patents essential to a standard and patents that are suitable substitutes—has not been captured in existing economic models. I present a model of competition among differentiated technologies, in which some patents are essential and some are not. I show that pools ...

  16. Generic Drugs: Questions and Answers

    Science.gov (United States)

    ... branded counterparts, they are typically sold at substantial discounts from the branded price. According to the Congressional ... for 20 years. The patent, which protects the company that made the drug first, doesn't allow ...

  17. Patents, Inducement Prizes, and Contestant Strategy

    DEFF Research Database (Denmark)

    Davis, Jerome; Davis, Lee N.

    2006-01-01

    Debate over the merits of patents versus inducement prizes has tended to ignore the signaling roles of patents, and totally ignores the impact of patent signaling on prize contests. This paper asks: How does patent signaling affect the strategic choices of firms considering entering prize contests......? First, we consider contests that do not allow patenting, then contests that do. If patenting is not allowed, we argue, patent-holders, both internal and external to the contest, can adversely impact prize contests by claiming prize winner violation of their patents, and suing for damages. The likelihood...... of such challenges being made can deter entry, particularly in contests requiring large sunk costs. Furthermore, the firm's decisionmaking process will discriminate against entering prize contests and favor R&D projects with patentable outcomes. Together, these problems may circumscribe any future...

  18. Reasons for Patent Protection and Cost-effective Patent Filing Options for SMEs

    Directory of Open Access Journals (Sweden)

    Art Brion

    2011-12-01

    Full Text Available Many innovative small and medium enterprises (SMEs do not seek patent protection for their innovations, either because they are skeptical about the perceived benefits or wary of the perceived costs. However, by failing to protect their intellectual property with patents, they leave themselves exposed to attack by other patent holders. This article explores arguments for patent protection as well as filing options that can protract the patenting process while simultaneously reducing patenting costs. By choosing their patent application filings wisely, SMEs can keep their patenting options open for as long as possible while delaying costs.

  19. Patents wars : Brevet d'invention et patent, une comparaison

    OpenAIRE

    Mangolte, Pierre-André

    2010-01-01

    Ce texte fait partie d'une étude générale sur les patents wars américaines de la fin du XIXème et du début du XXème siècle, dans trois industries émergentes : l'industrie du cinéma et les patents Edison, l'industrie automobile et l'affaire du brevet Selden, l'industrie de l'aviation et les patents des frères Wright. L'analyse est comparative, entre Etats-Unis et France, où, à la même époque, il n'y a aucun litige de même ordre, et de même importance. Cette première partie analyse plus spécifi...

  20. Need for improving quality of operating structures and processes for better ARV adherence for patients with HIV/AIDS in Tanzania and other African countries:an experi-ence from Tanzania

    Institute of Scientific and Technical Information of China (English)

    Irunde H; Nsimba SED; Comoro CJ

    2009-01-01

    Objective:The study was carried out in order to determine the following objectives:(1)To determine the pro-portion of patients who state achieving or not achieving optimal adherence to antiretroviral therapy (ART)in selected Care and Treatment Sites in Arusha and Dares Salaam regions in Tanzania.(2)To identify factors such as structural,cultural or disease related contributing to sub-optimal adherence to antiretroviral (ARVs). (3)To assess quality of operating structures and processes for provision of antiretroviral (ARVs)in the select-ed healthcare facilities.(4)To document suggestions and proposals for improving ART adherence among ARV users.Methods:Data from 7 studied facilities (3 public and 4 private /or faith based)includes 207 interviews from ARV users,28 staff interview staff,26 observations during consultations,8 focus group discussions,10 key informant interviews,and stock checks in 6 facilities.The study design was a cross-sectional using both qualitative and quantitative data collection techniques.Quantitative data were collected by using an adherence tool check list,while qualitative data were obtained using a consultation observation checklist,semi-structured interviews,focus group discussions (FGDs)and key informant interviews.Results:There were slight varia-tions in the quality of operating structures and processes in the two studied regions.However results indicate that ARV adherence in Arusha region was comparatively similar to that of Dares Salaam.The composite adher-ence for one month in seven facilities was 90 % and only 21 % of ARV users achieved optimal adherence. Conclusion:The overall mean composite adherence rate of 90 % in the two areas surveyed is encouraging. More efforts to improve the quality and processes of operating structures in our study facilities and others in Tanzania are needed to ensure optimal adherence among the larger group (79 %)of ARV users who are cur-rently taking less than the critical 95 % of their medications.

  1. Prevention of mother-to-child HIV-1 transmission in Burkina Faso: evaluation of vertical transmission by PCR, molecular characterization of subtypes and determination of antiretroviral drugs resistance

    Science.gov (United States)

    Sagna, Tani; Bisseye, Cyrille; Compaore, Tegewende R.; Kagone, Therese S.; Djigma, Florencia W.; Ouermi, Djeneba; Pirkle, Catherine M.; Zeba, Moctar T. A.; Bazie, Valerie J. T.; Douamba, Zoenabo; Moret, Remy; Pietra, Virginio; Koama, Adjirita; Gnoula, Charlemagne; Sia, Joseph D.; Nikiema, Jean-Baptiste; Simpore, Jacques

    2015-01-01

    Background Vertical human immunodeficiency virus (HIV) transmission is a public health problem in Burkina Faso. The main objective of this study on the prevention of mother-to-child HIV-1 transmission was to determine the residual risk of HIV transmission in infants born to mothers receiving highly active antiretroviral therapy (HAART). Moreover, we detect HIV antiretroviral (ARV) drug resistance among mother–infant pairs and identify subtypes and circulating recombinant forms (CRF) in Burkina Faso. Design In this study, 3,215 samples of pregnant women were analyzed for HIV using rapid tests. Vertical transmission was estimated by polymerase chain reaction in 6-month-old infants born to women who tested HIV positive. HIV-1 resistance to ARV, subtypes, and CRFs was determined through ViroSeq kit using the ABI PRISM 3,130 sequencer. Results In this study, 12.26% (394/3,215) of the pregnant women were diagnosed HIV positive. There was 0.52% (2/388) overall vertical transmission of HIV, with rates of 1.75% (2/114) among mothers under prophylaxis and 0.00% (0/274) for those under HAART. Genetic mutations were also isolated that induce resistance to ARV such as M184V, Y115F, K103N, Y181C, V179E, and G190A. There were subtypes and CRF of HIV-1 present, the most common being: CRF06_CPX (58.8%), CRF02_AG (35.3%), and subtype G (5.9%). Conclusions ARV drugs reduce the residual rate of HIV vertical transmission. However, the virus has developed resistance to ARV, which could limit future therapeutic options when treatment is needed. Resistance to ARV therefore requires a permanent interaction between researchers, physicians, and pharmacists, to strengthen the network of monitoring and surveillance of drug resistance in Burkina Faso. PMID:25630709

  2. Prevention of mother-to-child HIV-1 transmission in Burkina Faso: evaluation of vertical transmission by PCR, molecular characterization of subtypes and determination of antiretroviral drugs resistance

    Directory of Open Access Journals (Sweden)

    Tani Sagna

    2015-01-01

    Full Text Available Background: Vertical human immunodeficiency virus (HIV transmission is a public health problem in Burkina Faso. The main objective of this study on the prevention of mother-to-child HIV-1 transmission was to determine the residual risk of HIV transmission in infants born to mothers receiving highly active antiretroviral therapy (HAART. Moreover, we detect HIV antiretroviral (ARV drug resistance among mother–infant pairs and identify subtypes and circulating recombinant forms (CRF in Burkina Faso. Design: In this study, 3,215 samples of pregnant women were analyzed for HIV using rapid tests. Vertical transmission was estimated by polymerase chain reaction in 6-month-old infants born to women who tested HIV positive. HIV-1 resistance to ARV, subtypes, and CRFs was determined through ViroSeq kit using the ABI PRISM 3,130 sequencer. Results: In this study, 12.26% (394/3,215 of the pregnant women were diagnosed HIV positive. There was 0.52% (2/388 overall vertical transmission of HIV, with rates of 1.75% (2/114 among mothers under prophylaxis and 0.00% (0/274 for those under HAART. Genetic mutations were also isolated that induce resistance to ARV such as M184V, Y115F, K103N, Y181C, V179E, and G190A. There were subtypes and CRF of HIV-1 present, the most common being: CRF06_CPX (58.8%, CRF02_AG (35.3%, and subtype G (5.9%. Conclusions: ARV drugs reduce the residual rate of HIV vertical transmission. However, the virus has developed resistance to ARV, which could limit future therapeutic options when treatment is needed. Resistance to ARV therefore requires a permanent interaction between researchers, physicians, and pharmacists, to strengthen the network of monitoring and surveillance of drug resistance in Burkina Faso.

  3. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.

    Science.gov (United States)

    Cockburn, Iain; Long, Genia

    2015-07-01

    Patents have long been considered essential incentives to foster innovation, particularly the development of new prescription drugs, due to the lengthy, costly, and risky nature of the research and development (R&D) process as compared to the lower levels of investment and risk associated with generic drug entry. Compared with other forms of intellectual property protection (such as trade secrets, trademarks, and copyrights) and strategic complementary assets (such as lead time, sales and service, and manufacturing advantages), researchers focused on the US since the 1980s consistently have found patents to be relatively more important to R&D in pharmaceuticals than in other industries. Despite many changes in the market and patent landscape, the most recent data from government surveys and annual surveys of licensing professionals continue to find differential and high importance of patents to biopharmaceutical innovation. PMID:25927945

  4. Argonne National Laboratory patent portfolio

    International Nuclear Information System (INIS)

    This booklet contains the abstracts of all active U. S. patents on technology items that originated at ANL, the applicability of which is not limited to nuclear reactors. Also listed are the titles of all ANL-originated nuclear-related U. S. patents that are still in force. Selected technology items for which patent applications have been filed and are available for licensing are included in several categories. Categories included in this booklet are as follows: atmospheric and earth sciences; biological and medical sciences; chemistry and chemical engineering; cryogenics and superconductivity; electronics and electrical engineering; energy conversion; measurements and controls; methods and devices; materials and fabrication; physics, accelerators and fusion; and selected nuclear-related technology

  5. Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.

    Directory of Open Access Journals (Sweden)

    Maria Goretti P Fonseca

    Full Text Available BACKGROUND: The AIDS epidemic in Brazil remains concentrated in populations with high vulnerability to HIV infection, and the development of an HIV vaccine could make an important contribution to prevention. This study modeled the HIV epidemic and estimated the potential impact of an HIV vaccine on the number of new infections, deaths due to AIDS and the number of people receiving ARV treatment, under various scenarios. METHODS AND FINDINGS: The historical HIV prevalence was modeled using Spectrum and projections were made from 2010 to 2050 to study the impact of an HIV vaccine with 40% to 70% efficacy, and 80% coverage of adult population, specific groups such as MSM, IDU, commercial sex workers and their partners, and 15 year olds. The possibility of disinhibition after vaccination, neglecting medium- and high-risk groups, and a disease-modifying vaccine were also considered. The number of new infections and deaths were reduced by 73% and 30%, respectively, by 2050, when 80% of adult population aged 15-49 was vaccinated with a 40% efficacy vaccine. Vaccinating medium- and high-risk groups reduced new infections by 52% and deaths by 21%. A vaccine with 70% efficacy produced a great decline in new infections and deaths. Neglecting medium- and high-risk population groups as well as disinhibition of vaccinated population reduced the impact or even increased the number of new infections. Disease-modifying vaccine also contributed to reducing AIDS deaths, the need for ART and new HIV infections. CONCLUSIONS: Even in a country with a concentrated epidemic and high levels of ARV coverage, such as Brazil, moderate efficacy vaccines as part of a comprehensive package of treatment and prevention could have a major impact on preventing new HIV infections and AIDS deaths, as well as reducing the number of people on ARV. Targeted vaccination strategies may be highly effective and cost-beneficial.

  6. Patents and the supply of therapeutic products.

    Science.gov (United States)

    Hayhurst, W L

    1992-01-01

    In some countries protests against the grant of exclusive rights in developments that benefit humanity have caused limits to be placed on the scope of patent rights. A characteristic of all modern patent systems is that the invention that one seeks to patent must have some practical utility and be new. The US is making patent protection available even for methods of medical treatment and for non human living things. A patent will expire in most developed countries 20 years from the filing of the application except in the US which grants patents from 17 years. India, China, and Brazil grant patents for shorter terms. In Australia and New Zealand, the term of a patent may be extended. In France and the US; extensions of term are possible only for medically related inventions. A patent grants to the owner of the patent the right, during its term, to exclude others from making, using, or selling the patented inventions. A patent grants to the owner of the patent the rights, during its term, to exclude others from making, using, or selling the patented invention. A patent owner who attempts to enforce a patent may be faced with a challenge that the patentee has misbehaved. In the US an alleged infringer may argue that the patentee misled the Patent Office when applying for the patent. The Patent laws of many countries enable the government to use patented inventions but compensate patent owners. Under sections 37 and 38 of the French patent legislation the government may decree that licenses are available in the interests of public health. In connection with Roussel-Uclaf's mifepristone, RU-486 it has been reported that such a decree cannot be made for a medicine that has not been approved by the government for distribution. The Canadian government has announced its intention to cancel the provisions in the Canadian Patent Act relating to compulsory licensing of medicines. Negotiations are continuing under the General Agreement on Tariffs and Trade that may lead to an

  7. 48 CFR 1327.305 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Administration of patent... GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patent Rights Under Government Contracts 1327.305 Administration of patent rights clauses....

  8. 7 CFR 1210.367 - Patents, copyrights, inventions, and publications.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, inventions, and publications....367 Patents, copyrights, inventions, and publications. Any patents, copyrights, inventions, product... such patents, copyrights, inventions, product formulations, or publications shall be considered...

  9. 48 CFR 27.305 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Administration of patent... REGULATION GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patent Rights under Government Contracts 27.305 Administration of patent rights clauses....

  10. 48 CFR 27.201 - Patent and copyright infringement liability.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent and copyright... REGULATION GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patents and Copyrights 27.201 Patent and copyright infringement liability....

  11. 48 CFR 2427.305 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 6 2010-10-01 2010-10-01 true Administration of patent... AND URBAN DEVELOPMENT SOCIOECONOMIC PROGRAMS PATENTS, DATA, AND COPYRIGHTS Patent Rights Under Government Contracts 2427.305 Administration of patent rights clauses....

  12. 48 CFR 1427.201 - Patent and copyright infringement liability.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent and copyright... INTERIOR GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patents and Copyrights 1427.201 Patent and copyright infringement liability....

  13. 48 CFR 1227.305 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Administration of patent... TRANSPORTATION GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patent Rights Under Government Contracts 1227.305 Administration of patent rights clauses....

  14. Driving a decade of change: HIV/AIDS, patents and access to medicines for all

    OpenAIRE

    Hoen Ellen 't; Berger Jonathan; Calmy Alexandra; Moon Suerie

    2011-01-01

    Abstract Since 2000, access to antiretroviral drugs to treat HIV infection has dramatically increased to reach more than five million people in developing countries. Essential to this achievement was the dramatic reduction in antiretroviral prices, a result of global political mobilization that cleared the way for competitive production of generic versions of widely patented medicines. Global trade rules agreed upon in 1994 required many developing countries to begin offering patents on medic...

  15. Patent Medicine Sellers: How Can They Help Control Childhood Malaria?

    OpenAIRE

    Akuse, Rosamund M.; Edwin E Eseigbe; Abubakar Ahmed**; Brieger, William R

    2010-01-01

    Roll Back Malaria Initiative encourages participation of private health providers in malaria control because mothers seek care for sick children from them. This study investigated Patent Medicine Sellers (PMS) management of presumptive malaria in children in order to identify how they can assist malaria control. A cross-sectional survey of 491 PMS in Kaduna, Nigeria, was done using interviews and observation of shop activities. Most (80%) customers bought drugs without prescriptions. Only 29....

  16. The phage display technique: advantages and recent patents.

    Science.gov (United States)

    de Almeida, Sintia Silva; Magalhães, Aryane Aparecida C; de Castro Soares, Siomar; Zurita-Turk, Meritxell; Goulart, Luiz Ricardo; Miyoshi, Anderson; Azevedo, Vasco

    2011-08-01

    Phage display technology has advanced considerably since its creation, and the number of research projects using this technique is constantly increasing, generating numerous antibody and antigen libraries. These libraries, besides expediting library screening, improving selection methods and allowing evaluation of novel applications, have great potential for the development of new vaccines, drugs and diagnosis tests. Consequently, patent registries for the protection of these sequences are essential. PMID:21663585

  17. Patent Eligibility of Business Methods in Canada

    Institute of Scientific and Technical Information of China (English)

    Zheng Li; Brian Lee

    2011-01-01

    @@ While the same fundamental principles underlining patent law are generally accepted in every major jurisdiction in the world, the patent eligibility of computer-implemented business method inventions ("business methods") has received different treatment between jurisdictions.

  18. Retrieving Patents: An Overview for Pharmaceutical Industry

    Directory of Open Access Journals (Sweden)

    Pratibha Gokhale,

    2012-05-01

    Full Text Available Patent system worldwide, as known today, is about two hundred years old and existed in some format least about four hundred years ago in parts of Europe. However, over the last twenty years the volumeof patents has grown phenomenally with interdisciplinary and complex subjects and the existence of internetmakes most of the information available in some form or the other and has thus made the searchers’ questmore difficult. Thus, patent search has attained much greater significance as it is always interlinked withcommercial gains. India too has observed a quantum leap in patent applications in the last decade. Organisationsare attaching greater importance to patent filing and thus for patent searching too. Patent search, as aprofession has attained a significant position in the area of intellectual property .There has been severalattempts to simplify and make the patent search more efficient and effective. The present paper provides an overview of the same.

  19. On the Nature of Standards and Patents

    Institute of Scientific and Technical Information of China (English)

    Bing WANG; Xu LI; Lanxi XIONG

    2008-01-01

    @@ Introduction 'Standard' and 'patent' are the buzz words in China's information and communication technology (ICT) industry. While the government has expressed its intention to promote standardization and patent protec-tion, what direction should enterprises especially domestic ICT companies take?

  20. Patentability of methods of human enhancement

    DEFF Research Database (Denmark)

    Nordberg, Ana

    2015-01-01

    This article explores how to apply patentability rules to human enhancement, particularly focusing on Article 53(c) of the European Patent Convention (EPC). The global size and value of the cosmetic and wellness market and industry allow for the prediction of considerable market potential for human...... enhancement. Patents will be instrumental for companies to protect investment in innovation and tap into this potentially valuable market. The European patent system contains, in Article 53(c) EPC, an exception from patentability for methods for treatment and diagnostic methods. Such rule was created, and...... subsequently developed through European Patent Office (EPO) case law, by reference to the dichotomy between therapeutic and cosmetic methods. Subsuming enhancement methods under this patentability rule may be challenging. Ultimately, patentability of human enhancement will depend on the concept of health, its...

  1. Can this kind of idea be a patent?

    International Nuclear Information System (INIS)

    This book mentions patent such as application, what is patents, patent law, procedure and patent attorney, which includes business idea is patent. Is internet domain name or name-brand? We can make a big money with others idea, the difference among patent, trademark, utility model rights and registration of design, priority system, new weapon in digital period, patent is a knife and a shield, the cost from application to registration, what is hunting of patent information, writing document for patent, patent examination and patent lawyer.

  2. 78 FR 13685 - Determination of Regulatory Review Period for Purposes of Patent Extension; LAVIV

    Science.gov (United States)

    2013-02-28

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For human biological products, the testing phase begins when the exemption to permit the clinical investigations of...

  3. 77 FR 26290 - Determination of Regulatory Review Period for Purposes of Patent Extension; KRYSTEXXA

    Science.gov (United States)

    2012-05-03

    ... patented item (human drug product, animal drug product, medical device, food additive, or color additive... regulatory review period consists of two periods of time: A testing phase and an approval phase. For human biological products, the testing phase begins when the exemption to permit the clinical investigations of...

  4. 22 CFR 92.72 - Services in connection with patents and patent applications.

    Science.gov (United States)

    2010-04-01

    ... 22 Foreign Relations 1 2010-04-01 2010-04-01 false Services in connection with patents and patent... RELATED SERVICES Miscellaneous Notarial Services § 92.72 Services in connection with patents and patent applications. (a) Affidavit of applicant. The form of the affidavit of an applicant for a United States...

  5. Embryonic Stem Cell Patents and Human Dignity

    OpenAIRE

    Resnik, David B.

    2007-01-01

    This article examines the assertion that human embryonic stem cells patents are immoral because they violate human dignity. After analyzing the concept of human dignity and its role in bioethics debates, this article argues that patents on human embryos or totipotent embryonic stem cells violate human dignity, but that patents on pluripotent or multipotent stem cells do not. Since patents on pluripotent or multipotent stem cells may still threaten human dignity by encouraging people to treat ...

  6. Renewal of Patents and Government Financing

    OpenAIRE

    Svensson, Roger

    2008-01-01

    I apply a survival model to a detailed dataset of Swedish patents to estimate how different factors affect the likelihood of patent renewal. Since the owners know more about the patents than potential external financiers, there is a problem of asymmetric information. To overcome this, Sweden has for a long time relied on government support rather than private venture capital. The empirical results show that patents which have received soft government financing in the R&D-phase have a higher p...

  7. PCT Reforms Its Patent Filing System

    Institute of Scientific and Technical Information of China (English)

    2004-01-01

    As of January 1,2004,the first critical steps in seekingpatent protection in multiple countries will be easier as aresult of reforms to the international patent filing system.Aseries of reforms to the World Intellectual PropertyOrganisation's(WIPO)Patent Cooperation Treaty(PCT),ranging from a new simplified system of designatingcountries in which patent protection is sought to an enhancedsearch and preliminary examination system,will simplify thecomplex procedure of obtaining patent protection in severa...

  8. A quality index for patent systems

    OpenAIRE

    VAN POTTELSBERGHE Bruno; de Saint-Georges, Matthis

    2011-01-01

    This paper presents a quality index for patent systems. The index is composed of nine operational design components that help shape the transparency of patent systems and affect the extent to which they comply with patentability conditions. Seven factors are related to rules and regulations (e.g., grace period, opposition process and continuation-inparts), while two factors measure patent offices’ resource allocation (i.e., workload per examiner and incentives). The index is computed for 32 n...

  9. On Sharks, Trolls, and Other Patent Animals

    OpenAIRE

    Reitzig, Markus; Henkel, Joachim; Heath, Christopher

    2007-01-01

    Patent trolls (or sharks) are small patent holding individuals or firms who trap R&D intense manufacturers in patent infringement situations in order to receive damage awards for the illegitimate use of their technology. While of great concern to management, their existence and impact for both corporate decision makers and policy makers remains to be fully analyzed from an academic standpoint. In this paper we show why patent sharks can operate profitably, why they are of growing concern, how...

  10. Patent Laws and Innovation in China

    OpenAIRE

    Yueh, Linda

    2006-01-01

    This paper explores how the patent laws and intellectual property rights (IPR) system in China have affected innovation during the reform period. Subject to criticism due to imperfect enforcement, the patent law system has produced a stock of patents which has grown rapidly alongside economic growth. Despite significant regional disparities in income and the level of innovation, the success rates of patent applications are similar across the country. The application of the pate...

  11. Runner-up patents: is monopoly inevitable?

    OpenAIRE

    Henry, Emeric

    2010-01-01

    Exclusive patents sacrifice product competition to provide firms incentives to innovate. We characterize an alternative mechanism whereby later inventors are allowed to share the patent if they discover within a certain time period of the first inventor. These runner-up patents increase social welfare under very general conditions. Furthermore, we show that the time window during which later inventors can share the patent should become a new policy tool at the disposal of the designer. This i...

  12. The New Swiss Patent Ligitation System

    OpenAIRE

    Rigamonti, Cyrill

    2011-01-01

    Switzerland is about to implement a completely new patent litigation system, following the establishment of a new specialized federal patent trial court and the replacement of twenty-six cantonal codes of civil procedure with a single uniform federal code of civil procedure. This article provides an overview of the general structure and the most important features of the new patent litigation system that may be of interest to international patent litigants and litigators.

  13. Why Don't Inventors Patent?

    OpenAIRE

    Petra Moser

    2007-01-01

    This paper argues that the ability to keep innovations secret may be a key determinant of patenting. To test this hypothesis, the paper examines a newly-collected data set of more than 7,000 American and British innovations at four world's fairs between 1851 and 1915. Exhibition data show that the industry where an innovation is made is the single most important determinant of patenting. Urbanization, high innovative quality, and low costs of patenting also encourage patenting, but these infl...

  14. Patent Protection, Financial Development and Economic Growth

    OpenAIRE

    Shiyuan Pan; Mengbo Zhang; Heng-fu Zou

    2011-01-01

    This paper theoretically and empirically investigates the effects of patent protection on innovation and economic growth by looking at the interaction between patent system and financial system. On the one hand, patent protection accelerates economic growth through enhancing the value of innovation. On the other hand, it lowers the demand for capital by increasing the price, thereby weakening the learning-by-doing effect and raising the cost of production. It follows, in turn, patent protecti...

  15. Past, present and future of pharmaceutical patents under Korea-US Trade Agreement.

    Science.gov (United States)

    Shin, Yoon Suk

    2016-07-01

    The introduction of substance patents in 1987 was viewed with apprehension as it was believed that the system would only reinforce the domination of the technology of advanced countries based on the trade agreement between Korea and the USA. However, substance patents provided the Korean pharmaceutical industry with the driving force required to develop new substances, and the Korean pharmaceutical industry has been constantly improving its research and development capability. The patent-approval linkage system was implemented according to the Korea-US Free Trade Agreement in 2015. The system comprises the following: registering the drugs in the Green List, notifying the listed patent and marketing approval holders about the application for generic marketing approval, patent holder's request for staying generic sales and first generic exclusivity. Korean generic companies are expected to have opportunities that enable them to challenge the global market by accumulating experience of designing of generic products, making patent challenges and strategically developing of new drugs or incrementally modified drugs through the linkage system. PMID:27338849

  16. Patents as Options: Some Estimates of the Value of Holding European Patent Stocks

    OpenAIRE

    1984-01-01

    In many countries holders of patents must pay an annual renewal fee in order to keep their patents in force. This paper uses data on the proportion of patents renewed, and the renewal fees faced by, post World War II cohorts of patents in France, the United Kingdom, and Germany, in conjunction with a model of patent holders' renewal decisions, to estimate the returns earned from holding patents in these countries. Since patents are often applied for at a nearly stage in the innovation process...

  17. Understanding Patenting Decisions: A Classroom Exercise

    Science.gov (United States)

    Bernard, John C.; Yiannaka, Amalia

    2010-01-01

    Although many students have some knowledge of patents, it can be difficult for them to understand the components of an innovator's decision-making process. Key issues, such as whether to patent or to use trade secrecy, how broad a scope to claim, and what to do in the event of patent infringement, can be difficult to grasp from a standard lecture.…

  18. India's Journey Toward an Effective Patent System

    OpenAIRE

    Abramson, Bruce

    2007-01-01

    The decade following India's accession to the World Trade Organization's Trade-Related Aspects of Intellectual Property ushered in numerous changes to the country's patent system, culminating in a series of amendments in 2005. But a functioning patent system is more than a statute. This paper discusses the steps that India must still take to develop an effective, functioning patent syste...

  19. 48 CFR 970.2703 - Patent rights.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent rights. 970.2703 Section 970.2703 Federal Acquisition Regulations System DEPARTMENT OF ENERGY AGENCY SUPPLEMENTARY REGULATIONS DOE MANAGEMENT AND OPERATING CONTRACTS Patents, Data, and Copyrights 970.2703 Patent rights....

  20. 43 CFR 402.10 - Patent.

    Science.gov (United States)

    2010-10-01

    ... 43 Public Lands: Interior 1 2010-10-01 2010-10-01 false Patent. 402.10 Section 402.10 Public Lands... LANDS IN FEDERAL RECLAMATION PROJECTS Public Lands § 402.10 Patent. When a purchaser has complied fully... and patent and shall state the statutory authority for such liens. The receipt shall be submitted...

  1. 48 CFR 35.012 - Patent rights.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent rights. 35.012 Section 35.012 Federal Acquisition Regulations System FEDERAL ACQUISITION REGULATION SPECIAL CATEGORIES OF CONTRACTING RESEARCH AND DEVELOPMENT CONTRACTING 35.012 Patent rights. For a discussion of patent rights,...

  2. 37 CFR 1.705 - Patent term adjustment determination.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent term adjustment determination. 1.705 Section 1.705 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES Adjustment and Extension of Patent...

  3. The Tiger Awakens: The Tumultuous Transformation of India’s Patent System and the Rise of Indian Pharmaceutical Innovation

    OpenAIRE

    Janice M. Mueller

    2007-01-01

    The first day of January 2005 marked a dramatic turning point in the history of India. By deliberately excluding pharmaceutical products from patent protection for the previous 34 years, India became a world leader in high-quality generic drug manufacturing. But India’s entry into the global economy at the end of the 20th century, as evidenced by membership in the World Trade Organization (WTO), compelled the nation to once again award patents on drugs. Moreover, India henceforth would ...

  4. Patentering af det humane genom

    DEFF Research Database (Denmark)

    Sommer, Tine

    2004-01-01

    Direktiv 98/44/EF om retlig beskyttelse af bioteknologiske opfindelser blev gennemført i dansk ret med ikrafttrædelse den 30. juli 2000. Direktivet indeholder i artikel 5 en central bestemmelse som giver adgang til patent på humane gener. I artikel 5, stk. 3, er indføjet et skærpet krav til...

  5. A Study on Patent Mapping and Its Usage for Analyzing Patent Trends in Nuclear Fields

    International Nuclear Information System (INIS)

    The propose of this project is to construct our patent mapping system for its internal usage of patent map at our institute as well as preparation for our nation's related law and for obligation of patent mapping at national research institutes. The main contents carried out in this project are as follows: - Quantitative analysis about all intellectual properties applied in KAERI - Quantitative/qualitative analysis about all patents applied in food irradiation at main countries - Development of cooperation model for patent mapping

  6. Navigating the Patent Thicket: Cross Licenses, Patent Pools and Standard Setting

    OpenAIRE

    Shapiro, Carl

    2004-01-01

    In several key industries, including semiconductors, biotechnology, computer software, and the Internet, our patent system is creating a patent thicket: an overlapping set of patent rights requiring that those seeking to commercialize new technology obtain licenses from multiple patentees. The patent thicket is especially thorny when combined with the risk of hold-up, namely the danger that new products will inadvertently infringe on patents issued after these products were designed. The need...

  7. Compulsory licensing and access to drugs

    OpenAIRE

    Stavropoulou, C; Valletti, T.

    2015-01-01

    Compulsory licensing allows the use of a patented invention without the owner's consent, with the aim of improving access to essential drugs. The pharmaceutical sector argues that, if broadly used, it can be detrimental to innovation. We model the interaction between a company in the North that holds the patent for a certain drug and a government in the South that needs to purchase it. We show that both access to drugs and pharmaceutical innovation depend largely on the Southern country's abi...

  8. Chinese Patent Medicine Liu Wei Di Huang Wan Combined with Antihypertensive Drugs, a New Integrative Medicine Therapy, for the Treatment of Essential Hypertension: A Systematic Review of Randomized Controlled Trials

    OpenAIRE

    Jie Wang; Kuiwu Yao; Xiaochen Yang; Wei Liu; Bo Feng; Jizheng Ma; Xinliang Du; Pengqian Wang; Xingjiang Xiong

    2012-01-01

    Objectives. To assess the beneficial and adverse effects of Liu Wei Di Huang Wan (LWDHW), combined with antihypertensive drugs, for essential hypertension. Methods. Five major electronic databases were searched up to August 2012 to retrieve any potential randomized controlled trials designed to evaluate the clinical effectiveness of LWDHW combined with antihypertensive drugs for essential hypertension reported in any language, with main outcome measures as blood pressure. The quality of the i...

  9. Economic valuation of patents methods and applications

    CERN Document Server

    Munari, F

    2011-01-01

    The Economic Valuation of Patents provides an original and essential analysis of patent valuation, presenting the main methodologies to value patents in different contexts. Starting with an analysis of the relevance of patent valuation from a strategic, economic and legal perspective, the book undertakes a thorough review of the existing financial and qualitative valuation methodologies. The contributing authors, IP experts from academia and business, discuss the application of valuation issues in various contexts such as patent portfolio management, licensing agreements, IP litigation, IP-bac

  10. Entrepreneurial patent management in pharmaceutical startups.

    Science.gov (United States)

    Holgersson, Marcus; Phan, Tai; Hedner, Thomas

    2016-07-01

    Startups fill an increasingly important role as innovators in the pharmaceutical industry, and patenting is typically central to their success. This article aims to explore patent management in pharmaceutical startups. The results show that startups need to deal with several challenges related to patenting and an 'entrepreneurial' approach to patent management is called for. Resource constraints, venture capital provision, exits and other conditions and events must be readily considered in the patent management process to build a successful pharmaceutical venture, something that could benefit the pharmaceutical industry as a whole. PMID:26948802

  11. Patent=Monopoly: A Legal Fiction

    OpenAIRE

    Bostyn, S.; Petit, N.

    2013-01-01

    A patent right is an exclusionary right. With it, the patent holder can exclude third parties from making, using, selling, etc. products or processes protected by his patent. In the past, this right has also been referred to as a 'monopoly right' and this has lead to considerable confusion about the scope of patent rights and the role of the patent system in a modern economy. This paper seeks to provide some clarity on this issue and highlight the distinction between the exclusionary right gr...

  12. Patent data mining method and apparatus

    Science.gov (United States)

    Boyack, Kevin W.; Grafe, V. Gerald; Johnson, David K.; Wylie, Brian N.

    2002-01-01

    A method of data mining represents related patents in a multidimensional space. Distance between patents in the multidimensional space corresponds to the extent of relationship between the patents. The relationship between pairings of patents can be expressed based on weighted combinations of several predicates. The user can select portions of the space to perceive. The user also can interact with and control the communication of the space, focusing attention on aspects of the space of most interest. The multidimensional spatial representation allows more ready comprehension of the structure of the relationships among the patents.

  13. Analysis of US patents on spacer grids

    International Nuclear Information System (INIS)

    The total of 137 US patents on spacer grids patented from 1968 through 1993 are analyzed and summarized. Database is constituted with designing the appropriate fields by which each patent can be identified. The fields consist of patent number, inventor, assignee, date of patent, title and major foci of the patent. The major foci are again classified by detailed subjects such as the fretting failure and fuel rod support-related, the strength-related, the fabrication-related as for mechanical subjects, while the cooling performance-related and the pressure drop-related as for thermal-hydraulic one. The 92% of the patents analyzed were issued form nuclear companies of USA, France and Germany. Among the patents dealing with mechanical subjects, the fretting failure and fuel rod support-related is more than the pressure drop-related among the patents of thermal-hydraulic subjects. The number of patents issued from Japan ranks just after Germany i.e., the 4th country. It is thought that much concern as well as investment should be increased in this field, the patent of nuclear components. (author). 2 tabs., 5 figs

  14. Bioavailability and Bioequivalence in Drug Development

    OpenAIRE

    Chow, Shein-Chung

    2014-01-01

    Bioavailability is referred to as the extent and rate to which the active drug ingredient or active moiety from the drug product is absorbed and becomes available at the site of drug action. The relative bioavailability in terms of the rate and extent of drug absorption is considered predictive of clinical outcomes. In 1984, the United States Food and Drug Administration (FDA) was authorized to approve generic drug products under the Drug Price Competition and Patent Term Restoration Act base...

  15. US photovoltaic patents: 1991--1993

    Energy Technology Data Exchange (ETDEWEB)

    Pohle, L

    1995-03-01

    This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials as well as manufacturing and support functions. The patent entries in this document were issued from 1991 to 1993. The entries were located by searching USPA, the database of the US Patent Office. The final search retrieved all patents under the class ``Batteries, Thermoelectric and Photoelectric`` and the subclasses ``Photoelectric,`` ``Testing,`` and ``Applications.`` The search also located patents that contained the words ``photovoltaic(s)`` or ``solar cell(s)`` and their derivatives. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors, and subjects only peripherally concerned with photovoltaic. Some patents on these three subjects were included when ft appeared that those inventions might be of use in terrestrial PV power technologies.

  16. Idea on patent ; It is high time to stress quality

    International Nuclear Information System (INIS)

    This book deals with patent stressing on the quality, which includes from idea to technical business, It's simple to register the computer program, why do patent lawyer appoint the patent attorney's office? construction of patent right range, a good patent and a bad patent, strong patent and weak patent. It doesn't allow for Dus to use as we like, each patent has different value, Let's write technical specifications, advice on talking for invention with a patent attorney's office and what kind of task do intellectual property division do?

  17. Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials.

    Science.gov (United States)

    Wang, Jie; Yao, Kuiwu; Yang, Xiaochen; Liu, Wei; Feng, Bo; Ma, Jizheng; Du, Xinliang; Wang, Pengqian; Xiong, Xingjiang

    2012-01-01

    Objectives. To assess the beneficial and adverse effects of Liu Wei Di Huang Wan (LWDHW), combined with antihypertensive drugs, for essential hypertension. Methods. Five major electronic databases were searched up to August 2012 to retrieve any potential randomized controlled trials designed to evaluate the clinical effectiveness of LWDHW combined with antihypertensive drugs for essential hypertension reported in any language, with main outcome measures as blood pressure. The quality of the included studies was assessed with the Jadad scale and a customized standard quality assessment scale. Results. 6 randomized trials were included. The methodological quality of the trials was evaluated as generally low. The pooled results showed that LWDHW combined with antihypertensive drugs was more effective in blood pressure and the scale for TCM syndrome and symptom differentiation scores compared with antihypertensive drugs alone. Most of the trials did not report adverse events, and the safety is still uncertain. Conclusions. LWDHW combined with antihypertensive drugs appears to be effective in improving blood pressure and symptoms in patients with essential hypertension. However, the evidence remains weak due to the poor methodological quality of the included studies. PMID:23258998

  18. Chinese Patent Medicine Liu Wei Di Huang Wan Combined with Antihypertensive Drugs, a New Integrative Medicine Therapy, for the Treatment of Essential Hypertension: A Systematic Review of Randomized Controlled Trials

    Directory of Open Access Journals (Sweden)

    Jie Wang

    2012-01-01

    Full Text Available Objectives. To assess the beneficial and adverse effects of Liu Wei Di Huang Wan (LWDHW, combined with antihypertensive drugs, for essential hypertension. Methods. Five major electronic databases were searched up to August 2012 to retrieve any potential randomized controlled trials designed to evaluate the clinical effectiveness of LWDHW combined with antihypertensive drugs for essential hypertension reported in any language, with main outcome measures as blood pressure. The quality of the included studies was assessed with the Jadad scale and a customized standard quality assessment scale. Results. 6 randomized trials were included. The methodological quality of the trials was evaluated as generally low. The pooled results showed that LWDHW combined with antihypertensive drugs was more effective in blood pressure and the scale for TCM syndrome and symptom differentiation scores compared with antihypertensive drugs alone. Most of the trials did not report adverse events, and the safety is still uncertain. Conclusions. LWDHW combined with antihypertensive drugs appears to be effective in improving blood pressure and symptoms in patients with essential hypertension. However, the evidence remains weak due to the poor methodological quality of the included studies.

  19. Patent and exclusivity status of essential medicines for non-communicable disease.

    Directory of Open Access Journals (Sweden)

    Tim K Mackey

    Full Text Available OBJECTIVE: The threat of non-communicable diseases ("NCDs" is increasingly becoming a global health crisis and are pervasive in high, middle, and low-income populations resulting in an estimated 36 million deaths per year. There is a need to assess intellectual property rights ("IPRs" that may impede generic production and availability and affordability to essential NCD medicines. METHODS: Using the data sources listed below, the study design systematically eliminated NCD drugs that had no patent/exclusivity provisions on API, dosage, or administration route. The first step identified essential medicines that treat certain high disease burden NCDs. A second step examined the patent and exclusivity status of active ingredient, dosage and listed route of administration using exclusion criteria outlined in this study. MATERIALS: We examined the patent and exclusivity status of medicines listed in the World Health Organization's ("WHO" Model List of Essential Drugs (Medicines ("MLEM" and other WHO sources for drugs treating certain NCDs. i.e., cardiovascular and respiratory disease, cancers, and diabetes. We utilized the USA Food and Drug Administration Orange Book and the USA Patent and Trademark Office databases as references given the predominant number of medicines registered in the USA. RESULTS: Of the 359 MLEM medicines identified, 22% (79/359 address targeted NCDs. Of these 79, only eight required in-depth patent or exclusivity assessment. Upon further review, no NCD MLEM medicines had study patent or exclusivity protection for reviewed criteria. CONCLUSIONS: We find that ensuring availability and affordability of potential generic formulations of NCD MLEM medicines appears to be more complex than the presence of IPRs with API, dosage, or administration patent or exclusivity protection. Hence, more sophisticated analysis of NCD barriers to generic availability and affordability should be conducted in order to ensure equitable access to global

  20. Orphan drugs

    Directory of Open Access Journals (Sweden)

    Goločorbin-Kon Svetlana

    2013-01-01

    Full Text Available Introduction. Drugs used for treatment of rare diseases are known worldwide under the term of orphan drugs because pharmaceutical companies have not been interested in ”adopting” them, that is in investing in research, developing and producing these drugs. This kind of policy has been justified by the fact that these drugs are targeted for small markets, that only a small number of patients is available for clinical trials, and that large investments are required for the development of drugs meant to treat diseases whose pathogenesis has not yet been clarified in majority of cases. The aim of this paper is to present previous and present status of orphan drugs in Serbia and other countries. The beginning of orphan drugs development. This problem was first recognized by Congress of the United States of America in January 1983, and when the ”Orphan Drug Act” was passed, it was a turning point in the development of orphan drugs. This law provides pharmaceutical companies with a series of reliefs, both financial ones that allow them to regain funds invested into the research and development and regulatory ones. Seven years of marketing exclusivity, as a type of patent monopoly, is the most important relief that enables companies to make large profits. Conclusion. There are no sufficient funds and institutions to give financial support to the patients. It is therefore necessary to make health professionals much more aware of rare diseases in order to avoid time loss in making the right diagnosis and thus to gain more time to treat rare diseases. The importance of discovery, development and production of orphan drugs lies in the number of patients whose life quality can be improved significantly by administration of these drugs as well as in the number of potential survivals resulting from the treatment with these drugs. [Projekat Ministarstva nauke Republike Srbije, br. III 41012

  1. Information Extraction From Chemical Patents

    Directory of Open Access Journals (Sweden)

    Sandra Bergmann

    2012-01-01

    Full Text Available The development of new chemicals or pharmaceuticals is preceded by an indepth analysis of published patents in this field. This information retrieval is a costly and time inefficient step when done by a human reader, yet it is mandatory for potential success of an investment. The goal of the research project UIMA-HPC is to automate and hence speed-up the process of knowledge mining about patents. Multi-threaded analysis engines, developed according to UIMA (Unstructured Information Management Architecture standards, process texts and images in thousands of documents in parallel. UNICORE (UNiform Interface to COmputing Resources workflow control structures make it possible to dynamically allocate resources for every given task to gain best cpu-time/realtime ratios in an HPC environment.

  2. Patent Disclosure in Standard Setting

    OpenAIRE

    Bernhard Ganglmair; Emanuele Tarantino

    2012-01-01

    In a model of industry standard setting with private information about firms' intellectual property, we analyze (a) firms' incentives to contribute to the development and improvement of a standard, and (b) firms' decision to disclose the existence of relevant intellectual property to other participants of the standard-setting process. If participants can disclose after the end of the process and fully exploit their bargaining leverage, then patent holders aspire to disclose always after the e...

  3. Herbal nanoparticles: A patent review

    OpenAIRE

    Namdeo R Jadhav; Trupti Powar; Santosh Shinde; Sameer Nadaf

    2014-01-01

    Design and development of herbal nanoparticles has become a frontier research in the nanoformulation arena. To update researchers, an attempt has been made to review nanoformulation-based herbal patents. This article mainly covers herbal medicines are used for the treatment of cardiovascular diseases, Parkinsonism, pulmonary diseases, proliferative diseases, Alzheimer′s disease, diabetes, cancer therapy, anti-osteoporosis, and the like. It has been revealed that nanoparticles of Curcumin have...

  4. A Survey of the Economics of Patent Systems and Procedures

    OpenAIRE

    Eckert, Andrew; Langinier, Corinne

    2014-01-01

    The last several decades have seen increases in patenting activity worldwide, as well as growing issues related to patent quality. In response to these quality issues a recent patent literature has emerged, that investigates the behavior and incentives of patent examiners, applicants, and third parties. In this paper, we provide an overview of patent procedures, patent systems and a survey of the new economic literature on patent systems. Both theoretical and empirical papers are considered. ...

  5. Individual Inventors and Market Potentials: Evidence from US Patents

    OpenAIRE

    Agiakloglou, Christos; Drivas, Kyriakos; Karamanis, Dimitris

    2014-01-01

    This paper examines the commercialization propensities of individual inventors' patents. Exploiting a peculiarity of the US patent system, concerning patent renewal fees in order to obtain small or large entity status, we are able to distinguish patents that become part of a large corporation's patent portfolio. Using an extensive dataset of US patents, both for domestic and foreign individual inventors, we find that patent characteristics, size of research teams, prior experience and past co...

  6. Essential patents in pools: Is value intrinsinc or induced ?

    OpenAIRE

    Delcamp, Henry

    2010-01-01

    This paper analyzes empirically the value - as measured by patent citations - of a set of 1363 essential patents belonging to 9 different patent pools. We find that pooled patents receive more cites than control patents having the same characteristics but not included in a pool. This difference stems only partly from the pools' ability to select the most cited patents. Indeed we show that being included in a pool also tends to increase the value of patents. This induced effect reflects the in...

  7. Nikola Tesla’s Patent Applications for Which Patents Were Not Granted

    Directory of Open Access Journals (Sweden)

    S. Šarboh

    2013-06-01

    Full Text Available In this paper are presented the results of an investigation directed to discovering and identifying Nikola Tesla’s patent applications filed with the United States Patent Office, but for which appropriate patents were not granted to him. The investigation showed that Tesla had at least 33 American patent applications for which patents were not granted, that shed a new light on his inventive activities in the United States of America. The subject matter of these patent applications are different Tesla’s inventions in the fields of electrical engineering, mechanical engineering and processing technology, more precisely metallurgy.

  8. Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean.

    Science.gov (United States)

    Spaulding, Alicen B; Yu, Qilu; Civitello, Lucy; Mussi-Pinhata, Marisa M; Pinto, Jorge; Gomes, Ivete M; Alarcón, Jorge O; Siberry, George K; Harris, D Robert; Hazra, Rohan

    2016-04-01

    To evaluate antiretroviral (ARV) drug exposure and other factors during pregnancy that may increase the risk of neurologic conditions (NCs) in HIV-exposed/uninfected (HEU) infants. A prospective cohort study was conducted at 24 clinical sites in Latin America and the Caribbean. Data on maternal demographics, health, HIV disease status, and ARV use during pregnancy were collected. Infant data included measurement of head circumference after birth and reported medical diagnoses at birth, 6-12 weeks, and 6 months. Only infants with maternal exposure to combination ARV therapy (cART) (≥3 drugs from ≥2 drug classes) during pregnancy were included. Microcephaly, defined as head circumference for age z-score less than -2, and NC were evaluated for their association with covariates, including individual ARVs, using bivariable and logistic regression analyses. From 2002 to 2009, 1,400 HEU infants met study inclusion criteria. At least one NC was reported in 134 (9.6%; 95% confidence interval [CI]: 8.1-11.2), microcephaly in 105 (7.5%; 95% CI: 6.2-9.0), and specific neurologic diagnoses in 33 (2.4%; 95% CI: 1.6-3.3) HEU infants. Microcephaly and NC were not significantly associated with any specific ARV analyzed (p > 0.05). Covariates associated with increased odds of NC included male sex (odds ratio [OR] = 1.9; 95% CI: 1.3-2.8), birth weight <2.5 kg (OR = 3.1; 95% CI: 2.1-4.8), 1-min Apgar score <7 (OR = 2.5; 95% CI: 1.4-4.4), and infant infections (OR = 2.5; 95% CI: 1.5-4.1). No ARV investigated was associated with adverse neurologic outcomes. Continued investigation of such associations may be warranted as new ARVs are used during pregnancy and cART exposure during the first trimester becomes increasingly common. PMID:26879281

  9. The academic advantage: gender disparities in patenting.

    Science.gov (United States)

    Sugimoto, Cassidy R; Ni, Chaoqun; West, Jevin D; Larivière, Vincent

    2015-01-01

    We analyzed gender disparities in patenting by country, technological area, and type of assignee using the 4.6 million utility patents issued between 1976 and 2013 by the United States Patent and Trade Office (USPTO). Our analyses of fractionalized inventorships demonstrate that women's rate of patenting has increased from 2.7% of total patenting activity to 10.8% over the nearly 40-year period. Our results show that, in every technological area, female patenting is proportionally more likely to occur in academic institutions than in corporate or government environments. However, women's patents have a lower technological impact than that of men, and that gap is wider in the case of academic patents. We also provide evidence that patents to which women--and in particular academic women--contributed are associated with a higher number of International Patent Classification (IPC) codes and co-inventors than men. The policy implications of these disparities and academic setting advantages are discussed. PMID:26017626

  10. The academic advantage: gender disparities in patenting.

    Directory of Open Access Journals (Sweden)

    Cassidy R Sugimoto

    Full Text Available We analyzed gender disparities in patenting by country, technological area, and type of assignee using the 4.6 million utility patents issued between 1976 and 2013 by the United States Patent and Trade Office (USPTO. Our analyses of fractionalized inventorships demonstrate that women's rate of patenting has increased from 2.7% of total patenting activity to 10.8% over the nearly 40-year period. Our results show that, in every technological area, female patenting is proportionally more likely to occur in academic institutions than in corporate or government environments. However, women's patents have a lower technological impact than that of men, and that gap is wider in the case of academic patents. We also provide evidence that patents to which women--and in particular academic women--contributed are associated with a higher number of International Patent Classification (IPC codes and co-inventors than men. The policy implications of these disparities and academic setting advantages are discussed.

  11. 液质联用法检测中成药和保健食品中的6种肾上腺皮质激素%Determination of 6 adrenal corticosteroids in Chinese patent drugs or functional foods by HPLC-MS

    Institute of Scientific and Technical Information of China (English)

    关日晴; 刘敏敏; 李晨辉

    2011-01-01

    Objective To establish a method for determining 6 adrenal corticosteroids which may be added illegally to Chinese patent drugs or functional foods. Methods HPLC-MS was used after a serial extraction and separation procedure. HPLC conditions:C18-column at 30 ℃, eluting with acetonitrile-water(40: 60)at a flow rate of 1.0 mL/min,detecting at 240 nm wavelength, 10 μL injection volume;ESI-MS data was obtained in positive ion mode. Results 6 adrenal corticosteroids (dexamethasone acetate, prednisolone acetate, hydrocortisone acetate, prednisone acetate, cortisone acetate, betamethasone ) were accurately identified simultaneously. Conclusion The method was accurate and suitable for determining 6 adrenal corticosteroids which may be added illegally to Chinese patent drugs or functional foods.%目的 建立中成药或保健食品中非法添加的6种肾上腺皮质激素的检验方法.方法 样品经溶剂提取分离后,采用高效液相色谱-串联质谱法测定.色谱条件:色谱柱为C18柱,流动相为乙腈-水(体积比40∶60),检测波长240 nm,柱温30℃,流速1.0 mL/min,进样量10μL;质谱条件:以ESI电喷雾电离源正离子模式进行质谱数据采集.结果 可同时对中国药典收载的醋酸地塞米松、醋酸可的松、醋酸氢化可的松、醋酸泼尼松、醋酸泼尼松龙和倍他米松6种常用口服肾上腺皮质激素进行检查,准确率达到100%.结论 该方法准确性、专属性强,可作为中成药或保健食品中非法添加的6种肾上腺皮质激素的检验方法.

  12. Evidence from Patents and Patent Citations on the Impact of NASA and Other Federal Labs on Commercial Innovation

    OpenAIRE

    Jaffe, Adam B.; Michael S. Fogarty; Banks, Bruce A.

    1997-01-01

    We explore the commercialization of government-generated technology by analyzing patents awarded to the U.S. government and the citations to those patents from subsequent patents. We use information on citations to federal patents in two ways: (1) to compare the average technological impact of NASA patents, other Federal' patents, and a random sample of all patents using measures of importance' and generality;' and (2) to trace the geographic location of commercial development by focusing on ...

  13. The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good

    OpenAIRE

    Bermudez, Jorge; 't Hoen, Ellen

    2010-01-01

    Developing and delivering appropriate, affordable, well-adapted medicines for HIV/AIDS remains an urgent challenge: as first-line therapies fail, increasing numbers of people require costly second-line therapy; one-third of ARVs are not available in pediatric formulations; and certain key first- and second-line triple fixed-dose combinations do not exist or sufficient suppliers are lacking. UNITAID aims to help solve these problems through an innovative initiative for the collective managemen...

  14. Le paléogène détritique marin du pays des Arves (Savoie): analyse par thermoluminescence et paléogéographie

    OpenAIRE

    Ivaldi, Jean-Pierre

    1987-01-01

    Les caractères thermoluminescents des quartz détritiques des conglomérats, arkoses, grès et schistes à blocs paléogènes du Pays des Arves sont définis. Le champ d'application de la méthode d'analyse TL et ses limites sont précisés dans un contexte géologique régional marqué par une déformation ductile forte et un métamorphisme anchizonal à épizonal post-priaboniens générateurs de néoformations siliceuses possédant leur propre thermoluminescence. Le traitement statistique des données numérique...

  15. The Transformation of Science Into Patented Inventions

    DEFF Research Database (Denmark)

    Beukel, Karin

    This paper presents the results of a grounded theory study of the transformation of scientific discoveries into patented inventions. Using an algebraic interpretive approach, the narratives collected during interviews are analyzed as Bayesian inferences and the developed theory is tested. The...... findings recast the relationship between science and patents as a process in which the way the transformation of the scientific invention is handled has an effect on the breadth of the patent scope. Unleashing patent scope surplus is dependent on processes related to abstraction and cognitive variety......, which can be mobilized by patent experts with both an in-depth understanding of the scientific discovery, due to their educational background in the life sciences, and capabilities within the legal framework for patenting. More specifically, the findings reveal previously unreported aspects of the...

  16. Patentability of Parthenogenic Stem Cells: International Stem Cell Corporation v. Comptroller General of Patents.

    Science.gov (United States)

    Mansnérus, Juli

    2015-06-01

    The European Court of Justice (ECJ) has recently issued a ruling in Case C-364/13 International Stem Cell Corporation v. Comptroller General of Patents Designs and Tademarks (Case) that aims at harmonising the patenting practices regarding interpretation of Article 6.2.c of Directive 98/44/EC (Biotech Patent Directive) in respect of patentability of human parthenogenic stem cells (hpSCs). The Case alters the patenting regime for human embryonic stem cell (hESC) applications, by stating that moral restrictions against hESC-patents are only applicable to such cells derived from embryos that had the potential to develop into a human being. Consequently, hpSC-based inventions may be patentable in Europe. This Case represents a leap forward to striking a balance between protecting human dignity and integrity whilst granting patent incentives for biomedical research. PMID:26399046

  17. Contribution of rainfall, snow and ice melt to the hydrological regime of the Arve upper catchment and to severe flood events

    Science.gov (United States)

    Lecourt, Grégoire; Revuelto, Jesús; Morin, Samuel; Zin, Isabella; Lafaysse, Matthieu; Condom, Thomas; Six, Delphine; Vionnet, Vincent; Charrois, Luc; Dumont, Marie; Gottardi, Frédéric; Laarman, Olivier; Coulaud, Catherine; Esteves, Michel; Lebel, Thierry; Vincent, Christian

    2016-04-01

    In Alpine catchments, the hydrological response to meteorological events is highly influenced by the precipitation phase (liquid or solid) and by snow and ice melt. It is thus necessary to simulate accurately the snowpack evolution and its spatial distribution to perform relevant hydrological simulations. This work is focused on the upper Arve Valley (Western Alps). This 205 km2 catchment has large glaciated areas (roughly 32% of the study area) and covers a large range of elevations (1000-4500 m a.s.l.). Snow presence is significant year-round. The area is also characterized by steep terrain and strong vegetation heterogeneity. Modelling hydrological processes in such a complex catchment is therefore challenging. The detailed ISBA land surface model (including the Crocus snowpack scheme) has been applied to the study area using a topography based discretization (classifying terrain by aspect, elevation, slope and presence of glacier). The meteorological forcing used to run the simulations is the reanalysis issued from the SAFRAN model which assimilates meteorological observations from the Meteo-France networks. Conceptual reservoirs with calibrated values of emptying parameters are used to represent the underground water storage. This approach has been tested to simulate the discharge on the Arve catchment and three sub-catchments over 1990-2015. The simulations were evaluated with respect to observed water discharges for several headwaters with varying glaciated areas. They allow to quantify the relative contribution of rainfall, snow and ice melt to the hydrological regime of the basin. Additionally, we present a detailed analysis of several particular flood events. For these events, the ability of the model to correctly represent the catchment behaviour is investigated, looking particularly to the relevance of the simulated snowpack. Particularly, its spatial distribution is evaluated using MODIS snow cover maps, punctual snowpack observations and summer

  18. 37 CFR 1.14 - Patent applications preserved in confidence.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent applications preserved in confidence. 1.14 Section 1.14 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General...

  19. 37 CFR 1.46 - Assigned inventions and patents.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Assigned inventions and patents. 1.46 Section 1.46 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May...

  20. 37 CFR 1.177 - Issuance of multiple reissue patents.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Issuance of multiple reissue patents. 1.177 Section 1.177 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Reissues §...

  1. 37 CFR 1.215 - Patent application publication.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent application publication. 1.215 Section 1.215 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions...

  2. 37 CFR 11.9 - Limited recognition in patent matters.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Limited recognition in patent matters. 11.9 Section 11.9 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE REPRESENTATION OF OTHERS BEFORE THE UNITED STATES PATENT AND TRADEMARK...

  3. 37 CFR 1.314 - Issuance of patent.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Issuance of patent. 1.314 Section 1.314 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Allowance and Issue...

  4. 37 CFR 1.315 - Delivery of patent.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Delivery of patent. 1.315 Section 1.315 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Allowance and Issue...

  5. 37 CFR 3.81 - Issue of patent to assignee.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Issue of patent to assignee. 3.81 Section 3.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE... of patent to assignee. (a) With payment of the issue fee: An application may issue in the name of...

  6. 37 CFR 1.81 - Drawings required in patent application.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Drawings required in patent application. 1.81 Section 1.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions The...

  7. 77 FR 37879 - Cooperative Patent Classification External User Day

    Science.gov (United States)

    2012-06-25

    ... Patent and Trademark Office Cooperative Patent Classification External User Day AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Notice. SUMMARY: The United States Patent and Trademark Office (USPTO) is hosting a Cooperative Patent Classification (CPC) External User Day event at...

  8. 37 CFR 1.41 - Applicant for patent.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Applicant for patent. 1.41 Section 1.41 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May Apply for...

  9. Writing reports to facilitate patent applications.

    Energy Technology Data Exchange (ETDEWEB)

    Libman, George H.; Doerry, Armin Walter

    2004-06-01

    Brief disclosures may often be sufficient for the filing of a Technical Advance with Sandia's Intellectual Property Center, but still be inadequate to facilitate an optimum patent application where more detail and explanation are required. Consequently, the crafting of a patent application may require considerably more additional interaction between the application preparer and the inventors. This inefficiency can be considerably mitigated if the inventors address some critical aspects of a patent application when they write a technical report.

  10. Patent foramen ovale: clinical manifestations and treatment.

    OpenAIRE

    Kedia, G; Tobis, J; Lee, MS

    2008-01-01

    A persistent patent foramen ovale produces an intermittent intra-atrial right-to-left shunt and occurs in approximately 25% of the general population. Although the vast majority of people with patent foramen ovale are asymptomatic, a patent foramen ovale is believed to act as a pathway for chemicals or thrombus that can result in a variety of clinical manifestations, including stroke, migraine headache, decompression sickness, high-altitude pulmonary edema, and platypnea-orthodeoxia syndrome....

  11. India's journey toward an effective patent

    OpenAIRE

    Abramson, Bruce

    2007-01-01

    The decade following India's accession to the World Trade Organization's Trade-Related Aspects of Intellectual Property ushered in numerous changes to the country's patent system, culminating in a series of amendments in 2005. But a functioning patent system is more than a statute. This paper discusses the steps that India must still take to develop an effective, functioning patent system capable of attracting foreign direct investment, motivating domestic innovation and education, and filter...

  12. (When) Do Stronger Patents Increase Continual Innovation?

    OpenAIRE

    Chen, Yongmin; Pan, Shiyuan; Zhang, Tianle

    2012-01-01

    Under continual innovation, greater patent strength expands innovating firms’ profit against imitation, but also shifts profit from current to past innovators. We show how the impact of patents on innovation, as determined by these two opposing effects, varies with industry characteristics. When the discount factor is sufficiently high, the negative profit division effect is negligible, and innovation monotonically increases in patent strength; otherwise, innovation has an inverted-U relation...

  13. Academic patenting: the importance of industry support

    OpenAIRE

    Lawson, Cornelia

    2013-01-01

    This paper provides evidence that university-industry collaboration is important for turning commercial opportunities into patents. The results suggest that researchers who receive a large share of research grants from industry have a higher propensity to file a patent. Small dissemination grants generally exert a positive effect, whether they come from industry or not. It also finds that these interactions do not increase the number of industry owned patents alone but benefit universities’ c...

  14. Approved Animal Drug Products (Green Book)

    Data.gov (United States)

    U.S. Department of Health & Human Services — On November 16, 1988, the President of the United States signed into law the Generic Animal Drug and Patent Restoration Act (GADPTRA). Among its major provisions,...

  15. International Patent Protection: Time for a fully EU Functioning Supra-National Patent Mechanism

    OpenAIRE

    Donal Loftus

    2011-01-01

    Larger industrial companies have become increasingly global in their functions and aspirations. With regard to patents, it is increasingly common for a multinational company to face alleged infringing acts committed by the same competitor in several countries. Securing international patent protection both at the acquisition and the enforcement stage is the corollary to the cross border exploitation of patents. The regulation of transnational trade and the international exploitation of patent ...

  16. Nanotechnology Patents : The next technological revolution and the future of the patent system

    OpenAIRE

    Helwegen, Wim

    2013-01-01

    Experiences from ICT and biotechnology have shown that the current patent system has increasing difficulties with the numbers and complexity of patent applications. As a result, the patent system, which ultimate goal is to promote technological innovation and to reward the inventors, has been the subject of increasing criticism. Despite being in an early stage of development, nanotechnology is already the subject of a high amount of patents, and as noted by the European Parliament, the curre...

  17. Patents and Innovation: Friends or Foes?

    OpenAIRE

    Lévêque, François

    2007-01-01

    Over 2 million patents are currently in force in the EU and in the USA. Do they testify innovation is blockaded for they restrict freedom in research or do they give evidence innovation is flourishing for patent law provides incentives to invent new products and processes? In other terms do patents freeze or spur innovation? The question arises for massive anecdotal evidence shows the patent system may have turned on its head, e.g., USPTO and EPO examiners spend less than 30 hours pe...

  18. The transfer of patents in Imperial Germany

    OpenAIRE

    Burhop, Carsten

    2009-01-01

    We describe the transfer of patents in late 19th- and early 20th- century Germany using a new and comprehensive database containing information on about 20,000 transactions. The number of transactions shows an upward trend, in total numbers and as a share of patents in force. In total, about eight percent of patents were transferred at least once during their existence. Many transactions involved the transfer of patents with an above-average quality from individual inventors to firms and to n...

  19. Typology of the patent troll business

    OpenAIRE

    Pohlmann, Tim; Opitz, Marieke

    2010-01-01

    Patent trolls have many faces, since the media uses this expression in various ways. The patent troll phenomenon thus seems to be an ambiguous term that is discussed in several directions. This paper reveals that a patent troll as such has no distinct shape or appearance. Our analysis redeems a troll classification solely from firms’ market position, such as being non-practicing, and shows that a patent troll business can only be defined by the respective practice to enforce IPR. Using 10 cas...

  20. US Photovoltaic Patents, 1988--1990

    Energy Technology Data Exchange (ETDEWEB)

    1991-12-01

    This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials, as well as manufacturing and support functions. The patent entries in this document were issued from 1988 through 1990. The entries were located by searching USPA, the data base of the US Patent Office. The final search retrieved all patents under the class Batteries, Thermoelectric and Photoelectric'' and the subclasses Photoelectric,'' Testing,'' and Applications.'' The search also located patents that contained the words photovoltaic(s)'' or solar cell(s)'' and their derivatives. A manual search of the patents in the Solar Energy Research Institute (SERI) patent file augmented the data base search. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors and subjects only peripherally concerned with photovoltaics. Some patents on these three subjects were included when it appeared that those inventions might be of use in terrestrial PV power technologies.

  1. US Photovoltaic Patents, 1988--1990

    Energy Technology Data Exchange (ETDEWEB)

    1991-12-01

    This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials, as well as manufacturing and support functions. The patent entries in this document were issued from 1988 through 1990. The entries were located by searching USPA, the data base of the US Patent Office. The final search retrieved all patents under the class ``Batteries, Thermoelectric and Photoelectric`` and the subclasses ``Photoelectric,`` ``Testing,`` and ``Applications.`` The search also located patents that contained the words ``photovoltaic(s)`` or ``solar cell(s)`` and their derivatives. A manual search of the patents in the Solar Energy Research Institute (SERI) patent file augmented the data base search. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors and subjects only peripherally concerned with photovoltaics. Some patents on these three subjects were included when it appeared that those inventions might be of use in terrestrial PV power technologies.

  2. Current Challenges in Patent Information Retrieval

    CERN Document Server

    Lupu, Mihai; Tait, John; Trippe, Anthony J

    2011-01-01

    Patents form an important knowledge resource --much technical information represented in patents is not represented in scientific literature -- and at the same time they are important, and economically highly relevant, legal documents. Between 1998 and 2008, the number of patent applications filed yearly worldwide grew by more than 50 percent. Yet still we see a huge gap between, on the one hand, the technologies that emerged from research labs and are in use in major Internet search engines or in enterprise search systems, and, on the other hand, the systems used daily by the patent search co

  3. Performance of Patenting Firms in Danish Manufacturing

    DEFF Research Database (Denmark)

    Madsen, Erik Strøjer; Smith, Valdemar; Nielsen, Anders Østergaard

    2000-01-01

    Most countries focus on industries with high technology and the governments grant subsidies to innovating firms. However, there has been remarkable few studies of the performance of innovative firms or industries. This study examines the performance of patent active firms compared to the non-patenting...... firms within the manufacturing sector in Denmark. Performance is measured both by growth in employment as well as in the return on equity and profit share in turnover. The results suggest that differences in performance of patenting and non-patenting firms are very small, which questions the political...

  4. The Coordination of Independently-Owned Vacuum Tube Patents in the Alleged Early Radio Patent Thicket

    DEFF Research Database (Denmark)

    Howells, John; Ron D, Katznelson

    -examines the legal trajectories and entrepreneurial exploitation of these patents with a focus on vacuum tube technology where Fleming’s diode patent ‘overlapped’ with earlier prior art and, dependent on court decisions, with later commercial implementations of De Forest’s triode patents. We show, by means of...

  5. Interactive overlay maps for US Patent (USPTO) data based on International Patent Classifications (IPC)

    NARCIS (Netherlands)

    L. Leydesdorff; D. Kushnir; I. Rafols

    2014-01-01

    We report on the development of an interface to the US Patent and Trademark Office (USPTO) that allows for the mapping of patent portfolios as overlays to basemaps constructed from citation relations among all patents contained in this database during the period 1976-2011. Both the interface and the

  6. Using Patent Classification to Discover Chemical Information in a Free Patent Database: Challenges and Opportunities

    Science.gov (United States)

    Ha¨rtinger, Stefan; Clarke, Nigel

    2016-01-01

    Developing skills for searching the patent literature is an essential element of chemical information literacy programs at the university level. The present article creates awareness of patents as a rich source of chemical information. Patent classification is introduced as a key-component in comprehensive search strategies. The free Espacenet…

  7. 78 FR 51177 - Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage, LLC

    Science.gov (United States)

    2013-08-20

    ... Department of the Navy Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage... gives notice of its intent to grant to ICAP Patent Brokerage, LLC, a revocable, nonassignable, partially exclusive license in the United States to practice the Government-Owned inventions described in U.S....

  8. 78 FR 72872 - Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage, LLC

    Science.gov (United States)

    2013-12-04

    ... Department of the Navy Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage... gives notice of its intent to grant to ICAP Patent Brokerage, LLC, a revocable, nonassignable, partially exclusive license in the United States to practice the Government-Owned inventions described in U.S....

  9. 76 FR 18194 - Notice of Patent Application Deadline for Advanced Battery Technology Related Patents for...

    Science.gov (United States)

    2011-04-01

    ... following listing of intellectual property in the Federal Register on January 19, 2011 (76 FR 3118). A... Department of the Army Notice of Patent Application Deadline for Advanced Battery Technology Related Patents for Exclusive, Partially Exclusive, or Non- Exclusive Licenses; Battery Day Patent Licensing...

  10. The Coordination of Independently-Owned Vacuum Tube Patents in the Early Radio Alleged Patent “Thicket”

    DEFF Research Database (Denmark)

    Howells, John; Ron D, Katznelson

    entrepreneurial exploitation of patents on early vacuum tube technology where Fleming’s diode patent was alleged to have ”overlapped” with De Forest’s triode patents. We show, by means of the relevant historical record, patent claims, litigation records and other relevant law, how patent rights were resolved by...

  11. 37 CFR 1.378 - Acceptance of delayed payment of maintenance fee in expired patent to reinstate patent.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Acceptance of delayed payment of maintenance fee in expired patent to reinstate patent. 1.378 Section 1.378 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES...

  12. 78 FR 68422 - Patent Trial and Appeal Board (PTAB) Actions (Formerly Board of Patent Appeals and Interferences...

    Science.gov (United States)

    2013-11-14

    ... Patent and Trademark Office Patent Trial and Appeal Board (PTAB) Actions (Formerly Board of Patent... United States Patent and Trademark Office (USPTO), as part of its continuing efforts to reduce paperwork... Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Federal Rulemaking Portal:...

  13. 37 CFR 3.24 - Requirements for documents and cover sheets relating to patents and patent applications.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Requirements for documents and cover sheets relating to patents and patent applications. 3.24 Section 3.24 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL...

  14. Preliminary study into query translation for patent retrieval

    DEFF Research Database (Denmark)

    Jochim, C.; Lioma, Christina; Schütze, H.; Koch, S.; Ertl, T.

    Patent retrieval is a branch of Information Retrieval (IR) aiming to support patent professionals in retrieving patents that satisfy their information needs. Often, patent granting bodies require patents to be partially translated into one or more major foreign languages, so that language...... boundaries do not hinder their accessibility. This multilingual-ity of patent collections offers opportunities for improving patent retrieval. In this work we exploit these opportunities by applying query translation to patent retrieval. We expand monolingual patent queries with their translations, using...... both a domain-specific patent dictionary that we extract from the patent collection, and a general domain-free dictionary. Experimental evaluation on a standard CLEF-IP dataset shows that using either translation dictionary fetches similar results: query translation can help patent retrieval, but not...

  15. How a patent eligibility case could affect personalized medicine.

    Science.gov (United States)

    Brougher, Joanna T

    2010-01-01

    Personalized medicine may be in danger as the doctrine of patent eligibility -which determines technological innovations that warrant patent protection -faces legal challenges. Diagnostic tests, gene patents, and more are at stake. PMID:22478808

  16. 78 FR 30304 - Federal Acquisition Regulation; Information Collection; Patents

    Science.gov (United States)

    2013-05-22

    ... Regulation; Information Collection; Patents AGENCY: Department of Defense (DOD), General Services... requirement concerning patents. DATES: Submit comments on or before July 22, 2013. ADDRESSES: Submit comments identified by Information Collection 9000- 0096, Patents, by any of the following methods:...

  17. The roles of patents and research and development incentives in biopharmaceutical innovation.

    Science.gov (United States)

    Grabowski, Henry G; DiMasi, Joseph A; Long, Genia

    2015-02-01

    Patents and other forms of intellectual property protection play essential roles in encouraging innovation in biopharmaceuticals. As part of the "21st Century Cures" initiative, Congress is reviewing the policy mechanisms designed to accelerate the discovery, development, and delivery of new treatments. Debate continues about how best to balance patent and intellectual property incentives to encourage innovation, on the one hand, and generic utilization and price competition, on the other hand. We review the current framework for accomplishing these dual objectives and the important role of patents and regulatory exclusivity (together, the patent-based system), given the lengthy, costly, and risky biopharmaceutical research and development process. We summarize existing targeted incentives, such as for orphan drugs and neglected diseases, and we consider the pros and cons of proposed voluntary or mandatory alternatives to the patent-based system, such as prizes and government research and development contracting. We conclude that patents and regulatory exclusivity provisions are likely to remain the core approach to providing incentives for biopharmaceutical research and development. However, prizes and other voluntary supplements could play a useful role in addressing unmet needs and gaps in specific circumstances. PMID:25646111

  18. The Fate of Patents : An Exploratory Analysis of Patents as Signals of Reputational Advantage

    OpenAIRE

    Basir, Nada; Beyhaghi, Mehdi; Mohammadi, Ali

    2013-01-01

    Drawing on the reputation literature and signaling theory, this article builds on work that looks at patents as reputation signals.We build a multi-industry database of patents that expire due to lack of maintenance fee payments and test for a relationship between these patents and the firm’s IPO date.We find a significant and positive relationship between the likelihood of patents expiring due to lack of maintenance fee payments and the time to IPO. We also find that patents associated with ...

  19. THE FATE OF PATENTS: AN EXPLORATORY ANALYSIS OF PATENTS AS IPO SIGNALS OF REPUTATIONAL ADVANTAGE

    OpenAIRE

    Basir, Nada; Beyhaghi, Mehdi; Mohammadi, Ali

    2014-01-01

    Drawing on the reputation literature and signaling theory, this article builds on work that looks at patents as reputation signals. We build a multi-industry database of patents that expire due to lack of maintenance fee payments and test for a relationship between these patents and the firm’s IPO date. We find a significant and positive relationship between the likelihood of patents expiring due to lack of maintenance fee payments and the time to IPO. We also find that patents associated wit...

  20. International Patenting Strategies of Chinese Residents: an analysis of foreign-oriented patent families

    OpenAIRE

    Mila Kashcheeva; Sacha Wunsch-Vincent; Hao Zhou

    2014-01-01

    In terms of the number of its patent applications, in 2012 China has emerged as the country with the largest IP office in the world. The performance of the Chinese IP system is thus increasingly in the spotlight. While significant economic studies have been devoted to the rise of domestic patenting in China, hardly any study has focused on Chinese patent filings in foreign countries. This paper analyzes Chinese patenting abroad by using WIPO’s foreign-oriented patent family dataset and a resp...

  1. Patent foramen ovale: Unanswered questions.

    Science.gov (United States)

    Mojadidi, Mohammad Khalid; Christia, Panagiota; Salamon, Jason; Liebelt, Jared; Zaman, Tarique; Gevorgyan, Rubine; Nezami, Nariman; Mojaddedi, Sanaullah; Elgendy, Islam Y; Tobis, Jonathan M; Faillace, Robert

    2015-12-01

    The foramen ovale is a remnant of the fetal circulation that remains patent in 20-25% of the adult population. Although long overlooked as a potential pathway that could produce pathologic conditions, the presence of a patent foramen ovale (PFO) has been associated with a higher than expected frequency in a variety of clinical syndromes including cryptogenic stroke, migraines, sleep apnea, platypnea-orthodeoxia, deep sea diving associated decompression illness, and high altitude pulmonary edema. A unifying hypothesis is that a chemical or particulate matter from the venous circulation crosses the PFO conduit between the right and left atria to produce a variety of clinical syndromes. Although observational studies suggest a therapeutic benefit of PFO closure compared to medical therapy alone in patients with cryptogenic stroke, 3 randomized controlled trials (RCTs) did not confirm the superiority of PFO closure for the secondary prevention of stroke. However, meta-analyses of these RCTs demonstrate a significant benefit of PFO closure over medical therapy alone. Similarly, observational studies provide support for PFO closure for symptomatic relief of migraines. But one controversial randomized study failed to replicate the results of the observational studies while another two demonstrated a partial benefit. The goal of this review is to discuss the clinical conditions associated with PFO and provide internists and primary care physicians with current data on PFO trials, and clinical insight to help guide their patients who are found to have a PFO on echocardiographic testing. PMID:26489724

  2. Patents versus ex-post rewards : a new look

    OpenAIRE

    Julien Pénin

    2003-01-01

    Economic studies that aim at comparing the patent system social efficiency versus an ex-post reward system rest on a traditional view of patents. They make the hypothesis that firms use the patent system only in order to be granted a short-term monopoly rent and therefore that patents lead to strong and steady monopolies. This assumption is convenient because it allows straightforward comparisons between patent and reward systems. But empirical studies do not confirm this vision of patents. M...

  3. Patent Portfolio Races in Concentrated Markets for Technology

    OpenAIRE

    Florian Jell; Joachim Henkel

    2010-01-01

    Patent application numbers grow exponentially in many industries, a phenomenon that has been linked to high fragmentation of patent ownership. Contradicting these findings and theoretical arguments, we show that such fragmentation is not a precondition for sudden and strong increases in patenting. We describe and analyze a patent portfolio race in an industry with highly concentrated patent ownership, namely the newspaper printing machines oligopoly. Triangulating data from patent analysis, i...

  4. The Sources of Knowledge and the Value of Academic Patents

    OpenAIRE

    Sapsalis, Elefth駻ios; van Pottelsberghe de la Potterie, Bruno

    2003-01-01

    This paper aims at contributing to the literature on the determinants of patent value in two respects. It first puts forward new potential determinants of patent value which are mainly related to the identification of the institutional sources of knowledge and the geographical scope of patenting strategy. Second, it aims at validating the traditional and new determinants of patent value with academic patents. The empirical analysis focuses on 208 patent families applied by six main Belgian Un...

  5. Simple vs. sophisticated approaches for patent prior-art search

    OpenAIRE

    Magdy, Walid; Lopez, Patrice; JONES, GARETH J. F.

    2011-01-01

    Patent prior-art search is concerned with finding all filed patents relevant to a given patent application. We report a comparison between two search approaches representing the state-of-the-art in patent prior-art search. The first approach uses simple and straightforward information retrieval (IR) techniques, while the second uses much more sophisticated techniques which try to model the steps taken by a patent examiner in patent search. Experiments show that the retrieval effectiveness us...

  6. Pelletization processes for pharmaceutical applications: a patent review.

    Science.gov (United States)

    Politis, Stavros N; Rekkas, Dimitrios M

    2011-01-01

    Pellets exhibit major therapeutic and technical advantages which have established them as an exceptionally useful dosage form. A plethora of processes and materials is available for the production of pellets, which practically allows inexhaustible configurations contributing to the flexibility and versatility of pellets as drug delivery systems. The scope of this review is to summarize the recent literature on pelletization processes for pharmaceutical applications, focusing on the awarded and pending patents in this technical field. The first part of the article provides an overview of innovation in pelletization processes, while the second part evaluates their novel applications. PMID:21143125

  7. The Cross-Referenced Patent Cooperation Treaty

    NARCIS (Netherlands)

    Mulder, C.A.M.

    2015-01-01

    'The Cross-Referenced Patent Cooperation Treaty' is a book covering the 'Patent Cooperation Treaty (PCT)' and the 'Regulations under the PCT'. The large number of references in the articles and rules makes the PCT difficult to read. The idea behind this book is to add cross-references to the article

  8. The Cross-Referenced Patent Cooperation Treaty

    NARCIS (Netherlands)

    Mulder, C.A.M.

    2012-01-01

    'The Cross-Referenced Patent Cooperation Treaty' is a book covering the 'Patent Cooperation Treaty (PCT)' and the 'Regulations under the PCT'. The large number of references in the articles and rules makes the PCT difficult to read. The idea behind this book is to add cross-references to the article

  9. The cross-Referenced Patent Cooperation Treaty

    NARCIS (Netherlands)

    Mulder, C.A.M.

    2014-01-01

    'The Cross-Referenced Patent Cooperation Treaty' is a book covering the 'Patent Cooperation Treaty (PCT)' and the 'Regulations under the PCT'. The large number of references in the articles and rules makes the PCT difficult to read. The idea behind this book is to add cross-references to the article

  10. The Cross-Referenced Patent Cooperation Treaty

    NARCIS (Netherlands)

    Mulder, C.A.M.

    2013-01-01

    'The Cross-Referenced Patent Cooperation Treaty' is a book covering the 'Patent Cooperation Treaty (PCT)' and the 'Regulations under the PCT'. The large number of references in the articles and rules makes the PCT difficult to read. The idea behind this book is to add cross-references to the article

  11. The Cross-Referenced Patent Cooperation Treaty

    NARCIS (Netherlands)

    Mulder, C.A.M.

    2009-01-01

    'The Cross-Referenced Patent Cooperation Treaty' is a book covering the 'Patent Cooperation Treaty (PCT)' and the 'Regulations under the PCT'. The large number of references in the articles and rules makes the PCT difficult to read. The idea behind this book is to add cross-references to the article

  12. Ranking Patents for Better Search Capabilities

    Directory of Open Access Journals (Sweden)

    Mihai VLASE

    2009-12-01

    Full Text Available The continuous increasing number of patents worldwide makes the searchingin these vast databases a real challenge. In the present paper we present a method, basedon a computed rank that attempts to order the patents by a relevant order transforming along list of hundreds of search results into a list ordered by relevance.

  13. Patenting life forms and preserving human values.

    Science.gov (United States)

    Lisson, E L

    1981-01-01

    Utilitarian, pragmatic, and legal considerations, while valid, must not overshadow Catholic moral theology's concern about patenting life in view of natural law. The fundamental issues remain: Does technology diminish human values? Does the patent system's own monopolistic power pose its own risk? PMID:10289283

  14. Patent protection and licensing in microfluidics.

    Science.gov (United States)

    Yetisen, Ali K; Volpatti, Lisa R

    2014-07-01

    Microfluidic devices offer control over low-volume samples in order to achieve high-throughput analysis, and reduce turnaround time and costs. Their efficient commercialisation has implications for biomedical sciences, veterinary medicine, environmental monitoring and industrial applications. In particular, market diffusion of microfluidic laboratory and point-of-care diagnostic devices can contribute to the improvement of global health. In their commercialisation, consultancy and patent protection are essential elements that complement academic publishing. The awareness of knowledge transfer strategies can help academics to create value for their research. The aim of this article is to provide a guidance to (1) overview the terminology in patent law, (2) elucidate the process of filing a patent in the US, EU, Japan and internationally, (3) discuss strategies to licence a patent, and (4) explain tactics to defend a patent in a potential infringement. Awareness of the patent law and rights allows obtaining optimised, valid and valuable patents, while accelerating implementation to market route. Striking a balance between academic publishing, consultancy to industry and patent protection can increase commercial potential, enhance economic growth and create social impact. PMID:24825780

  15. The Unified Patent Court (UPC) in Action

    DEFF Research Database (Denmark)

    Petersen, Clement Salung; Schovsbo, Jens Hemmingsen; Riis, Thomas

    2015-01-01

    The new common judiciary for European patents (UPC) will play a crucial role in the future European patent system. The UPC will be a very specialised court that i.a. recruits judges from specialists’ circles and has as part of its mission to develop a coherent and autonomous body of case law. The...

  16. Patents | NCI Technology Transfer Center | TTC

    Science.gov (United States)

    Timely reporting of discoveries is critical, because patent protection may be lost if an invention is publicly disclosed prior to filing a patent application. A public disclosure may include Talks, presentations, posters; Publications, including titles and abstracts posted on websites; Internet postings; Graduate student theses, job interviews; andDiscussions with non-NIH personnel without a Confidential Disclosure Agreement (CDA) in place.

  17. 15 CFR 734.10 - Patent applications.

    Science.gov (United States)

    2010-01-01

    ... and Trademark Office, 37 CFR part 5; 1 or 1 Regulations issued by the Patent and Trademark Office in 37 CFR part 5 provide for the export to a foreign country of unclassified technical data in the form... 15 Commerce and Foreign Trade 2 2010-01-01 2010-01-01 false Patent applications. 734.10...

  18. Patent Office Hands Blackboard a Setback

    Science.gov (United States)

    Mangan, Katherine

    2008-01-01

    In March the U.S. Patent and Trademark Office issued a preliminary decision that could have significant ramifications for universities that use course-management software, as well as for the companies that make it. The "nonfinal" decision rejects all 44 claims Blackboard Inc. made for its controversial patent of an online-learning system.…

  19. 78 FR 12330 - Determination of Regulatory Review Period for Purposes of Patent Extension; SAPIEN TRANSCATHETER...

    Science.gov (United States)

    2013-02-22

    ... Patent Extension; SAPIEN TRANSCATHETER HEART VALVE AGENCY: Food and Drug Administration, HHS. ACTION... SAPIEN TRANSCATHETER HEART VALVE and is publishing this notice of that determination as required by law... submission of an application to market the device and continues until permission to market the device...

  20. Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus

    NARCIS (Netherlands)

    Touw, D J; Proost, J H; Stevens, R; Lafeber, H N; van Weissenbruch, M M

    2001-01-01

    BACKGROUND AND AIM: A patent ductus arteriosus (PDA) may influence renal and hepatic blood flow and hence pharmacokinetics of drugs in neonates compared to neonates with a closed ductus arteriosus (CDA). A 10-percent difference of gentamicin pharmacokinetic parameters between PDA and CDA has been re

  1. The Patent Literature As A Shortcut To Identify Knowledge Suppliers

    DEFF Research Database (Denmark)

    Søberg, Peder Veng

    patents which decreases the time span between a patent is filed and its value can be evaluated when searching the patent literature. A potential benefit thereof could be that the patent literature could become relevant in order to identify potential knowledge suppliers.......The present paper explores characteristics of valuable patents that have been subject to litigation which resulted in some of the largest fines to patent infringers reported in history. The valuable patents are compared with less valuable patents in order to identify new methods of evaluating...

  2. Patent foramen ovale: clinical manifestations and treatment.

    Science.gov (United States)

    Kedia, Gautam; Tobis, Jonathan; Lee, Michael S

    2008-01-01

    A persistent patent foramen ovale produces an intermittent intra-atrial right-to-left shunt and occurs in approximately 25% of the general population. Although the vast majority of people with patent foramen ovale are asymptomatic, a patent foramen ovale is believed to act as a pathway for chemicals or thrombus that can result in a variety of clinical manifestations, including stroke, migraine headache, decompression sickness, high-altitude pulmonary edema, and platypnea-orthodeoxia syndrome. The optimal management of patients with patent foramen ovale who experience cryptogenic stroke is unclear. Percutaneous closure appears to have a low risk profile and has been considered in high-risk patients who are not candidates for randomized clinical trials. Randomized clinical trials that are underway should help define the best management of patent foramen ovale, as well as the true safety and efficacy of percutaneous closure devices. PMID:18953276

  3. Section for Standard and Patents - Standardization and Patents

    International Nuclear Information System (INIS)

    Standardization; cooperation with the Patent Office Republic of Poland in the areas of inventiveness and patents. (author)

  4. Development of Japanese Patent Stock and Citation-Weighted Patent Stock-An Application of HJT Model to Japanese Patent Data- (in Japanese)

    OpenAIRE

    Setsuo Yamada

    2008-01-01

    This paper develops patent stock and citation-weighted patent stock using Japanese patent data. In constructing database, I refer to the method of the correction of truncation bias by Hall, Jaffe and Trajtenberg(2000,2001). However, due to the differences in patent systems between Japan and the United States, I cannot simply apply the method to Japanese data. I had to adjust the method suitable for Japanese patent system. In addition, I estimate the Cobb-Douglas production function including ...

  5. How rules and procedures for reviewing patent applications and those for enforcing patents can hamper patent quality and innovation in China

    OpenAIRE

    Prud'homme, Dan

    2012-01-01

    This chapter finds that there are a variety of concerning rules and procedures for patent application review and enforcement of patent rights in China that hamper patent quality. These range from inadequate review systems to requirements and practices that generally weaken the efficiency and effectiveness of the patent enforcement environment, which in-turn ultimately somewhat discourage building of quality patents and related innovation in China.

  6. 辨明Patent Troll

    Institute of Scientific and Technical Information of China (English)

    柳建朋

    2012-01-01

    它,究竟是凶恶的巨怪,还是可爱的精灵? 它,竟究是正当的手段,还是无赖的工具? 长久以来,patent troll便是国外学术圈、实务界探讨的焦点话题之一,如今其又转到了国内,而近来表现的越发激烈。各派对其是否应当存在、存在合法与否等等进行了持续不休的讨论与争吵,

  7. Herbal nanoparticles: A patent review

    Directory of Open Access Journals (Sweden)

    Namdeo R Jadhav

    2014-01-01

    Full Text Available Design and development of herbal nanoparticles has become a frontier research in the nanoformulation arena. To update researchers, an attempt has been made to review nanoformulation-based herbal patents. This article mainly covers herbal medicines are used for the treatment of cardiovascular diseases, Parkinsonism, pulmonary diseases, proliferative diseases, Alzheimer′s disease, diabetes, cancer therapy, anti-osteoporosis, and the like. It has been revealed that nanoparticles of Curcumin have been widely designed to increase its bioavailability and for treatment of cancers like breast cancer, lung cancer, pancreatic cancer, and so on. The common nanoformulated herbal medicines are Panax ginseng, Curcuma longa, Silybum marianum, Withania somnifera, Gymnema sylvestre, Salvia miltiorrhiza, and the like, having a profound future potential.

  8. Teaching Chemistry Students How To Use Patent Databases and Glean Patent Information

    Science.gov (United States)

    MacMillan, Margy; Shaw, Lawton

    2008-07-01

    Patent literature is an important source of chemical information that is often neglected by chemical educators. This paper describes an effort to teach chemistry students how to use patent databases to search for information on applied chemical technology related to the manufacture of industrial and specialty chemicals. Students in a second-year-level organic chemistry class were shown how to search patent literature as part of a group research paper assignment that involved determining the feasibility of starting an industrial chemical operation to manufacture a given industrial chemical. Students who were assigned high value or specialty chemicals were most likely to cite patent literature in their final papers. Students who were assigned plastics or bulk commodity chemicals were less likely to cite patents. It is suggested that students made choices about the usefulness of patent literature and that patents were most useful when current patents existed and provided the patent owner a competitive advantage. For plastics or commodity chemicals, manufacturing technologies tend to be mature and are well described by more accessible information sources. Suggestions are made for effective introduction of patent literature instruction into upper-level chemistry courses.

  9. A Clustering Method of Highly Dimensional Patent Data Using Bayesian Approach

    OpenAIRE

    Sunghae Jun

    2012-01-01

    Patent data have diversely technological information of any technology field. So, many companies have managed the patent data to build their RD policy. Patent analysis is an approach to the patent management. Also, patent analysis is an important tool for technology forecasting. Patent clustering is one of the works for patent analysis. In this paper, we propose an efficient clustering method of patent documents. Generally, patent data are consisted of text document. The patent documents have...

  10. Note on a Heuristic Procedure to Identify the Most Valuable Chain of Patent Priority Network

    OpenAIRE

    Yu-Hsin Chang; Kuei-Kuei Lai; Wen-Goang Yang; Ming-Chung Yang

    2015-01-01

    A patent portfolio is more valuable than a single patent. However, the analysis approach of a company's patent portfolio is still ambiguous. The patent priority approach (PPA) presented a clearer analysis method to explore the interior of a patent family; patent families provide an outline of the patent portfolio. A patent priority analysis (PPA) could give a better picture of the patent portfolio path, and provide technical tracks through the patent family priorities. This paper evaluates th...

  11. AVC/H.264 patent portfolio license

    Science.gov (United States)

    Skandalis, Dean A.

    2006-08-01

    MPEG LA, LLC offers a joint patent license for the AVC (a/k/a H.264) Standard (ISO/IEC IS 14496-10:2004). Like MPEG LA's other licenses, the AVC Patent Portfolio License is offered for the convenience of the marketplace as an alternative enabling users to access essential intellectual property owned by many patent holders under a single license rather than negotiating licenses with each of them individually. The AVC Patent Portfolio License includes essential patents owned by DAEWOO Electronics Corporation; Electronics and Telecommunications Research Institute (ETRI); France Telecom, societe anonyme; Fujitsu Limited; Hitachi, Ltd.; Koninklijke Philips Electronics N.V.; LG Electronics Inc.; Matsushita Electric Industrial Co., Ltd.; Microsoft Corporation; Mitsubishi Electric Corporation; Robert Bosch GmbH; Samsung Electronics Co., Ltd.; Sedna Patent Services, LLC; Sharp Kabushiki Kaisha; Siemens AG; Sony Corporation; The Trustees of Columbia University in the City of New York; Toshiba Corporation; UB Video Inc.; and Victor Company of Japan, Limited. Another is expected also to join as of August 1, 2006. MPEG LA's objective is to provide worldwide access to as much AVC essential intellectual property as possible for the benefit of AVC users. Therefore, any party that believes it has essential patents is welcome to submit them for evaluation of their essentiality and inclusion in the License if found essential.

  12. Whither ink jet? Current patent trends

    Science.gov (United States)

    Pond, Stephen F.; Karz, Robert S.

    1995-04-01

    The status and potential of ink jet technology is discernible in its major technical literature forum: worldwide patents. Most ink jet technical activity is focused in commercial research and development laboratories where proprietary considerations make patents the norm for publication. Currently there are about 2,000 ink jet disclosures issued annually with over 200 enterprises represented. Ink jet patent activity is increasing about 25% per year driven by a rapidly expanding base of products, applications, and revenue. An analysis of the ink jet patent literature reveals a few major themes (i.e. continuous ink jet, piezoelectric drop-on-demand, and thermal ink jet) and numerous minor ones (i.e. electrohydro-dynamic extraction, magnetic drop-on-demand, Hertz continuous, acoustic ink printing). Patents bear witness to transformations in the industry as dominant players of the 1970's have given way to new leaders in the 1990's. They also foretell important commercial developments in ink jet's near term future. When studied in aggregate, the patent record reveals patterns for the industry in general as well as for individual companies. It becomes possible to use the patent data base not only to identify technical approaches and problems for specific firms, but also to track progress and monitor changing strategies. In addition, international filing patterns can provide insights into industry priorities. This paper presents an overview of ink jet technology as revealed by the patent literature. It will include a 25 year perspective, a review of trends over the past five years, and a survey of today's most active companies and their technical approaches. With this analysis, it will be shown that the information inherent in the patent record is more than the sum of its individual disclosures. Indeed, by using it, we can outlook whither goes ink jet.

  13. Exploring Contextual Models in Chemical Patent Search

    Science.gov (United States)

    Urbain, Jay; Frieder, Ophir

    We explore the development of probabilistic retrieval models for integrating term statistics with entity search using multiple levels of document context to improve the performance of chemical patent search. A distributed indexing model was developed to enable efficient named entity search and aggregation of term statistics at multiple levels of patent structure including individual words, sentences, claims, descriptions, abstracts, and titles. The system can be scaled to an arbitrary number of compute instances in a cloud computing environment to support concurrent indexing and query processing operations on large patent collections.

  14. A PATENT PRIZE SYSTEM TO PROMOTE DEVELOPMENT OF NEW ANTIBIOTICS AND CONSERVATION OF EXISTING ONES

    Directory of Open Access Journals (Sweden)

    Mark Nickas

    2012-04-01

    Full Text Available Antibiotics are valuable drugs that fight bacterial infections, but our supply of antibiotics is at risk. Existing antibiotics gradually lose their effectiveness due to bacterial resistance, and few new antibiotics are being developed to replace them. A variety of models have been proposed to promote the conservation of existing antibiotics or incentivize private actors, i.e., drug companies, to develop new ones. Previous models, however, all encourage investment in antibiotic research and development via patent rights, which also create an incentive to oversell antibiotics. Because the inappropriate use of antibiotics accelerates the development of resistance, patent rights put the public health objectives of antibiotic development and conservation in tension with one another. This article proposes an antibiotic-specific patent prize system that uncouples the two policy objectives necessary to achieve a stable antibiotic supply. Although others have proposed patent prize systems to promote drug development generally, the system described here is tailored to address the unique features of antibiotic markets.

  15. Frequency of etiological factors leading to patent ductus arteriosus

    International Nuclear Information System (INIS)

    Background: Patent Ductus Arteriosus (PDA) is developing as major problem in our society. Many studies in Pakistan has been done to analyze the efficacy of surgical procedures but no one tried to find the frequency of factors leading to this problem. Objective: The purpose of this study was to find out the frequency of factors leading to patent ductus arteriosus in children presented at Punjab Institute of Cardiology. Method: A cross sectional study was conducted on 242 patients of PDA who already have been treated during the year 2006 - 2007. They were interviewed on their regular follow up visits. Their operative information was gathered from their files. Results: Mean age of children at time of treatment was 6.12 + 5.203 years. Out of 242 children, there were more female (62.8%) as compared to male (37.2%). In this study, 17.8% children inherited the disease from their close relatives and 105 (43.4%) mothers had some infectious problems during pregnancy. 103 (42.6%) mothers used antibiotics or other drugs during pregnancy. 11 (4.5%) children had Down syndrome. One hundred and thirty seven (56.61%) children had premature birth. Conclusion: Female gender, preterm birth, infection during pregnancy, mother's exposure to drugs and smoking, low birth weight may be etiological factors for development of PDA. (author)

  16. Conductive Composite Biosensor System for Electrochemical Indinavir Drug Detection

    Directory of Open Access Journals (Sweden)

    Natasha Ross

    2015-01-01

    Full Text Available Indinavir is a protease inhibitor antiretroviral (ARV drug, which forms part of the highly active antiretroviral therapy during the treatment of HIV/AIDS. Indinavir undergoes first-pass metabolism through the cytochrome P450 (CYP enzymes in the human liver, of which CYP3A4 is the most influential isoenzyme. Multidrug combination therapy and, as such, therapeutic drug monitoring (TDM during HIV/AIDS treatment are therefore critical, to prevent adverse interactions. The conventional sensitive and specific assays available for quantifying ARV drugs, however, suffer from distinct disadvantages. In this regard, biosensors can be used to provide real time information on the metabolic profile of the drug. In this study, a biosensor with cobalt(III sepulchrate trichloride {CoSep3+} as diffusional mediator was constructed. The biosensor platform consisted of CYP3A4 immobilized onto a gold nanoparticle (GNP overoxidized polypyrrole (OvOxPpy carrier matrix. The biosensor exhibited reversible electrochemistry, with formal potential determined as −624 ± 5 mV, from voltammetric analysis, with overall electron transfer being diffusion controlled. The biosensor showed typical electrocatalytic response to dioxygen (O2, exemplified by the distinct increase in the cathodic peak current (Ip,c. A concentration-dependent increase in Ip,c was observed in response to consecutive additions of Indinavir.

  17. Valuing patents on cost-reducing technology: A case study

    NARCIS (Netherlands)

    Triest, van Sander; Vis, Wim

    2007-01-01

    We present an approach for valuing patents on production process improvements. Specifically, we focus on valuing a patent on cost-reducing process improvements from the viewpoint of the patent holding firm. We do this by considering the relevant cash flows that result from owning the patent. The pat

  18. Preliminary analysis of patent trends for magnetic fusion technology

    International Nuclear Information System (INIS)

    This study presents a preliminary analysis of development trends in magnetic fusion technology based on data from US patents. The research is limited to identification and description of general patent activity and ownership characteristics for 373 patents. The results suggest that more detailed studies of fusion patents could provide useful R and D planning information

  19. Preliminary analysis of patent trends for magnetic fusion technology

    Energy Technology Data Exchange (ETDEWEB)

    Levine, L.O.; Ashton, W.B.; Campbell, R.S.

    1984-02-01

    This study presents a preliminary analysis of development trends in magnetic fusion technology based on data from US patents. The research is limited to identification and description of general patent activity and ownership characteristics for 373 patents. The results suggest that more detailed studies of fusion patents could provide useful R and D planning information.

  20. 76 FR 11206 - Proposed Collection; Patent Examiner Employment Application

    Science.gov (United States)

    2011-03-01

    ... Patent and Trademark Office Proposed Collection; Patent Examiner Employment Application ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its... Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450....

  1. 75 FR 30773 - United States Patent Applicant Survey

    Science.gov (United States)

    2010-06-02

    ... Patent and Trademark Office United States Patent Applicant Survey ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing effort.... Fawcett, Records Officer, Office of the Chief Information Officer, U.S. Patent and Trademark Office,...

  2. 76 FR 40339 - Patent Prosecution Highway (PPH) Program

    Science.gov (United States)

    2011-07-08

    ... patent offices. Originally, the PPH program was limited to the utilization of search and examination... Patent and Trademark Office Patent Prosecution Highway (PPH) Program ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing...

  3. 76 FR 53885 - Patent and Trademark Resource Centers Metrics

    Science.gov (United States)

    2011-08-30

    ..., Public Search Services Division, Office of the Chief Information Officer, United States Patent and... United States Patent and Trademark Office Patent and Trademark Resource Centers Metrics ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of...

  4. 77 FR 269 - Matters Related to Patent Appeals

    Science.gov (United States)

    2012-01-04

    ... United States Patent and Trademark Office Matters Related to Patent Appeals ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing...: Email: InformationCollection@uspto.gov . Include ``0651- 00xx Matters Related to Patent Appeals...

  5. 76 FR 34062 - Patent and Trademark Financial Transactions

    Science.gov (United States)

    2011-06-10

    ... Patent and Trademark Office Patent and Trademark Financial Transactions ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its continuing... States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Federal Rulemaking...

  6. 37 CFR 401.13 - Administration of patent rights clauses.

    Science.gov (United States)

    2010-07-01

    ... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Administration of patent rights clauses. 401.13 Section 401.13 Patents, Trademarks, and Copyrights ASSISTANT SECRETARY FOR... patent rights clauses. (a) In the event a subject invention is made under funding agreements of more...

  7. 7 CFR 1250.542 - Patents, copyrights, trademarks, and information.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, trademarks, and information... AGRICULTURE EGG RESEARCH AND PROMOTION Rules and Regulations Patents, Copyrights, Trademarks, and Information § 1250.542 Patents, copyrights, trademarks, and information. Patents, copyrights, trademarks,...

  8. 45 CFR 650.2 - National Science Foundation patent policy.

    Science.gov (United States)

    2010-10-01

    ... 45 Public Welfare 3 2010-10-01 2010-10-01 false National Science Foundation patent policy. 650.2... FOUNDATION PATENTS § 650.2 National Science Foundation patent policy. As authorized by the National Science... adopted the following statement of NSF patent policy. (a) In accordance with the Bayh-Dole Act and...

  9. 14 CFR 1214.112 - Patent, data and information matters.

    Science.gov (United States)

    2010-01-01

    ... 14 Aeronautics and Space 5 2010-01-01 2010-01-01 false Patent, data and information matters. 1214... Customers § 1214.112 Patent, data and information matters. (a) Patent and data rights. NASA will not acquire rights to inventions, patents or proprietary data which may be used in, or arise from, activities...

  10. 7 CFR 1220.254 - Patents, copyrights, inventions, and publications.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, inventions, and publications... Miscellaneous § 1220.254 Patents, copyrights, inventions, and publications. (a) Any patents, copyrights..., franchising, or other uses of such patents, copyrights, inventions, or publications, inure to the benefit...

  11. 48 CFR 3027.305 - Administration of Patent Rights Clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 7 2010-10-01 2010-10-01 false Administration of Patent... SECURITY, HOMELAND SECURITY ACQUISITION REGULATION (HSAR) SOCIOECONOMIC PROGRAMS PATENTS, DATA, AND COPYRIGHTS Patent Rights under Government Contracts 3027.305 Administration of Patent Rights Clauses....

  12. 7 CFR 1230.88 - Patents, copyrights, inventions, and publications.

    Science.gov (United States)

    2010-01-01

    ... 7 Agriculture 10 2010-01-01 2010-01-01 false Patents, copyrights, inventions, and publications... Information Order Miscellaneous § 1230.88 Patents, copyrights, inventions, and publications. Any patents..., leasing, franchising, or other uses of such patents, copyrights, inventions, or publications inure to...

  13. 48 CFR 1327.201 - Patent and copyright infringement liability.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent and copyright infringement liability. 1327.201 Section 1327.201 Federal Acquisition Regulations System DEPARTMENT OF COMMERCE GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patents and Copyrights 1327.201 Patent...

  14. 77 FR 14766 - Patents for Humanity Program (Formerly Humanitarian Program)

    Science.gov (United States)

    2012-03-13

    ... United States Patent and Trademark Office Patents for Humanity Program (Formerly Humanitarian Program) ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office...- 0066 Patents for Humanity Program comment'' in the subject line of the message. Mail: Susan K....

  15. 48 CFR 1852.227-84 - Patent rights clauses.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 6 2010-10-01 2010-10-01 true Patent rights clauses. 1852... 1852.227-84 Patent rights clauses. The contracting officer shall insert the following provision as prescribed in 1827.303-70(e): Patent Rights Clauses (DEC 1989) This solicitation contains the patent...

  16. 77 FR 29340 - Intent To Grant Patent License

    Science.gov (United States)

    2012-05-17

    ... AGENCY Intent To Grant Patent License AGENCY: Environmental Protection Agency (EPA). ACTION: Notice of Intent to Grant Co-Exclusive Patent License. SUMMARY: Pursuant to 35 U.S.C. 207 (Patents) and 37 CFR part 404 (U.S. Government patent licensing regulations), EPA hereby gives notice of its intent to grant...

  17. 76 FR 3128 - Intent to Grant Patent License

    Science.gov (United States)

    2011-01-19

    ... AGENCY Intent to Grant Patent License AGENCY: Environmental Protection Agency (EPA). ACTION: Notice of Intent to Grant Co-Exclusive Patent License. SUMMARY: Pursuant to 35 U.S.C. 207 (Patents) and 37 CFR part 404 (U.S. Government patent licensing regulations), EPA hereby gives notice of its intent to grant...

  18. 48 CFR 31.205-30 - Patent costs.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent costs. 31.205-30....205-30 Patent costs. (a) The following patent costs are allowable to the extent that they are incurred... patent application where title or royalty-free license is to be conveyed to the Government. (b)...

  19. 50 CFR 401.21 - Patents and inventions.

    Science.gov (United States)

    2010-10-01

    ... 50 Wildlife and Fisheries 7 2010-10-01 2010-10-01 false Patents and inventions. 401.21 Section 401... CONSERVATION, DEVELOPMENT AND ENHANCEMENT § 401.21 Patents and inventions. Determination of the patent rights... to the Act shall be consistent with the “Government Patent Policy” (President's memorandum for...

  20. Patent Medicine Sellers: How Can They Help Control Childhood Malaria?

    Directory of Open Access Journals (Sweden)

    Rosamund M. Akuse

    2010-01-01

    Full Text Available Roll Back Malaria Initiative encourages participation of private health providers in malaria control because mothers seek care for sick children from them. This study investigated Patent Medicine Sellers (PMS management of presumptive malaria in children in order to identify how they can assist malaria control. A cross-sectional survey of 491 PMS in Kaduna, Nigeria, was done using interviews and observation of shop activities. Most (80% customers bought drugs without prescriptions. Only 29.5% were given instructions about doses. Between 40–100% doses of recommended antimalarials were incorrect. Some (22% PMS did not ask questions about illness for which they were consulted. Most children treated in shops received injections. PMS facilitate homecare but have deficiencies in knowledge and practice. Interventions must focus on training them to accurately determine doses, give advice about drug administration, use oral medication, and ask about illness. Training should be made a prerequisite for registering and reregistering shops.

  1. Patent medicine sellers: how can they help control childhood malaria?

    Science.gov (United States)

    Akuse, Rosamund M; Eseigbe, Edwin E; Ahmed, Abubakar; Brieger, William R

    2010-01-01

    Roll Back Malaria Initiative encourages participation of private health providers in malaria control because mothers seek care for sick children from them. This study investigated Patent Medicine Sellers (PMS) management of presumptive malaria in children in order to identify how they can assist malaria control. A cross-sectional survey of 491 PMS in Kaduna, Nigeria, was done using interviews and observation of shop activities. Most (80%) customers bought drugs without prescriptions. Only 29.5% were given instructions about doses. Between 40-100% doses of recommended antimalarials were incorrect. Some (22%) PMS did not ask questions about illness for which they were consulted. Most children treated in shops received injections. PMS facilitate homecare but have deficiencies in knowledge and practice. Interventions must focus on training them to accurately determine doses, give advice about drug administration, use oral medication, and ask about illness. Training should be made a prerequisite for registering and reregistering shops. PMID:22332020

  2. Japan's Patent System and Business Innovation: Reassessing Pro-patent Policies

    OpenAIRE

    Kazuyuki Motohashi

    2003-01-01

    TSince current Japanese patent law was enacted in 1959, it has been revised several times, mainly for the purpose of international harmonization. Recently the Japanese government stresses the importance of pro-patent policies, i.e., strengthening intellectual property right in order to stimulate business innovation and to regain international competitiveness. This paper assesses the impact of series of revisions of Japanese patent system on firm's innovation activities, by using statistical d...

  3. Trends in Indian Patent Filing in Chemical Sciences: An Analysis

    Directory of Open Access Journals (Sweden)

    N.B. Dahibhate,

    2012-05-01

    Full Text Available The paper analyses the trends in Indian patents filed in the area of chemical sciences during 1995 to2008. It highlights the importance of patent literature in scientific developments and global trends in patentfilings. A result of Indian patent filing analysis indicated that filing in India is increasing in the past few yearsand many public and private organisations are filing patents in India and in other countries for protecting theinventions. Among India patent filing activities, chemical and pharmaceutical sciences are the prominent areas.Individual inventors and assignees from private and public organisations are filing patents, but in India, Councilof Scientific & Industrial Research (CSIR is leading patent filer.

  4. A Database of EPO-Patenting Firms in Denmark

    DEFF Research Database (Denmark)

    Nielsen, Anders Østergaard

    1998-01-01

    The first section gives a brief introduction of the basic stages to be observed by the patent applicant from idea to the patent is granted. Section two presents three examples of how patents are registered in the online patent database INPADOC. Section three accounts for the initial analysis of the...... existing patent stock issued to firms with domicile in Denmark. Sections four and five report the basic characteristics of the EPO-patent sample and the procedures for linking the patent statistics to accounting data at the firm level, and finally they present the basic properties of the resulting database...

  5. The Coordination of Independently-Owned Vacuum Tube Patents in the Alleged Early Radio Patent Thicket

    DEFF Research Database (Denmark)

    Howells, John; Ron D, Katznelson

    It has been proposed that when multiple, independently-owned and ‘over-lapping’ patents must be licensed for legal technology development the difficulty of negotiating cross-licenses may lead entrepreneurs to hold-up or deter that development. Our literature review finds these features allegedly......-examines the legal trajectories and entrepreneurial exploitation of these patents with a focus on vacuum tube technology where Fleming’s diode patent ‘overlapped’ with earlier prior art and, dependent on court decisions, with later commercial implementations of De Forest’s triode patents. We show, by means of...

  6. Managing the patent thicket and maximizing patent lifetime in vaccine technology.

    Science.gov (United States)

    Mertes, Maria M M; Stötter, Gerd

    2010-10-01

    Patents are exclusive rights for a limited period of time that are granted to provide an incentive for innovation and in exchange for the public disclosure of an invention. Patenting in the medical field, especially in the field of human vaccine technologies, is full of pitfalls, because the products that finally access the market are often covered by a multitude of exclusive IP rights. This commentary gives an overview on obstacles in vaccine patenting and how to overcome them, and intends to provide a patenting guideline for researchers. PMID:20948289

  7. Patent law in dentistry: An overview

    Directory of Open Access Journals (Sweden)

    Mohammed Nadeem A Bijle

    2011-01-01

    Full Text Available Dentistry in recent years has developed interest in the field of intellectual property rights (IPR and Patents due to extensive research in the fraternity and existing competition. There have been various patent applications and grants in the field of dentistry abroad due to better understanding of IPR but India still has very few patent grants and applications on the subject matter. This review article in particular deals with the understanding of IPR and Patents as a whole, especially for dental professionals involved in research and development. Hence, this would also act as an asset for dental researchers to explore and expand their scope of activities, with special privileges empowered for their work.

  8. Patent documentation - comparison of two MT strategies

    DEFF Research Database (Denmark)

    Offersgaard, Lene; Povlsen, Claus

    2007-01-01

    This paper focuses on two matters: A comparison of how two different MT strategies manage translating the text type of patent documentation and a survey of what is needed to transform a MT research prototype system to a translation application for patent texts. The two MT strategies is represented...... distinctive text type of patents pose special demands for machine translation and these aspects are discussed based on linguistic observations with focus on the users point of view. Two main demands are automatic pre processing of the documents and implementation of a module which in a flexible and user......-friendly manner offers the opportunity to extend the lexical coverage of the system. These demands and the comparison of the two MT strategies are discussed on the basis of proofread patents....

  9. Revising the Complex Economics of Patent Scope

    DEFF Research Database (Denmark)

    Howells, John

    Merges and Nelson claim to have provided an empirically grounded argument that pioneer patents of 'broad' scope are used to block technological development. It is widely understood in both law and economics that they have, as they claim, faulted Kitch's 'prospect theory' of patents, a theory that a...... function of patents is to enable the coordinated development of novel technical ideas. This article is a critical review of Merges and Nelson's historical empirical evidence. I find that, first, 'broad' scope is only implicated in one of the examples cited by Merges and Nelson as supportive evidence - the...... Wright brothers' warped-wing patent; second, that strict development block, defined as the prevention, or retardation of the development of technology understood to be capable of useful development, was not illustrated by any of their examples. Therefore I conclude that their general thesis is not...

  10. Patent ductus venosus: diagnosis by MR angiography

    International Nuclear Information System (INIS)

    We report a 15-year-old boy with patent ductus venosus in whom the diagnosis was made by MR angiography. A patent ductus venosus Arantii is a rare form of portosystemic shunt. Only a few cases have been reported in adults and children. The diagnosis is usually made by US and digital subtraction angiography. In our patient, the diagnosis was first made by MR angiography. This demonstrates the excellent diagnostic potential of the method in paediatric patients. (orig.)

  11. Strategic management of innovation and patenting performances

    OpenAIRE

    Peeters, Carine; Van Pottelsberghe, Bruno

    2003-01-01

    This paper intends to contribute to the literature on the determinants of firms' patenting performances. In this respect it puts forward several new hypotheses related to the relationship between the strategic management of innovation and patenting performances. It relies on an original survey questionnaire on innovation competencies, innovation strategy and the perceived innovation barriers of 148 large firms in Belgium. The econometric results confirm several hypotheses already tested in th...

  12. India’s patent laws under pressure

    OpenAIRE

    Roderick, Peter; Pollock, Allyson M

    2016-01-01

    Pending cases against India's patent laws threaten public health and misinterpret international intellectual property agreements. In trying to limit compulsory licences and avoid efficacy tests on products, the Bayer and Novartis cases are seeking to undermine public health considerations aimed at improving access and therapeutic advantage. The TRIPS Agreement does not limit the grounds on which compulsory licences can be granted, and does not prevent patent applicants from having to ...

  13. Patent Reform: Aligning Reward and Contribution

    OpenAIRE

    Shapiro, Carl

    2007-01-01

    Economists and policy makers have long recognized that innovators must be able to appropriate a reasonable portion of the social benefits of their innovations if innovation is to be suitably rewarded and encouraged. However, this paper identifies a number of specific fact patterns under which the current U.S. patent system allows patent holders to capture private rewards that exceed their social contributions. Such excessive patentee rewards are socially costly, since they raise the deadweigh...

  14. Patents as Signals for Startup Financing

    OpenAIRE

    Annamaria Conti; Jerry Thursby; Thursby, Marie C

    2013-01-01

    We examine the role of patents as signals used to reduce information asymmetries in entrepreneurial finance. A theoretical model gives conditions for a unique separating equilibrium in which startup founders file for patents to signal invention quality to investors, as well as appropriating value. The theory allows for heterogeneous investors and examine the optimal match of different types of startups, as defined by the quality of their technology, to investors who differ in the amount of no...

  15. Patent Licensing in Selected European Countries

    OpenAIRE

    Wisła, Rafał; Sierotowicz, Tomasz

    2015-01-01

    The issue of the commercialization of patents, as an exemplification of the industrial property, is mostly considered at the microeconomic level. Patent commercialization belongs to the innovation management process, which takes place in innovative organizations. Such microeconomic research approach does not take into account the phenomenon of the intellectual property simultaneous spread and use of scientific and technical knowledge in the economy. These observations lead to u...

  16. The governance of the European patent system:

    DEFF Research Database (Denmark)

    Borras, Susana

    2006-01-01

    formal and informal dimensions of interactions in economic systems. This is further developed into an analytical framework which is then used in the assessment of the structural features of the current European patent system, one of the most advanced, complex, and contested economic systems in Europe....... The conclusions elaborate on the normative implications regarding the current weaknesses of the European patent system, and examine the general theoretical implications of the findings, particularly looking at the effectiveness and legitimacy of technically complex governance systems....

  17. Software Patent and its Impact on Software Innovation in Japan

    OpenAIRE

    Motohashi, Kazuyuki

    2009-01-01

    In Japan, the software patent system has been reformed and now software has become a patentable subject matter. In this paper, this pro-patent shift on software is surveyed and its impact on software innovation is analyzed. Before the 1990's, inventions related to software could not be patented by themselves, but they could be applied when combined with hardware related inventions. Therefore, integrated electronics firms used to be the major software patent applicants. However, during the per...

  18. Relationships between Claim Structure and the Competitiveness of a Patent

    OpenAIRE

    Takashi Miyazawa; Hiroshi Osada

    2010-01-01

    A patent’s competitiveness becomes crucial for the enforcement of patent right to protect business and ensure profits of companies. This study quantitatively analyses patent applications related to patent infringement lawsuits filed in trial courts in Japan. The total number of independent claims (k) and the maximum number of independent claims within a single claim category (l) at the time of filing patent applications of winning patents are found to have significant positive correlation w...

  19. Are Patent Litigation Insurances Fit for the Dynamics of Innovation?

    OpenAIRE

    Christian Ben Lakhdar

    2005-01-01

    Patent insurance policies allow firms to externalise the legal cost in case of conflicts. These litigation insurances may incite innovators to sue more often, which would increase the social cost of litigation. By modelling a patent file, we show that these patent litigation insurances incite innovators to claim for wider breadth patent too. Wider breadth patents could lead to an increased number of legal conflicts but could also lead to a slackening in the process of innovation improvement. ...

  20. PROFITING FROM INVENTION: BUSINESS MODELS OF PATENT AGGREGATING COMPANIES

    OpenAIRE

    CAROL A. KRECH; FRAUKE RÜTHER; OLIVER GASSMANN

    2015-01-01

    Patent aggregating companies are institutions that aggregate patents for different purposes. From a managerial perspective as well as a theoretical perspective, it is interesting to understand what value such novel business models provide to inventing companies. In this paper we focus on the question how patent holders can use patent aggregating companies as means to capture value from their inventions. Therefore the business models of patent aggregating companies need to be understood. Exist...